<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Immun Inflamm Dis</journal-id><journal-id journal-id-type="iso-abbrev">Immun Inflamm Dis</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2050-4527</journal-id><journal-id journal-id-type="publisher-id">IID3</journal-id><journal-title-group><journal-title>Immunity, Inflammation and Disease</journal-title></journal-title-group><issn pub-type="epub">2050-4527</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4768070</article-id><article-id pub-id-type="doi">10.1002/iid3.92</article-id><article-id pub-id-type="publisher-id">IID392</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The role of BST&#x02010;2/Tetherin in host protection and disease manifestation</article-title><alt-title alt-title-type="right-running-head">BST&#x02010;2: role in viral infection and breast cancer</alt-title><alt-title alt-title-type="left-running-head">W. D. Mahauad&#x02010;Fernandez &#x00026; C. M. Okeoma</alt-title></title-group><contrib-group><contrib id="iid392-cr-0001" contrib-type="author"><name><surname>Mahauad&#x02010;Fernandez</surname><given-names>Wadie D.</given-names></name><xref ref-type="aff" rid="iid392-aff-0001"><sup>1</sup>
</xref><xref ref-type="aff" rid="iid392-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="iid392-cr-0002" contrib-type="author" corresp="yes"><name><surname>Okeoma</surname><given-names>Chioma M.</given-names></name><xref ref-type="aff" rid="iid392-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="iid392-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="iid392-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Microbiology</named-content><named-content content-type="organisation-division">Carver College of Medicine</named-content><institution>University of Iowa</institution><named-content content-type="city">Iowa City</named-content><named-content content-type="country-part">IA</named-content><named-content content-type="post-code">52242</named-content><country country="US">USA</country></aff><aff id="iid392-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Interdisciplinary Program in Molecular and Cellular Biology</named-content><institution>University of Iowa</institution><named-content content-type="city">Iowa City</named-content><named-content content-type="country-part">IA</named-content><named-content content-type="post-code">52242</named-content><country country="US">USA</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Chioma M. Okeoma, Department of Microbiology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA. Tel.: 319&#x02010;335&#x02010;7906; 319&#x02010;335&#x02010;7612; Fax: 319&#x02010;335&#x02010;9006<break/>
E&#x02010;mail: 
<email>chioma-okeoma@uiowa.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2016</year></pub-date><volume>4</volume><issue>1</issue><issue-id pub-id-type="doi">10.1002/iid3.2016.4.issue-1</issue-id><fpage>4</fpage><lpage>23</lpage><history><date date-type="received"><day>01</day><month>9</month><year>2015</year></date><date date-type="rev-recd"><day>07</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>09</day><month>11</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 John Wiley & Sons Ltd. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. <italic>Immunity, Inflammation and Disease</italic> Published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:IID3-4-04.pdf"/><abstract abstract-type="main"><title>Abstract</title><p>Host cells respond to viral infections by activating immune response genes that are not only involved in inflammation, but may also predispose cells to cancerous transformation. One such gene is BST&#x02010;2, a type II transmembrane protein with a unique topology that endows it tethering and signaling potential. Through this ability to tether and signal, BST&#x02010;2 regulates host response to viral infection either by inhibiting release of nascent viral particles or in some models inhibiting viral dissemination. However, despite its antiviral functions, BST&#x02010;2 is involved in disease manifestation, a function linked to the ability of BST&#x02010;2 to promote cell&#x02010;to&#x02010;cell interaction. Therefore, modulating BST&#x02010;2 expression and/or activity has the potential to influence course of disease.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="iid392-kwd-0001">Antagonists</kwd><kwd id="iid392-kwd-0002">breast cancer</kwd><kwd id="iid392-kwd-0003">BST&#x02010;2</kwd><kwd id="iid392-kwd-0004">cancer</kwd><kwd id="iid392-kwd-0005">HIV&#x02010;1</kwd><kwd id="iid392-kwd-0006">malignancies</kwd><kwd id="iid392-kwd-0007">tethering</kwd><kwd id="iid392-kwd-0008">viruses</kwd></kwd-group><counts><page-count count="20"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>iid392</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.6 mode:remove_FC converted:26.02.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="iid392-note-0001"><p>
<bold>Funding information</bold>
</p></fn><fn id="iid392-note-0002"><p>No funding information provided.</p></fn></fn-group></notes></front><body><p>Early studies performed with monoclonal antibody (anti HM1.24) identified as HM1.24 antigen, that is, today called BST&#x02010;2 <xref rid="iid392-bib-0001" ref-type="ref">1</xref>. It was then suggested that BST&#x02010;2 is expressed in terminally differentiated B cells and may be involved in early pre&#x02010;B&#x02010;cell development <xref rid="iid392-bib-0001" ref-type="ref">1</xref>. However, emerging evidence suggest that although BST&#x02010;2 is broadly expressed in host cells, suppressing BST&#x02010;2 levels may be well tolerated as these mice do not present gross phenotypic defects and have no fertility issues compared to BST&#x02010;2&#x02010;expressing mice <xref rid="iid392-bib-0002" ref-type="ref">2</xref>, <xref rid="iid392-bib-0003" ref-type="ref">3</xref>, <xref rid="iid392-bib-0004" ref-type="ref">4</xref>. Nonetheless, the functions of BST&#x02010;2 are still evolving and a more comprehensive study of BST&#x02010;2 knockout mice is necessary to better understand cell/tissue type&#x02010;dependent functions of BST&#x02010;2. The level and expression pattern of BST&#x02010;2 is variable, depends on cell or tissue types <xref rid="iid392-bib-0004" ref-type="ref">4</xref>, <xref rid="iid392-bib-0005" ref-type="ref">5</xref>, and can be induced by types I and II interferons, as well as by mitogens, such as lipopolysaccharide (LPS) <xref rid="iid392-bib-0004" ref-type="ref">4</xref>, <xref rid="iid392-bib-0006" ref-type="ref">6</xref>, <xref rid="iid392-bib-0007" ref-type="ref">7</xref>, <xref rid="iid392-bib-0008" ref-type="ref">8</xref>. BST&#x02010;2 is primarily located on the apical membrane <xref rid="iid392-bib-0009" ref-type="ref">9</xref> with some expression present in the trans&#x02010;Golgi network (TGN) and in vesicular compartments <xref rid="iid392-bib-0010" ref-type="ref">10</xref>. Endogenously expressed BST&#x02010;2 protein contains complex carbohydrate modifications and presents as a smear of multiple 30&#x02013;40&#x02009;kDa bands presumed to be due to N&#x02010;linked glycosylation <xref rid="iid392-bib-0011" ref-type="ref">11</xref>. In contrast, exogenously expressed BST&#x02010;2 is modified by high&#x02010;mannose carbohydrates with predicted molecular weight of 28&#x02013;29&#x02009;kDa <xref rid="iid392-bib-0011" ref-type="ref">11</xref>.</p><p>BST&#x02010;2 is a type II transmembrane protein of 180 amino acids <xref rid="iid392-bib-0012" ref-type="ref">12</xref>. Structurally, BST&#x02010;2 is composed of an N&#x02010;terminal cytoplasmic tail followed by a transmembrane domain (TM), a coiled&#x02013;coiled ectodomain, and a C&#x02010;terminal glycosylphosphatidylinositol (GPI)&#x02010;anchor <xref rid="iid392-bib-0009" ref-type="ref">9</xref> (Fig. <xref rid="iid392-fig-0001" ref-type="fig">1</xref>). The C&#x02010;terminal membrane anchor is thought to be a second TM domain rather than a GPI anchor <xref rid="iid392-bib-0012" ref-type="ref">12</xref>. The cytoplasmic tail of BST&#x02010;2 contains a highly conserved double tyrosine motif (6<bold>Y</bold>7&#x02009;&#x000d7;&#x02009;8<bold>Y</bold>) implicated in clathrin&#x02010;dependent endocytosis of BST&#x02010;2 <xref rid="iid392-bib-0013" ref-type="ref">13</xref> and in nuclear factor &#x003ba;&#x02010;B (NF&#x02010;&#x003ba;B) activation <xref rid="iid392-bib-0014" ref-type="ref">14</xref>, <xref rid="iid392-bib-0015" ref-type="ref">15</xref>, <xref rid="iid392-bib-0016" ref-type="ref">16</xref>, <xref rid="iid392-bib-0017" ref-type="ref">17</xref> (Fig. <xref rid="iid392-fig-0001" ref-type="fig">1</xref>). The N&#x02010;terminal TM domain and the C&#x02010;terminal GPI anchor are separated by 120 residues that make up the coiled&#x02010;coil ectodomain <xref rid="iid392-bib-0018" ref-type="ref">18</xref>, <xref rid="iid392-bib-0019" ref-type="ref">19</xref>, <xref rid="iid392-bib-0020" ref-type="ref">20</xref>. The N&#x02010;terminus of BST&#x02010;2 ectodomain comprises of three cysteine residues that are implicated in the formation of covalent cysteine&#x02010;linked dimers (home&#x02010;dimers and &#x02010;tetramers) <xref rid="iid392-bib-0001" ref-type="ref">1</xref>, <xref rid="iid392-bib-0011" ref-type="ref">11</xref>, <xref rid="iid392-bib-0021" ref-type="ref">21</xref>, <xref rid="iid392-bib-0022" ref-type="ref">22</xref>. The cysteine residues are located at positions 53, 63, and 91 of the human BST&#x02010;2 and at positions 58, 68, and 96 of the mouse BST&#x02010;2 <xref rid="iid392-bib-0018" ref-type="ref">18</xref>. Any of these three cysteines is functional and independently contribute to the formation of cysteine&#x02010;linked dimers <xref rid="iid392-bib-0011" ref-type="ref">11</xref>, <xref rid="iid392-bib-0022" ref-type="ref">22</xref>.</p><fig fig-type="Figure" xml:lang="en" id="iid392-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>BST&#x02010;2 structure: BST&#x02010;2 is a type II transmembrane protein with a N&#x02010;terminal cytoplasmic tail (CT) followed by a transmembrane domain (TM), a coiled&#x02010;coil domain and a glycosylphosphatidylinositol (GPI) anchor embedded in lipid rafts in the cell membrane. The amino acid sequence of BST&#x02010;2 depicted in the gray box is color coded with their respective domains. Numbers on top of amino acids correspond to amino acid location. Underneath the amino acid sequences are colored boxes corresponding to different functions and characteristics of BST&#x02010;2 including NF&#x02010;&#x003ba;B activation (yellow), dimerization (blue), virus tethering (light purple), endocytosis/adaptor protein (AP) binding (green), sites of glycosylation (red), Vpu binding (orange), actin association (purple), motifs for ADCC induction (brown). Also included are some hypothetical characteristics/functions including sites of ubiquitination (light orange), cancer cell adhesion (light green), and induction of cancer&#x02010;promoting genes, such as matrix metalloproteinases, CXCR4, CXCL12, and other signaling molecules (gray). BST&#x02010;2 contains two translational start sites at methionine 1 and 13 (red) generating a long and short isoform, respectively. The short isoform cannot induce NF&#x02010;&#x003ba;B activation since it lacks the YXY motif. BST&#x02010;2 forms homo&#x02010;dimers and&#x02014;tetramers through 3 conserved cytosine residues at positions 53, 63 and 91. Leucine residues at positions 70 and 123 are important for maintaining the structure of BST&#x02010;2 and for virus tethering, which also requires the C&#x02010;terminal GPI anchor.</p></caption><graphic id="nlm-graphic-3" xlink:href="IID3-4-04-g002"><permissions><copyright-holder>Copyright &#x000a9; 2015 Wiley Periodicals, Inc.</copyright-holder></permissions></graphic></fig><p>Additionally, BST&#x02010;2 molecules form homo&#x02010;tetramers, mediated by leucine residues 70 and 123 that are implicated in promoting proper BST&#x02010;2 trafficking <xref rid="iid392-bib-0020" ref-type="ref">20</xref>. Furthermore, BST&#x02010;2 ectodomain is post&#x02010;translationally modified by N&#x02010;linked glycosylation of two asparagine residues at positions 65 and 92 <xref rid="iid392-bib-0009" ref-type="ref">9</xref>, <xref rid="iid392-bib-0011" ref-type="ref">11</xref>, <xref rid="iid392-bib-0021" ref-type="ref">21</xref>. Although the function of BST&#x02010;2 glycosylation for inhibition of virus release is unclear <xref rid="iid392-bib-0011" ref-type="ref">11</xref>, <xref rid="iid392-bib-0022" ref-type="ref">22</xref>, this post&#x02010;translational modification is important for proper folding and trafficking of BST&#x02010;2 through the endoplasmic reticulum (ER) and the Golgi <xref rid="iid392-bib-0023" ref-type="ref">23</xref>. BST&#x02010;2 molecule associates with lipid rafts <xref rid="iid392-bib-0001" ref-type="ref">1</xref>, <xref rid="iid392-bib-0009" ref-type="ref">9</xref>, <xref rid="iid392-bib-0013" ref-type="ref">13</xref>, <xref rid="iid392-bib-0024" ref-type="ref">24</xref>, <xref rid="iid392-bib-0025" ref-type="ref">25</xref>, <xref rid="iid392-bib-0026" ref-type="ref">26</xref> through the GPI anchor <xref rid="iid392-bib-0009" ref-type="ref">9</xref> (Fig. <xref rid="iid392-fig-0001" ref-type="fig">1</xref>). Removal of the anchor does not affect association of BST&#x02010;2 with the cell membrane; however, lipid raft localization of BST&#x02010;2 is lost <xref rid="iid392-bib-0009" ref-type="ref">9</xref>.</p><p>Emerging experimental and clinical evidence on the various functions of BST&#x02010;2 and the progress in our understanding of the involvement of innate immune responses to viral infections, inflammation, and cancer has prompted the need for a discussion on the role of BST&#x02010;2 in the host. Availability of genetically modified mice and human cell lines has revealed the range of phenotypes associated with BST&#x02010;2 in different cells at various physiological and pathophysiological conditions. We start by discussing the role of BST&#x02010;2 in viral infections and evolutionary adaptation of viruses to BST&#x02010;2, to the new discoveries about the involvement of BST&#x02010;2 in disease manifestation. We then describe the various regulatory mechanisms of BST&#x02010;2 and by BST&#x02010;2, and conclude with perspectives and future possibilities.</p><sec id="iid392-sec-0003"><title>BST&#x02010;2/Tetherin: Roles in Viral Pathogenesis</title><p>In 2008, BST&#x02010;2 was rediscovered as the host factor responsible for preventing the release of HIV&#x02010;1 with mutated Vpu (HIV&#x02010;1 &#x00394;Vpu) from host cells <xref rid="iid392-bib-0006" ref-type="ref">6</xref>, <xref rid="iid392-bib-0007" ref-type="ref">7</xref>. Following these discoveries, BST&#x02010;2 was renamed tetherin <xref rid="iid392-bib-0007" ref-type="ref">7</xref>. Since then, the tethering effect of BST&#x02010;2 has been shown to extend to other enveloped viruses including rhabdoviruses <xref rid="iid392-bib-0027" ref-type="ref">27</xref>, alphaviruses <xref rid="iid392-bib-0028" ref-type="ref">28</xref>, <xref rid="iid392-bib-0029" ref-type="ref">29</xref>, arenaviruses <xref rid="iid392-bib-0030" ref-type="ref">30</xref>, filoviruses <xref rid="iid392-bib-0031" ref-type="ref">31</xref>, <xref rid="iid392-bib-0032" ref-type="ref">32</xref>, herpesviruses <xref rid="iid392-bib-0033" ref-type="ref">33</xref>, paramyxoviruses <xref rid="iid392-bib-0030" ref-type="ref">30</xref>, orthomyxoviruses <xref rid="iid392-bib-0030" ref-type="ref">30</xref>, <xref rid="iid392-bib-0034" ref-type="ref">34</xref>, orthohepadnaviruses <xref rid="iid392-bib-0035" ref-type="ref">35</xref>, flaviviruses <xref rid="iid392-bib-0036" ref-type="ref">36</xref>, <xref rid="iid392-bib-0037" ref-type="ref">37</xref>, <xref rid="iid392-bib-0038" ref-type="ref">38</xref>, and retroviruses <xref rid="iid392-bib-0004" ref-type="ref">4</xref>, <xref rid="iid392-bib-0007" ref-type="ref">7</xref>, <xref rid="iid392-bib-0039" ref-type="ref">39</xref>, <xref rid="iid392-bib-0040" ref-type="ref">40</xref> (Table <xref rid="iid392-tbl-0001" ref-type="table-wrap">1</xref>). Aside from virus tethering, BST&#x02010;2 possesses other antiviral functions and viruses have evolved mechanisms to antagonize BST&#x02010;2.</p><table-wrap id="iid392-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Viruses susceptible to BST&#x02010;2 tethering</p></caption><table frame="hsides" rules="groups"><col span="1"/><col span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Virus</th><th align="center" valign="bottom" rowspan="1" colspan="1">Family</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HIV&#x02010;1, HIV&#x02010;2, SIV, EIAV, MLV, MMTV</td><td align="center" rowspan="1" colspan="1">Retroviridae</td></tr><tr><td align="left" rowspan="1" colspan="1">CHIKV, SFV</td><td align="center" rowspan="1" colspan="1">Togaviridae</td></tr><tr><td align="left" rowspan="1" colspan="1">Ebola, Marburg</td><td align="center" rowspan="1" colspan="1">Filoviridae</td></tr><tr><td align="left" rowspan="1" colspan="1">VSV</td><td align="center" rowspan="1" colspan="1">Rhabdoviridae</td></tr><tr><td align="left" rowspan="1" colspan="1">LASV, MACV</td><td align="center" rowspan="1" colspan="1">Arenaviridae</td></tr><tr><td align="left" rowspan="1" colspan="1">HSV&#x02010;1, HSV&#x02010;2, HH&#x02010;8</td><td align="center" rowspan="1" colspan="1">Herpesviridae</td></tr><tr><td align="left" rowspan="1" colspan="1">Dengue, Hepatitis C viruses</td><td align="center" rowspan="1" colspan="1">Flaviviridae</td></tr><tr><td align="left" rowspan="1" colspan="1">HBV</td><td align="center" rowspan="1" colspan="1">Orthohepadnaviridae</td></tr><tr><td align="left" rowspan="1" colspan="1">Influenza A virus</td><td align="center" rowspan="1" colspan="1">Orthomyxoviridae</td></tr></tbody></table><permissions><copyright-holder>&#x000a9; 2015 The Authors. Immunity, Inflammation and Disease Published by John Wiley &#x00026; Sons Ltd.</copyright-holder></permissions></table-wrap><sec id="iid392-sec-0004"><title>Virus tethering</title><p>The unique topology of BST&#x02010;2 (Fig. <xref rid="iid392-fig-0001" ref-type="fig">1</xref>) allows it to tether enveloped viruses to the surface of infected cells <xref rid="iid392-bib-0009" ref-type="ref">9</xref>, <xref rid="iid392-bib-0041" ref-type="ref">41</xref>. One of the structural arrangements that facilitates efficient virion tethering by BST&#x02010;2 is one in which the GPI anchor of cell&#x02010;associated BST&#x02010;2 inserts into the viral membrane of budding virus <xref rid="iid392-bib-0022" ref-type="ref">22</xref>, <xref rid="iid392-bib-0041" ref-type="ref">41</xref> as the cytoplasmic tail of BST&#x02010;2 is necessary to initiate intracellular signaling cascades (Fig. <xref rid="iid392-fig-0002" ref-type="fig">2</xref> #1). However, structures in which the transmembrane domain inserts into the viral membrane is plausible <xref rid="iid392-bib-0042" ref-type="ref">42</xref>. Also possible is an arrangement in which the entire BST&#x02010;2 protein buds along with the virus <xref rid="iid392-bib-0022" ref-type="ref">22</xref>, <xref rid="iid392-bib-0043" ref-type="ref">43</xref>, <xref rid="iid392-bib-0044" ref-type="ref">44</xref> (Fig. <xref rid="iid392-fig-0002" ref-type="fig">2</xref> #2). Virus tethering by BST&#x02010;2 is mediated in part by the ability of BST&#x02010;2 to form homo&#x02010;dimers through covalent bonds between cysteine residues in the ectodomain of BST&#x02010;2 <xref rid="iid392-bib-0042" ref-type="ref">42</xref>. By tethering enveloped viruses to the surface of infected cells, BST&#x02010;2 not only restricts virus release but it also elicits and amplifies innate immune responses through the induction of cytokine/chemokine expression <xref rid="iid392-bib-0014" ref-type="ref">14</xref>, <xref rid="iid392-bib-0045" ref-type="ref">45</xref>, a process believed to largely involve BST&#x02010;2 cytoplasmic tail. Indeed, the Y&#x02009;&#x000d7;&#x02009;Y motif on BST&#x02010;2 cytoplasmic tail is implicated in NF&#x02010;&#x003ba;B activation involving recruitment of TAK1, Ubc13, TRAF2, and TRAF6 <xref rid="iid392-bib-0014" ref-type="ref">14</xref>, <xref rid="iid392-bib-0046" ref-type="ref">46</xref> (Fig. <xref rid="iid392-fig-0002" ref-type="fig">2</xref> #1). Moreover, BST&#x02010;2 associates with the cortical actin cytoskeleton through the Rac&#x02010;GAP&#x02010;containing protein RICH2 (Fig. <xref rid="iid392-fig-0001" ref-type="fig">1</xref>) and abrogation of this interaction significantly diminishes NF&#x02010;&#x003ba;B activation <xref rid="iid392-bib-0047" ref-type="ref">47</xref>. In virus infected cells, the cortical actin cytoskeleton mediates BST&#x02010;2 phosphorylation and recognition of the YXY motif by the spleen tyrosine kinase (Syk) and subsequent NF&#x02010;&#x003ba;B activation, culminating in expression of CXCL10 and IL&#x02010;6 <xref rid="iid392-bib-0047" ref-type="ref">47</xref>. Additionally, NF&#x02010;&#x003ba;B activation by BST&#x02010;2 is not only mediated by virus tethering but can also result from antibody crosslinking <xref rid="iid392-bib-0014" ref-type="ref">14</xref>, suggesting that BST&#x02010;2&#x02010;induced signaling and cytokine/chemokine production could result from a variety of stimuli.</p><fig fig-type="Figure" xml:lang="en" id="iid392-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>BST&#x02010;2 in viral infection: BST&#x02010;2 tethers viruses to the cell membrane and to each other (1) and (2). Tethered viruses may be internalized through clathrin coated pits mediated by the YXY motif on BST&#x02010;2's cytoplasmic tail (CT). Virus tethering by BST&#x02010;2 also induces the activation of NF&#x02010;&#x003ba;B through BST&#x02010;2's YXY motif which interacts with TRAF and requires Ubc13, Tab1, Tab2, and TAK1 (1). NF&#x02010;&#x003ba;B activation induces the expression of cytokines, such as CXCL10 and Il&#x02010;6 and may induce the expression of BST&#x02010;2 since the BST&#x02010;2 promoter contains elements for NF&#x02010;&#x003ba;B binding (1). In the early endosome (EE), TLRs recognize different viral factors and induce the expression of cytokines, chemokines and several antiviral factors that contain IFN&#x02010;sensitive response elements (ISRE) on their promoter (3). Signaling through TLRs regulates BST&#x02010;2 in a positive and/or a negative manner (3). BST&#x02010;2 tethering is also required for the induction of antibody&#x02010;dependent cellular cytotoxicity (ADCC) which in turn induces the degranulation of effector cells, such as natural killer (NK) cells, through the Fc&#x003b3;IIIA receptors (4). Viruses have evolved mechanisms to antagonize BST&#x02010;2. The best studied BST&#x02010;2 antagonist is Vpu which interacts with BST&#x02010;2 at the endoplasmic reticulum (ER), trans&#x02010;Golgi network (TGN) and early endosomes. Vpu sequesters BST&#x02010;2 at all of these sites. Vpu can also prevent anterograde transport of BST&#x02010;2 from the ER to the TGN, and prevent BST&#x02010;2 recycling from TGN to the plasma membrane (5). Vpu also promotes BST&#x02010;2 degradation (Degrad) through the lysosomal pathway (Lys&#x02009;=&#x02009;lysosome) (6). BST&#x02010;2 is a ligand for ILT7 (immunoglobulin&#x02010;like transcript 7) at least in plasmacytoid dendritic (pDC) cells. Engagement of ILT7 by BST&#x02010;2 represses IFN&#x003b1; expression which in turn can induce BST&#x02010;2 levels (7).</p></caption><graphic id="nlm-graphic-5" xlink:href="IID3-4-04-g003"><permissions><copyright-holder>Copyright &#x000a9; 2015 Wiley Periodicals, Inc.</copyright-holder></permissions></graphic></fig><p>NF&#x02010;&#x003ba;B is a promiscuous transcription factor that regulates the expression of several cytokines and chemokines <xref rid="iid392-bib-0014" ref-type="ref">14</xref>. It is still contested whether internalized or cell membrane&#x02010;associated BST&#x02010;2 mediates NF&#x02010;&#x003ba;B activation <xref rid="iid392-bib-0014" ref-type="ref">14</xref>, <xref rid="iid392-bib-0046" ref-type="ref">46</xref>. Following virus tethering, BST&#x02010;2 facilitates virus internalization to early endosomes and subsequent lysosomal degradation. The resulting viral products serve as PAMPs that activate TLRs <xref rid="iid392-bib-0006" ref-type="ref">6</xref>, <xref rid="iid392-bib-0048" ref-type="ref">48</xref>, <xref rid="iid392-bib-0049" ref-type="ref">49</xref> (Fig. <xref rid="iid392-fig-0002" ref-type="fig">2</xref> #3). Interestingly, TLR4 positively regulates BST&#x02010;2 expression <xref rid="iid392-bib-0008" ref-type="ref">8</xref>; a scenario that may lead to a feedback loop following recognition of PAMPs by TLRs, as well as activation of signal transduction cascade capable of inhibiting viral replication or possibly promoting replication if enhancing factors are induced.</p><p>Aside from inhibiting viral clearance through activation of signal transduction pathways, tethered viruses may regulate cell&#x02010;to&#x02010;cell viral spread. BST&#x02010;2 may enhance cell&#x02010;to&#x02010;cell viral spread by the formation of viral clusters <xref rid="iid392-bib-0050" ref-type="ref">50</xref>. However, inhibition of cell&#x02010;to&#x02010;cell viral spread by BST&#x02010;2 could occur by initiation of virological synapses, by trapping viruses in intracellular compartments <xref rid="iid392-bib-0051" ref-type="ref">51</xref>, <xref rid="iid392-bib-0052" ref-type="ref">52</xref>, <xref rid="iid392-bib-0053" ref-type="ref">53</xref>, or by eliciting antibody&#x02010;dependent cellular cytotoxicity (ADCC) <xref rid="iid392-bib-0054" ref-type="ref">54</xref>, <xref rid="iid392-bib-0055" ref-type="ref">55</xref>, <xref rid="iid392-bib-0056" ref-type="ref">56</xref> (Fig. <xref rid="iid392-fig-0002" ref-type="fig">2</xref> #4). Indeed, the Env of tethered viruses may contain epitopes recognized by cytotoxic&#x02010;inducing antibodies (Abs). Binding of these Abs to Env leads to degranulation of effector cells, such as NK cells via FC&#x003b3;IIIA receptors <xref rid="iid392-bib-0056" ref-type="ref">56</xref>, resulting in the release of perforins and granzymes, that may lyse and kill infected cells, respectively <xref rid="iid392-bib-0057" ref-type="ref">57</xref>. Although no primary data exist in support of ADCC&#x02010;mediated enhancement of infection, it is noteworthy that ADCC&#x02010;mediated cell lysis may result in the release of viral particles that are tethered or trapped in intracellular compartments resulting in viral spread. Further research is needed to better understand the phenomenon of ADCC and in BST&#x02010;2&#x02010;mediated antiviral activities.</p></sec><sec id="iid392-sec-0005"><title>Inhibition of virus replication</title><p>The role of BST&#x02010;2 in the replication of various viral families is beginning to emerge, albeit slowly. In mouse model of alphavirus infection, BST&#x02010;2 potently inhibits Chikungunya virus (CHIKV) infection and viral replication. BST&#x02010;2 deficiency increases viral load at the inoculation site, enhances plasma viremia and lymphoid tissues viral tropism <xref rid="iid392-bib-0045" ref-type="ref">45</xref>. Moreover, BST&#x02010;2 deficiency impairs CHIKV&#x02010;induced inflammatory response that manifests as reduced levels of IFN&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and CD40 ligand <xref rid="iid392-bib-0045" ref-type="ref">45</xref>. Aside from its role in alphavirus replication, BST&#x02010;2 inhibits replication of retroviruses including MMTV and MLV in mice <xref rid="iid392-bib-0003" ref-type="ref">3</xref>, <xref rid="iid392-bib-0004" ref-type="ref">4</xref>, <xref rid="iid392-bib-0058" ref-type="ref">58</xref>. Inhibition of retrovirus replication is thought to be partly the result of endocytosed BST&#x02010;2&#x02010;mediated induction of IFN&#x003b3; production and degranulation of effector cells (NK and CD8+ T cells) <xref rid="iid392-bib-0058" ref-type="ref">58</xref>. Interestingly, endocytosis&#x02010;defective BST&#x02010;2, which is highly concentrated on cell membranes, is less efficient in restricting viral spread compared to an endocytosis&#x02010;competent BST&#x02010;2 <xref rid="iid392-bib-0058" ref-type="ref">58</xref>. These data suggest that while the tetherin function of BST&#x02010;2 is important, virus tethering may be dispensable or play a sensing role in the induction of immune response and BST&#x02010;2&#x02010;mediated inhibition of virus replication in vivo.</p></sec></sec><sec id="iid392-sec-0006"><title>Viral Antagonists of BST&#x02010;2 and Neutralization of BST&#x02010;2 Antiviral Function</title><p>Different viral proteins antagonize BST&#x02010;2. The mechanisms of BST&#x02010;2 antagonism by these viral proteins vary and include protein trapping in intracellular compartments, proteasomal and lysosomal degradation of BST&#x02010;2, inhibition of BST&#x02010;2 anterograde transport, inhibition of recycling, and other yet to be identified mechanisms. In the following section, we discuss viral antagonists of BST&#x02010;2 and the known or putative mechanisms of action.</p><sec id="iid392-sec-0007"><title>HIV&#x02010;1 Vpu</title><p>HIV&#x02010;1 Viral protein U (Vpu) <xref rid="iid392-bib-0059" ref-type="ref">59</xref>, <xref rid="iid392-bib-0060" ref-type="ref">60</xref> is renowned for its role in proteasomal degradation of CD4 <xref rid="iid392-bib-0061" ref-type="ref">61</xref>, <xref rid="iid392-bib-0062" ref-type="ref">62</xref> and enhancement of HIV&#x02010;1 release from infected cells <xref rid="iid392-bib-0063" ref-type="ref">63</xref>, <xref rid="iid392-bib-0064" ref-type="ref">64</xref>, <xref rid="iid392-bib-0065" ref-type="ref">65</xref> in a cell type&#x02010;dependent manner <xref rid="iid392-bib-0066" ref-type="ref">66</xref>. In 2008, two independent laboratories showed that cell type&#x02010;specific expression of BST&#x02010;2 correlates with Vpu&#x02010;dependent release of HIV&#x02010;1. Suppression of endogenous BST&#x02010;2 expression resulted in Vpu&#x02010;independent virus release whereas rescue of expression with exogenous BST&#x02010;2 in cells that otherwise do not have high BST&#x02010;2 renders these cells Vpu&#x02010;dependent for virus release <xref rid="iid392-bib-0006" ref-type="ref">6</xref>, <xref rid="iid392-bib-0007" ref-type="ref">7</xref>. These findings revealed that BST&#x02010;2 is an inhibitor of virus release and a target of Vpu <xref rid="iid392-bib-0006" ref-type="ref">6</xref>, <xref rid="iid392-bib-0007" ref-type="ref">7</xref>. These observations gave credence to an earlier study in 2006 that showed that expression of Vpu&#x02010;reduced BST&#x02010;2 levels in HeLa cells <xref rid="iid392-bib-0067" ref-type="ref">67</xref>, thus providing a functional association between Vpu and BST&#x02010;2. The interaction between Vpu and BST&#x02010;2 requires the transmembrane domain of both Vpu <xref rid="iid392-bib-0068" ref-type="ref">68</xref>, <xref rid="iid392-bib-0069" ref-type="ref">69</xref> and BST&#x02010;2 <xref rid="iid392-bib-0070" ref-type="ref">70</xref>, <xref rid="iid392-bib-0071" ref-type="ref">71</xref>, <xref rid="iid392-bib-0072" ref-type="ref">72</xref> (Fig. <xref rid="iid392-fig-0001" ref-type="fig">1</xref>). To neutralize the effect of BST&#x02010;2, Vpu utilizes various mechanisms as discussed below.</p></sec><sec id="iid392-sec-0008"><title>Enhancement of BST&#x02010;2 degradation</title><p>Vpu promotes intracellular down&#x02010;regulation of BST&#x02010;2 <xref rid="iid392-bib-0073" ref-type="ref">73</xref>, <xref rid="iid392-bib-0074" ref-type="ref">74</xref>, a mechanism that involves beta&#x02010;transducin repeat containing protein 2 (&#x003b2;&#x02010;TrCP2) <xref rid="iid392-bib-0075" ref-type="ref">75</xref>, <xref rid="iid392-bib-0076" ref-type="ref">76</xref>. &#x003b2;&#x02010;TrCP2 is an E3 ligase that forms the SCF<sup>&#x003b2;&#x02010;TrCP2</sup> complex involved in lysosomal degradation <xref rid="iid392-bib-0077" ref-type="ref">77</xref>. Phosphorylation of serine residues at positions 52 and 56 (catalyzed by casein kinase II (CK2) of Vpu is critical for the interaction of Vpu with &#x003b2;&#x02010;TrCP2 and for BST&#x02010;2 degradation <xref rid="iid392-bib-0078" ref-type="ref">78</xref>, <xref rid="iid392-bib-0079" ref-type="ref">79</xref>. Following Vpu and &#x003b2;&#x02010;TrCP2 interaction, the latter interacts with E3 ligase core component Cullin1 (Cul1) through the S&#x02010;phase kinase associated protein 1 (Skp1) forming the SCF&#x003b2;&#x02010;TrCP2 complex. Cul1 then associates with ring&#x02010;box protein 1 (Rbx1) mediating Cul1 neddylation (addition of an ubiquitin&#x02010;like NEDD8 moiety), which changes the conformation of Cul1 allowing recruitment of specific E2 enzymes. Generally, the SCF<sup>&#x003b2;&#x02010;TrCP2</sup> complex ubiquitinates substrates bound to &#x003b2;&#x02010;TrCP2 <xref rid="iid392-bib-0080" ref-type="ref">80</xref>. However, in HIV&#x02010;1 infected cells, Vpu acts as an adaptor to facilitate &#x003b2;&#x02010;TrCP2 recruitment and BST&#x02010;2 ubiquitination <xref rid="iid392-bib-0079" ref-type="ref">79</xref>. How Vpu commits BST&#x02010;2 to lysosomal degradation and avoids a similar fate is unknown. Possibly, Vpu dissociates from BST&#x02010;2 and &#x003b2;&#x02010;TrCP2 in the early endosome after endosomal sorting complex required for transport&#x02010;0 (ESCRT&#x02010;0) recognizes and ubiquitinates BST&#x02010;2. ESCRT&#x02010;0 acts as a checkpoint to commit a protein for lysosomal degradation and it is essential for BST&#x02010;2 degradation by Vpu <xref rid="iid392-bib-0081" ref-type="ref">81</xref>, <xref rid="iid392-bib-0082" ref-type="ref">82</xref>. ESCRT&#x02010;0 contains two subunits&#x02014;signal transducing adaptor molecule 1 (STAM1) and hepatocyte growth factor&#x02010;regulated tyrosine kinase substrate (HRS) <xref rid="iid392-bib-0083" ref-type="ref">83</xref>. These subunits contain two ubiquitin binding domains (UBDs)&#x02014;UIM (ubiquitin interacting motif) and VHS (Vps27/Hrs/STAM) <xref rid="iid392-bib-0084" ref-type="ref">84</xref>. The domain(s) necessary for ubiquitinated BST&#x02010;2 recognition and degradation are yet to be identified.</p><p>Although much of the mechanistic details of this interaction have been resolved, there is no consensus on specific residues on BST&#x02010;2 cytoplasmic tail that are ubiquitinated and the ubiquitin topology involved in BST&#x02010;2 degradation is unknown (Fig. <xref rid="iid392-fig-0001" ref-type="fig">1</xref>). As the SCF<sup>&#x003b2;&#x02010;TrCP2</sup> complex leads to lysosomal degradation, the K63 topology of the ubiquitin chain may be involved. Despite all the evidence supporting the role of Vpu in neutralizing BST&#x02010;2&#x02010;mediated tethering of HIV&#x02010;1 particles and subsequent viral spread, loss of Vpu does not completely prevent cell&#x02010;free HIV&#x02010;1 dissemination but pushes the mechanism of virus dissemination toward a cell&#x02010;to&#x02010;cell&#x02010;based mode. Moreover, primary HIV&#x02010;1 isolates in which Vpu harbors a start codon mutation are capable of disseminating in vivo <xref rid="iid392-bib-0085" ref-type="ref">85</xref>, <xref rid="iid392-bib-0086" ref-type="ref">86</xref>. Therefore, the role of BST&#x02010;2 and Vpu in HIV&#x02010;1 infection and/or host response to HIV&#x02010;1 still remains unresolved.</p></sec><sec id="iid392-sec-0009"><title>Inhibition of anterograde transport</title><p>Vpu and BST&#x02010;2 are both present in early endosomes <xref rid="iid392-bib-0087" ref-type="ref">87</xref>. The close cellular localization of Vpu and BST&#x02010;2 suggest that Vpu may either recruit the SCF<sup>&#x003b2;&#x02010;TrCP2</sup> complex to ubiquitinate BST&#x02010;2 and commit it to lysosomal degradation <xref rid="iid392-bib-0023" ref-type="ref">23</xref>, <xref rid="iid392-bib-0088" ref-type="ref">88</xref> as discussed above or shuttle BST&#x02010;2 to the TGN for possible degradation. Experimental evidence suggest that Vpu does not affect BST&#x02010;2 internalization, but rather prevents proper intracellular transportation of newly synthesized BST&#x02010;2 from the ER and TGN to the cell membrane <xref rid="iid392-bib-0089" ref-type="ref">89</xref>, <xref rid="iid392-bib-0090" ref-type="ref">90</xref> (Fig. <xref rid="iid392-fig-0002" ref-type="fig">2</xref> #5) and/or from early endosomes to the cell surface <xref rid="iid392-bib-0044" ref-type="ref">44</xref>, <xref rid="iid392-bib-0088" ref-type="ref">88</xref>, <xref rid="iid392-bib-0091" ref-type="ref">91</xref> (Fig. <xref rid="iid392-fig-0002" ref-type="fig">2</xref> #6). Vpu&#x02010;mediated inhibition of BST&#x02010;2 anterograde transport occurs in the absence of Ser52 and Ser56 phosphorylation <xref rid="iid392-bib-0089" ref-type="ref">89</xref>, <xref rid="iid392-bib-0090" ref-type="ref">90</xref>, <xref rid="iid392-bib-0091" ref-type="ref">91</xref>.</p></sec><sec id="iid392-sec-0010"><title>Removal from lipid rafts</title><p>Studies that examined the activity of certain Vpu mutants revealed that surface down&#x02010;regulation and/or degradation of BST&#x02010;2 are not enough to explain Vpu&#x02010;mediated enhancement of virion release <xref rid="iid392-bib-0073" ref-type="ref">73</xref>. HIV&#x02010;1 preferentially buds from areas of the cell membrane that contains lipid rafts where BST&#x02010;2 C&#x02010;terminal GPI anchor is embedded. Indeed, the GPI anchor is incorporated into newly formed viral membrane as the virus buds <xref rid="iid392-bib-0022" ref-type="ref">22</xref>, <xref rid="iid392-bib-0043" ref-type="ref">43</xref>. To remove BST&#x02010;2 from lipid rafts, Vpu forms a complex with BST&#x02010;2 through a tryptophan residue at position 76 (Trp&#x02010;76) located on the cytoplasmic tail of Vpu that functions to anchor Vpu C terminus to the lipid bilayer, thus displacing BST&#x02010;2 from virion&#x02010;assembly sites, while maintaining the levels of BST&#x02010;2 in the cell <xref rid="iid392-bib-0092" ref-type="ref">92</xref>.</p></sec><sec id="iid392-sec-0011"><title>Inhibition of antibody&#x02010;dependent cellular cytotoxicity (ADCC)</title><p>Vpu potently counteracts BST&#x02010;2&#x02010;mediated ADCC activity <xref rid="iid392-bib-0054" ref-type="ref">54</xref>, <xref rid="iid392-bib-0055" ref-type="ref">55</xref> via a mechanism that is not clearly understood (Fig. <xref rid="iid392-fig-0002" ref-type="fig">2</xref> #4). Available data suggest that Vpu prevents BST&#x02010;2&#x02010;mediated ADCC by trapping BST&#x02010;2 in intracellular compartments and that Vpu&#x02010;mediated degradation of BST&#x02010;2 is dispensable <xref rid="iid392-bib-0055" ref-type="ref">55</xref>.</p></sec></sec><sec id="iid392-sec-0012"><title>Viral Glycoproteins and BST&#x02010;2 Neutralization</title><p>Neutralization of BST&#x02010;2 by the envelope glycoprotein (gp41) of HIV&#x02010;2 (HIV&#x02010;2 Env) occurs through sequestration of BST&#x02010;2 in perinuclear compartments, most likely at the TGN <xref rid="iid392-bib-0093" ref-type="ref">93</xref> in the absence of BST&#x02010;2 degradation. This Env&#x02010;mediated neutralization of BST&#x02010;2 effect is similarly to the antagonistic actions of Vpu <xref rid="iid392-bib-0093" ref-type="ref">93</xref>, <xref rid="iid392-bib-0094" ref-type="ref">94</xref> and as reported earlier for Vpu in promoting viral particle release <xref rid="iid392-bib-0095" ref-type="ref">95</xref>, <xref rid="iid392-bib-0096" ref-type="ref">96</xref>, <xref rid="iid392-bib-0097" ref-type="ref">97</xref>, <xref rid="iid392-bib-0098" ref-type="ref">98</xref>, <xref rid="iid392-bib-0099" ref-type="ref">99</xref>. Env interacts with BST&#x02010;2 but the domains involved in the interaction are yet to be identified. However, the tyrosine&#x02010;based endocytic motif GYxx&#x003b8; on Env cytoplasmic tail binds AP&#x02010;2 allowing clathrin&#x02010;mediated endocytosis, required for BST&#x02010;2 downregulation from the cell surface <xref rid="iid392-bib-0094" ref-type="ref">94</xref>, <xref rid="iid392-bib-0099" ref-type="ref">99</xref>, <xref rid="iid392-bib-0100" ref-type="ref">100</xref>. The host GTPase dynamin 2 that pinches off clathrin&#x02010; and non&#x02010;clathrin&#x02010;coated vesicles is involved in HIV Env&#x02010;mediated antagonistic effect on BST&#x02010;2 <xref rid="iid392-bib-0100" ref-type="ref">100</xref>. In addition, the envelope proteins from other lentiviruses, such as SIV or EIAV are known BST&#x02010;2 antagonists because their presence enhances viral release in cultured cells <xref rid="iid392-bib-0040" ref-type="ref">40</xref>.</p><p>Aside from lentiviral Env, other viral glycoproteins, such as Ebola (Ebo GP) and herpesviruses (HSV) glycoproteins neutralize BST&#x02010;2&#x02010;mediated tethering. Ebola GP antagonizes BST&#x02010;2 tethering function without removing BST&#x02010;2 from lipid rafts <xref rid="iid392-bib-0031" ref-type="ref">31</xref>. In the presence of Ebo GP surface BST&#x02010;2 protein is greatly reduced <xref rid="iid392-bib-0032" ref-type="ref">32</xref> without affecting total protein levels, suggesting that GP may downregulate BST&#x02010;2 from the cell surface. Considering the findings from both studies <xref rid="iid392-bib-0031" ref-type="ref">31</xref>, <xref rid="iid392-bib-0032" ref-type="ref">32</xref>, a model where Ebo GP internalizes BST&#x02010;2 in its lipid raft complex can be envisioned. In addition, GP prevents the interaction of BST&#x02010;2 with Ebola VP40 (viral matrix protein) which may prevent virus tethering <xref rid="iid392-bib-0101" ref-type="ref">101</xref>. Despite its ability to tether Ebola particles, BST&#x02010;2 does not inhibit Ebola replication <xref rid="iid392-bib-0102" ref-type="ref">102</xref>.</p><p>BST&#x02010;2&#x02010;mediated tethering of <italic>Herpesviridae</italic> family of viruses is controversial. BST&#x02010;2 tethers &#x003b3;&#x02010;herpesvirus&#x02014;KSHV <xref rid="iid392-bib-0103" ref-type="ref">103</xref>, and &#x003b1;&#x02010;herpesviruses&#x02014;herpes virus simplex 1 and 2 (HSV&#x02010;1 and HSV&#x02010;2) <xref rid="iid392-bib-0104" ref-type="ref">104</xref>, <xref rid="iid392-bib-0105" ref-type="ref">105</xref> and BST&#x02010;2 incorporates into HSV&#x02010;2 virions <xref rid="iid392-bib-0104" ref-type="ref">104</xref>. However, BST&#x02010;2 does not tether the &#x003b2;&#x02010;herpesvirus&#x02014;human cytomegalovirus (HCMV). Rather, it was reported that BST&#x02010;2 enhanced HCMV entry into host cells <xref rid="iid392-bib-0106" ref-type="ref">106</xref>. Similar to HIV, the tethering functions of BST&#x02010;2 on HSV&#x02010;1 and HSV&#x02010;2 is neutralized by various viral products. HSV&#x02010;1 glycoprotein gM but not gB and gD neutralizes BST&#x02010;2 tethering <xref rid="iid392-bib-0105" ref-type="ref">105</xref>. In contrast, HSV&#x02010;2 glycoproteins gB, gD, gH, gL but not gE, gG, or gM reduces the levels of BST&#x02010;2 via unknown mechanisms <xref rid="iid392-bib-0104" ref-type="ref">104</xref>.</p><p>Other viral glycoproteins of interest are the Sendai virus (SV), fusion (F), and hemagglutinin&#x02010;neuraminidase (HN). These SV glycoproteins synergistically neutralize BST&#x02010;2 by mechanisms that may involve BST&#x02010;2 degradation <xref rid="iid392-bib-0107" ref-type="ref">107</xref>. It has recently been shown that BST&#x02010;2 tethers hepatitis B virus (HBV) and that HBV antagonizes BST&#x02010;2 <xref rid="iid392-bib-0108" ref-type="ref">108</xref>. The tethering function of BST&#x02010;2 is also neutralized by hepatitis B virus (HBV) surface protein (HBs). The mechanism of neutralization is thought to involve the ability of HBs to bind BST&#x02010;2 and prevents BST&#x02010;2 homodimerization <xref rid="iid392-bib-0035" ref-type="ref">35</xref>.</p></sec><sec id="iid392-sec-0013"><title>Antagonism of BST&#x02010;2 by HIV&#x02010;2 and SIV Negative Regulatory Factor (Nef)</title><p>Nef is a 27&#x02010;35&#x02009;kDa myristoylated protein encoded by human and simian immunodeficiency viruses; HIV and SIV. Interaction of BST&#x02010;2 and Nef occurs through association of BST&#x02010;2 cytoplasmic tail with residues in the Nef N&#x02010;terminus that interacts with AP&#x02010;2 proteins involved in clathrin&#x02010;mediated endocytosis <xref rid="iid392-bib-0109" ref-type="ref">109</xref>, <xref rid="iid392-bib-0110" ref-type="ref">110</xref>, <xref rid="iid392-bib-0111" ref-type="ref">111</xref>. Although the precise mechanism of BST&#x02010;2 neutralization by Nef is unknown, it is possible that Nef uses the lysosomal pathway similar to that used in degradation of MHC class I and CD4 <xref rid="iid392-bib-0112" ref-type="ref">112</xref>, <xref rid="iid392-bib-0113" ref-type="ref">113</xref> to degrade BST&#x02010;2 <xref rid="iid392-bib-0109" ref-type="ref">109</xref>.</p></sec><sec id="iid392-sec-0014"><title>Herpesvirus 8 K3 and K5&#x02010;Mediated Neutralization of BST&#x02010;2</title><p>Herpesvirus 8 also known as Kaposi sarcoma&#x02010;associated herpesvirus (KSHV) contains viral factors, K3/MIR1 and K5/MIR2. These proteins are part of the RING&#x02010;CH (MARCH) ubiquitin ligase family and are involve in the proteasomal degradation of several antiviral factors including MHC class I receptors, B7&#x02010;2, CD166, CD31, ICAM&#x02010;1, and BST&#x02010;2 <xref rid="iid392-bib-0114" ref-type="ref">114</xref>. K3 and K5 ubiquitinate lysine residues located on BST&#x02010;2 cytoplasmic tail as BST&#x02010;2 is processed out of the ER resulting to the proteasomal degradation of BST&#x02010;2 and enhanced KSHV release <xref rid="iid392-bib-0103" ref-type="ref">103</xref>, <xref rid="iid392-bib-0115" ref-type="ref">115</xref>.</p></sec><sec id="iid392-sec-0015"><title>Chikungunya Virus Nonstructural Protein 1 (CHIKV nsP1) Antagonizes BST&#x02010;2</title><p>CHIKV and Semliki Forest virus (SFV) are two alphaviruses that are susceptible to BST&#x02010;2 tethering effect <xref rid="iid392-bib-0028" ref-type="ref">28</xref>, <xref rid="iid392-bib-0029" ref-type="ref">29</xref>, <xref rid="iid392-bib-0045" ref-type="ref">45</xref>. Of all CHIKV envelope proteins (E1, E2, and E3) and non&#x02010;structural proteins (nsP1, nsP2, nsP3, and nsP4), only E1 and nsP1 co&#x02010;localize with BST&#x02010;2. However, only nsP1 overcomes BST&#x02010;2&#x02010;mediated tethering and enhances CHIKV release through unknown mechanisms <xref rid="iid392-bib-0028" ref-type="ref">28</xref>.</p></sec><sec id="iid392-sec-0016"><title>Influenza Neuraminidases Neutralizes BST&#x02010;2</title><p>In cultured cells, influenza neuraminidase (N) N1 and N2 antagonize the effects of BST&#x02010;2 and rescue influenza release through a yet to be determined mechanism <xref rid="iid392-bib-0034" ref-type="ref">34</xref>, <xref rid="iid392-bib-0116" ref-type="ref">116</xref>. Influenza nonstructural protein 1 (NS1) also antagonizes BST&#x02010;2 by averting IFN signaling and infection with this virus results in loss of BST&#x02010;2 steady state levels <xref rid="iid392-bib-0117" ref-type="ref">117</xref>. Contrary to the report on the susceptibility of influenza virus to BST&#x02010;2&#x02010;mediated tethering, a study suggests that BST&#x02010;2 does not tether influenza virus and influenza neuraminidase, hemagglutinin, and NS1 are unable to neutralize BST&#x02010;2 <xref rid="iid392-bib-0118" ref-type="ref">118</xref>.</p></sec><sec id="iid392-sec-0017"><title>BST&#x02010;2/Tetherin: Roles in Carcinogenesis</title><p>Despite all we have learnt about the antiviral functions of BST&#x02010;2 and evolutionary adaptation of viruses to this protein, intriguing new discoveries about the involvement of BST&#x02010;2 in carcinogenesis has opened another world of possibilities for BST&#x02010;2 biology and function.</p><p>The spectrum of BST&#x02010;2 expression in various cancers has been revealed using meta analyses studies of large tumor datasets <xref rid="iid392-bib-0119" ref-type="ref">119</xref>. In solid tumors, BST&#x02010;2 expression is elevated in head and neck cancer <xref rid="iid392-bib-0120" ref-type="ref">120</xref>, lung cancer <xref rid="iid392-bib-0121" ref-type="ref">121</xref>, breast cancer <xref rid="iid392-bib-0119" ref-type="ref">119</xref>, <xref rid="iid392-bib-0122" ref-type="ref">122</xref>, <xref rid="iid392-bib-0123" ref-type="ref">123</xref>, cervical cancer <xref rid="iid392-bib-0124" ref-type="ref">124</xref>, myelomas <xref rid="iid392-bib-0125" ref-type="ref">125</xref>, <xref rid="iid392-bib-0126" ref-type="ref">126</xref>, endometrial cancer <xref rid="iid392-bib-0127" ref-type="ref">127</xref>, and glioblastoma <xref rid="iid392-bib-0128" ref-type="ref">128</xref>. In addition, data from <ext-link ext-link-type="uri" xlink:href="http://proteinatlas.org">proteinatlas.org</ext-link> reveal that BST&#x02010;2 is overexpressed in colorectal cancer, ovarian cancer, thyroid cancer, and pancreatic cancer (<ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org/ENSG00000130303-BST2/cancer">http://www.proteinatlas.org/ENSG00000130303-BST2/cancer</ext-link>). The significance of elevated BST&#x02010;2 in various cancers is beginning to evolve. However, not all cancers have elevated BST&#x02010;2 <xref rid="iid392-bib-0119" ref-type="ref">119</xref> (Table <xref rid="iid392-tbl-0002" ref-type="table-wrap">2</xref>). Compared to normal tissues, BST&#x02010;2 expression in lung adenocarcinoma and thyroid cancer is unchanged <xref rid="iid392-bib-0119" ref-type="ref">119</xref> whereas levels of BST&#x02010;2 in lung squamous cell carcinoma, kidney papillary cell carcinoma, kidney chromophobe carcinoma, liver, and prostate cancer is significantly downregulated <xref rid="iid392-bib-0119" ref-type="ref">119</xref>. Thus, in some cancers, constitutive upregulation of BST&#x02010;2 expression and BST&#x02010;2 activity correlates with disease pathology in human and have been functionally demonstrated to cause disease in mouse models of breast cancer.</p><table-wrap id="iid392-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>BST&#x02010;2 mRNA profile in different cancers</p></caption><table frame="hsides" rules="groups"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><thead valign="bottom"><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Profile of BST&#x02010;2 transcript between normal and tumor tissue</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Cancer type</th><th align="center" valign="bottom" rowspan="1" colspan="1">Unchanged</th><th align="center" valign="bottom" rowspan="1" colspan="1">Suppressed</th><th align="center" valign="bottom" rowspan="1" colspan="1">Elevated</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Lung adenocarcinoma</td><td align="center" rowspan="1" colspan="1">X</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Thyroid cancer</td><td align="center" rowspan="1" colspan="1">X</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lung squamous cell carcinoma</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Kidney papillary cell carcinoma</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Kidney chromophobe carcinoma</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Liver cancer</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Head and neck cancer</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">Lung cancer</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">Cervical cancer</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">Myelomas</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">Endometrial cancer</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td></tr><tr><td align="left" rowspan="1" colspan="1">Glioblastoma</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">X</td></tr></tbody></table><permissions><copyright-holder>&#x000a9; 2015 The Authors. Immunity, Inflammation and Disease Published by John Wiley &#x00026; Sons Ltd.</copyright-holder></permissions></table-wrap><sec id="iid392-sec-0018"><title>Functional roles of BST&#x02010;2 in cancer</title><p>Correlation studies using meta analyses of various tumor datasets showed that BST&#x02010;2 levels are proportional to the aggressiveness of different cancers including breast <xref rid="iid392-bib-0123" ref-type="ref">123</xref>, <xref rid="iid392-bib-0129" ref-type="ref">129</xref>, brain <xref rid="iid392-bib-0128" ref-type="ref">128</xref>, and oral cavity cancers <xref rid="iid392-bib-0120" ref-type="ref">120</xref>. In vitro, overexpression of BST&#x02010;2 in breast cancer cells enhanced cell migration, invasion, proliferation, and anchorage&#x02010;independent growth <xref rid="iid392-bib-0119" ref-type="ref">119</xref>, <xref rid="iid392-bib-0123" ref-type="ref">123</xref>, <xref rid="iid392-bib-0129" ref-type="ref">129</xref> whereas BST&#x02010;2 suppression results in reduced migration, invasion, anchorage&#x02010;independent growth but not cell proliferation <xref rid="iid392-bib-0045" ref-type="ref">45</xref>. In contrast to the effects of BST&#x02010;2 on breast cancer cells, in HT1080 (human fibrosarcoma epithelial cell line) and MDCK (canine kidney cells) cells, overexpression of BST&#x02010;2 decreased cell growth and migration due to reduced matrix metalloproteinase 2 (MMP&#x02010;2) activity <xref rid="iid392-bib-0130" ref-type="ref">130</xref>. Differences in BST&#x02010;2 effect on cancer cells could be due to the cell types used.</p><p>Despite the contradictory effects of BST&#x02010;2 in various cancers in vitro, Sayeed et. al., showed that elevated BST&#x02010;2 expression renders high grade breast cancer cells resistant to pro&#x02010;apoptotic drug (tamoxifen and staurosporine) treatment <xref rid="iid392-bib-0123" ref-type="ref">123</xref>. These data point to a functional role of BST&#x02010;2 in breast cancer both in the promotion/progression of breast cancer and its resistance to treatments. The Okeoma group used two syngeneic metastatic breast cancer models to demonstrate that BST&#x02010;2 plays a functional role in driving breast cancer in vivo <xref rid="iid392-bib-0122" ref-type="ref">122</xref>. Mice injected with metastatic breast cancer cell lines in which BST&#x02010;2 was downregulated showed decreased tumor growth at the primary and metastatic sites with resultant increase in survival of tumor bearing mice <xref rid="iid392-bib-0131" ref-type="ref">131</xref>. Although elevated BST&#x02010;2 expression enhanced tumor growth, there was no correlation between tumor growth at the primary and secondary sites; suggesting that BST&#x02010;2 effects on primary tumor growth are independent of its effects on metastatic tumor growth <xref rid="iid392-bib-0131" ref-type="ref">131</xref>.</p><p>The molecular mechanism by which BST&#x02010;2 promotes cancer remains to be determined. BST&#x02010;2 dimerization mediated by three cysteine residues located in the ectodomain is required for viral lipid membrane association with the host membrane. It is possible that BST&#x02010;2 uses this mechanism to &#x0201c;tether&#x0201d; cells to each other thereby promoting cell&#x02010;to&#x02010;cell interaction. Indeed, BST&#x02010;2 mediates adhesion of monocytes to endothelial cells <xref rid="iid392-bib-0132" ref-type="ref">132</xref>. The ability of BST&#x02010;2 to mediate adhesion was also demonstrated in breast cancer cells where suppression of BST&#x02010;2 significantly decreased cell&#x02010;to&#x02010;cell interaction as well as cell to extracellular matrix (ECM) interactions with collagen and fibronectin <xref rid="iid392-bib-0122" ref-type="ref">122</xref> (Fig. <xref rid="iid392-fig-0003" ref-type="fig">3</xref>, Box 1). The significance of BST&#x02010;2 to facilitate cell adhesion is under investigation. However, cell&#x02013;cell interactions between cancer cells and stromal cells or between cancer cells and ECM facilitate tumor growth at the primary and distal sites. The ubiquitous presence of BST&#x02010;2 in breast cancer cells and the enhanced cell adhesion of these cells suggest effect on tumor growth. Mahauad&#x02010;Fernandez et al., 2014 revealed that cancer cells with suppressed BST&#x02010;2 are defective in the formation of primary and metastatic tumors and that growth of BST&#x02010;2&#x02010;suppressed cells in agar (colonies) was diminished compared to high BST&#x02010;2 expressing cells <xref rid="iid392-bib-0122" ref-type="ref">122</xref>. In colony formation assay, tumor colonies result from the growth of single cells independent of attachment to plastic. However, cells have to associate with each other and BST&#x02010;2 appears to promote this association.</p><fig fig-type="Figure" xml:lang="en" id="iid392-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>BST&#x02010;2 in cancer: BST&#x02010;2 is overexpressed in several cancers including breast cancer. In a murine breast cancer model, BST&#x02010;2 was found to enhance the adhesion of cancer cells to fibroblasts and may also mediate the adhesion between cancer cells and between other cells found in the tumor microenvironment, such as endothelial cells or macrophages. This ability of BST&#x02010;2 may be involved in primary and secondary (distal) tumor formation (Box 1). Once a primary tumor forms, some cells acquire an invasive phenotype a step that may also involve BST&#x02010;2 via its ability to induce NF&#x02010;&#x003ba;B activation. Through its YXY motif, BST&#x02010;2 may induce the expression of metastatic factors, such as CXCR4 (C&#x02010;X&#x02010;C chemokine receptor type 4) and its ligand CXCL12 (C&#x02010;X&#x02010;C motif chemokine 12) or invasive factors such as matrix metalloproteinases (MMPs) or proteases that degrade extracellular matrix (ECM) proteins (Box 2). Following invasion through the ECM, cancer cells metastasize to distal sites after intravasation. BST&#x02010;2 is involved in monocyte adhesion to endothelial cells and may also allow cancer cell adhesion to endothelial cells prior to reaching blood vessels (Box 3). Metastatic cells must survive in circulation and become resistant to anoikis. Thus, BST&#x02010;2 may render cancer cells resistance to anoikis and may enhance cell clustering and cell survival in circulation. To colonize secondary sites, cancer cells must adhere to ECM. BST&#x02010;2 mediates cancer cell adhesion to fibronectin and collagen, two well&#x02010;known ECM proteins. BST&#x02010;2 also enhances cancer cell to cancer cell adhesion. These processes may promote survival by associating cancer cells to each other (Box 4). The increase in tumor growth and metastasis due to high BST&#x02010;2 levels results in decreased host survival (Box 5). The gray box to the right is the key.</p></caption><graphic id="nlm-graphic-7" xlink:href="IID3-4-04-g004"><permissions><copyright-holder>Copyright &#x000a9; 2015 Wiley Periodicals, Inc.</copyright-holder></permissions></graphic></fig><p>Another plausible mechanism by which BST&#x02010;2 may promote cancer development and progression is through activating NF&#x02010;&#x003ba;B&#x02010;mediated signal transduction pathways. We posit that BST&#x02010;2&#x02010;mediated cell&#x02010;to&#x02010;cell adhesion (that mimics BST&#x02010;2&#x02010;mediated virus tethering) is the mechanism of NF&#x02010;&#x003ba;B activation. BST&#x02010;2&#x02010;mediated activation of NF&#x02010;&#x003ba;B <xref rid="iid392-bib-0014" ref-type="ref">14</xref>, <xref rid="iid392-bib-0015" ref-type="ref">15</xref>, <xref rid="iid392-bib-0016" ref-type="ref">16</xref>, <xref rid="iid392-bib-0017" ref-type="ref">17</xref> may result in the induction of several factors involved in cancer cell migration and invasion including matrix metalloproteases, chemokines, or growth factors (Fig. <xref rid="iid392-fig-0003" ref-type="fig">3</xref>, Box 2), as well as in intravasation of tumor cells (Fig. <xref rid="iid392-fig-0003" ref-type="fig">3</xref>, Box 3), and resistance to anoikis <xref rid="iid392-bib-0133" ref-type="ref">133</xref>, <xref rid="iid392-bib-0134" ref-type="ref">134</xref> (Fig. <xref rid="iid392-fig-0003" ref-type="fig">3</xref>, Box 4). Anoikis is a detachment&#x02010;induced cell death and normal adherent cells with low BST&#x02010;2 undergo anoikis in the absence of anchor. The ability of BST&#x02010;2&#x02010;expressing cancer cells to grow and form colonies independent of anchor positively correlates with anoikis resistance. In this case, the outcome of elevated BST&#x02010;2 in breast cancer is poor survival (Fig. <xref rid="iid392-fig-0003" ref-type="fig">3</xref>, Box 5) as revealed by meta analyses of large human datasets <xref rid="iid392-bib-0123" ref-type="ref">123</xref>, <xref rid="iid392-bib-0131" ref-type="ref">131</xref> and experimental evidence in mouse models of breast cancer <xref rid="iid392-bib-0131" ref-type="ref">131</xref>.</p></sec></sec><sec id="iid392-sec-0019"><title>BST&#x02010;2 as a Therapeutic Target for Cancer Immunotherapy</title><p>Multiple myeloma (MM) is a type of blood cancer in which plasma cells become malignant. MM is characterized by elevated BST&#x02010;2 (HM1.24) expression in malignant plasma cells and in MM cancer stem cells (CSC). Monoclonal antibodies (mAb) against BST&#x02010;2 have been used for radioimmunodetection of human MM xenografts <xref rid="iid392-bib-0135" ref-type="ref">135</xref>. These antibodies induced antibody&#x02010;mediated cellular cytotoxicity and cytotoxic T cell (CTL) responses against MM cells <xref rid="iid392-bib-0136" ref-type="ref">136</xref>, resulting in MM CSC elimination <xref rid="iid392-bib-0137" ref-type="ref">137</xref>. Similar to MM, anti&#x02010;BST&#x02010;2 mAb was used as treatment for lung cancer. The treatment elicited ADCC and other complement&#x02010;dependent cytotoxicity (CDC) in lung cancer cells <xref rid="iid392-bib-0121" ref-type="ref">121</xref>, <xref rid="iid392-bib-0125" ref-type="ref">125</xref>, <xref rid="iid392-bib-0138" ref-type="ref">138</xref>. The anti&#x02010;BST&#x02010;2 mAb&#x02010;mediated ADCC effect on lung cancer cells was enhanced following treatment with IFN&#x003b2; and IFN&#x003b3; <xref rid="iid392-bib-0121" ref-type="ref">121</xref>. In a renal cell carcinoma xenograft model, IFN&#x02010;induced BST&#x02010;2 enhanced anti&#x02010;BST&#x02010;2 mAb&#x02010;mediated ADCC <xref rid="iid392-bib-0139" ref-type="ref">139</xref>. Additionally, mAb against BST&#x02010;2 induced ADCC and CDC in BST&#x02010;2 positive endometrial cancer cells in vitro and tumor growth inhibition was achieved in a xenograft model <xref rid="iid392-bib-0127" ref-type="ref">127</xref>.</p><p>Although some success with antibody against BST&#x02010;2 on some cancers was achieved, an experiment with orthotopic mouse brain tumor model (using GL261 brain tumor cells) was unsuccessful <xref rid="iid392-bib-0128" ref-type="ref">128</xref>. Even though the levels or BST&#x02010;2 were high in these brain tumor cells, there was no therapeutic significance following RNAi&#x02010;mediated downregulation of BST&#x02010;2 or pretreatment of cells with anti&#x02010;BST&#x02010;2 mAb <xref rid="iid392-bib-0128" ref-type="ref">128</xref>.</p><p>In virus infected cells, antibody against BST&#x02010;2 enhances virus release by redistributing and removing BST&#x02010;2 from the sites of virus budding <xref rid="iid392-bib-0140" ref-type="ref">140</xref>. It is possible that antibody cross&#x02010;linking with BST&#x02010;2 may change BST&#x02010;2 localization and enhance BST&#x02010;2&#x02010;mediated signaling <xref rid="iid392-bib-0014" ref-type="ref">14</xref>, <xref rid="iid392-bib-0140" ref-type="ref">140</xref>. With these in mind, it remains to be determined whether anti&#x02010;BST&#x02010;2 mAb&#x02010;based immunotherapy has a long term therapeutic effect on the cancers discussed above as well as on other solid cancers. As at the time of this review, no other BST&#x02010;2&#x02010;based therapeutic attempts have been made.</p></sec><sec id="iid392-sec-0020"><title>Other Roles That BST&#x02010;2/Tetherin Plays</title><p>Various other functions have been associated with BST&#x02010;2. BST&#x02010;2 plays a role in regulating the development of regulatory T (Treg) cells in the thymus <xref rid="iid392-bib-0141" ref-type="ref">141</xref>. BST&#x02010;2 also regulates autophagy by interacting with the autophagy/mitophagy suppressor LRPPRC and preventing LRPPRC from binding to Beclin 1 and the anti&#x02010;apoptotic protein Bcl&#x02010;2. This interaction abrogates binding of Beclin 1 to PI3KCIII, thus initiating autophagy <xref rid="iid392-bib-0142" ref-type="ref">142</xref>. A caveat is that these experiments were performed in transformed HeLa and 293T cells. Whether BST&#x02010;2 induces autophagy in immune cells that are relevant to most virus infection is yet to be determined. BST&#x02010;2 in guinea pig is necessary for the maintenance of Golgi integrity and function <xref rid="iid392-bib-0143" ref-type="ref">143</xref>. Moreover, BST&#x02010;2 is important for the organization of membrane micro&#x02010;domains. BST&#x02010;2 plays a role in organization of lipids in the plasma membrane and in the distribution of proteins that are confined to lipid rafts <xref rid="iid392-bib-0144" ref-type="ref">144</xref>. All domains of BST&#x02010;2 are important for this function as opposed to other functions of BST&#x02010;2 such as virus tethering in which the cytoplasmic tail of BST&#x02010;2 is dispensable. This suggests that BST&#x02010;2's ability to homo&#x02010;dimerize or tetramerize <xref rid="iid392-bib-0087" ref-type="ref">87</xref> and its ability to interact with the actin cytoskeleton <xref rid="iid392-bib-0047" ref-type="ref">47</xref> are essential for its micro&#x02010;domain organizing function.</p></sec><sec id="iid392-sec-0021"><title>BST&#x02010;2 Regulation</title><sec id="iid392-sec-0022"><title>Interferon (IFN)&#x02010;mediated BST&#x02010;2 regulation</title><p>IFNs play important roles in host defense against viral infection by inducing the expression of a diverse range of antiviral factors, including BST&#x02010;2. In various cells, BST&#x02010;2 is induced by type I IFN (IFN&#x003b1; and IFN&#x003b2;), type II IFN (IFN&#x003b3;), and type III IFN (IFN&#x003bb;) <xref rid="iid392-bib-0038" ref-type="ref">38</xref>, <xref rid="iid392-bib-0145" ref-type="ref">145</xref>. Induction of BST&#x02010;2 by IFNs occur in a broad range of cell lines, primary cells, and in vivo <xref rid="iid392-bib-0004" ref-type="ref">4</xref>, <xref rid="iid392-bib-0008" ref-type="ref">8</xref>, <xref rid="iid392-bib-0028" ref-type="ref">28</xref>, <xref rid="iid392-bib-0038" ref-type="ref">38</xref>, <xref rid="iid392-bib-0045" ref-type="ref">45</xref>. The effect of IFNs is cell type dependent. In some cells, IFN&#x003b1; is a better inducer of BST&#x02010;2. However, in hepatocytes, IFN&#x003b3; and IFN&#x003bb; are more potent inducers of BST&#x02010;2 <xref rid="iid392-bib-0038" ref-type="ref">38</xref>. IFNs from different species are highly conserved among vertebrates <xref rid="iid392-bib-0146" ref-type="ref">146</xref>. IFNs have cross&#x02010;species activity on BST&#x02010;2 and possibly other IFN&#x02010;inducible genes. BST&#x02010;2 from one species is responsive to IFNs from another species <xref rid="iid392-bib-0147" ref-type="ref">147</xref>, <xref rid="iid392-bib-0148" ref-type="ref">148</xref>, suggesting that induction of BST&#x02010;2 by IFNs may not be an evolutionarily acquired trait. Types I, II, and III IFNs exhibit similar biological and functional activities although they bind to different receptors. Thus, the induction of BST&#x02010;2 by all three types of IFNs indicates that multiple signaling pathways regulate BST&#x02010;2 expression at least in human hepatocytes <xref rid="iid392-bib-0038" ref-type="ref">38</xref>. Indeed, BST&#x02010;2 promoter contains binding elements for STAT1 and STAT3 <xref rid="iid392-bib-0021" ref-type="ref">21</xref>, <xref rid="iid392-bib-0149" ref-type="ref">149</xref>. Other sequences present in the promoter region of BST&#x02010;2 include that of NF&#x02010;&#x003ba;B binding sites <xref rid="iid392-bib-0145" ref-type="ref">145</xref>, AP&#x02010;2, and GATA1 <xref rid="iid392-bib-0021" ref-type="ref">21</xref>, <xref rid="iid392-bib-0149" ref-type="ref">149</xref>, as well as IL&#x02010;6&#x02010;responsive elements <xref rid="iid392-bib-0021" ref-type="ref">21</xref>. IFN&#x02010;mediated signaling has been used to induce BST&#x02010;2 to prevent viral replication and release, as well as an &#x0201c;adjuvant&#x0201d; to enhance the therapeutic potential of anti&#x02010;BST&#x02010;2 antibodies <xref rid="iid392-bib-0038" ref-type="ref">38</xref>, <xref rid="iid392-bib-0121" ref-type="ref">121</xref>, <xref rid="iid392-bib-0139" ref-type="ref">139</xref>. Contrary to the induction of BST&#x02010;2 by IFN, it has been shown that BST&#x02010;2 regulates IFN&#x003b1; and IFN&#x003b3; during CHIKV infection <xref rid="iid392-bib-0045" ref-type="ref">45</xref> because loss of BST&#x02010;2 results in increased viremia and reduced expression of IFN&#x003b1;, IFN&#x003b3;, and other signaling molecules that are normally increased in CHIKV infected wild&#x02010;type mice <xref rid="iid392-bib-0045" ref-type="ref">45</xref>.</p><p>BST&#x02010;2 is a biological ligand for ILT7 <xref rid="iid392-bib-0150" ref-type="ref">150</xref>. Engagement of ILT7 by BST&#x02010;2 regulates innate immune functions of pDCs, especially suppression of IFN in an inflammatory environment <xref rid="iid392-bib-0150" ref-type="ref">150</xref> (Fig. <xref rid="iid392-fig-0002" ref-type="fig">2</xref> #7). However, in a tumor microenvironment where BST&#x02010;2 is constitutively elevated, BST&#x02010;2&#x02013;ILT7 interaction is predicted to suppress pDCs&#x02010;mediated normal IFN response to TLR ligands <xref rid="iid392-bib-0150" ref-type="ref">150</xref>. As the interaction between BST&#x02010;2 and ILT7 suppress pDCs&#x02010;mediated IFN responses required for deterring tumor growth <xref rid="iid392-bib-0151" ref-type="ref">151</xref>, <xref rid="iid392-bib-0152" ref-type="ref">152</xref>, it is tempting to speculate that elevated BST&#x02010;2 in tumors <xref rid="iid392-bib-0119" ref-type="ref">119</xref>, <xref rid="iid392-bib-0131" ref-type="ref">131</xref>, <xref rid="iid392-bib-0153" ref-type="ref">153</xref> and engagement of ILT7 by BST&#x02010;2 may contribute to tumor tolerance and progression.</p></sec><sec id="iid392-sec-0023"><title>Cytokine&#x02010;mediated BST&#x02010;2 regulation</title><p>BST&#x02010;2 expression is inducible in immune and cancer cells by cytokines. Treatment of monocytes and T cells with IL&#x02010;27 induces BST&#x02010;2 in an IFN signaling&#x02010;independent manner <xref rid="iid392-bib-0154" ref-type="ref">154</xref>. IL&#x02010;27 is a cytokine produced by myeloid cells <xref rid="iid392-bib-0155" ref-type="ref">155</xref> and functions to inhibit HIV&#x02010;1 replication in various cell types <xref rid="iid392-bib-0156" ref-type="ref">156</xref>, <xref rid="iid392-bib-0157" ref-type="ref">157</xref>, <xref rid="iid392-bib-0158" ref-type="ref">158</xref>. Whether BST&#x02010;2 is one of the effectors of anti&#x02010;HIV&#x02010;1 activity of IL&#x02010;27 is yet to be determined.</p><p>In cancer cells, BST&#x02010;2 expression is transcriptionally regulated in TGF&#x02010;&#x003b2; responsive breast cancer cells <xref rid="iid392-bib-0123" ref-type="ref">123</xref>. Treatment of low grade (grades 1 and 2) breast cancer cell lines with TGF&#x02010;&#x003b2; resulted in suppression of BST&#x02010;2 transcripts. In contrast, grade 3 cancer cell lines are unresponsive to TGF&#x02010;&#x003b2; signaling and BST&#x02010;2 expression is not inhibited. Reduction in BST&#x02010;2 expression upon TGF&#x02010;&#x003b2; treatment correlates with enhanced AP2 binding to the BST&#x02010;2 promoter <xref rid="iid392-bib-0123" ref-type="ref">123</xref>. AP2 is a transcription factor involved in repression of promoter sequences of at least one oncogene ERBB2 <xref rid="iid392-bib-0159" ref-type="ref">159</xref>. These findings suggest that in breast cancer cells, there is a progressive loss of TGF&#x02010;&#x003b2; signaling responsiveness that may result in aberrant BST&#x02010;2 overexpression.</p></sec></sec><sec id="iid392-sec-0024"><title>Induction of BST&#x02010;2 by Toll&#x02010;Like Receptors (TLRs)</title><p>TLR&#x02010;mediated signaling depends on conserved intracytoplasmic TIR domains. Functionally, TLRs recognize specific but conserved pathogenic components and have been established to play an essential role in the activation of innate immunity, including induction of antiviral factors, such as BST&#x02010;2 <xref rid="iid392-bib-0008" ref-type="ref">8</xref>. TLRs have been reported to regulate BST&#x02010;2 expression and function in different cell types and conditions as discussed below.</p><sec id="iid392-sec-0025"><title>TLR3</title><p>In human monocyte derived macrophages (MDM), TLR3 induces the expression of BST&#x02010;2 upon infection with HIV&#x02010;1. Signaling through TLR3 mediates restriction of virus infection and replication in MDMs <xref rid="iid392-bib-0160" ref-type="ref">160</xref>. This observation was made in macrophages derived from rhesus macaques where TLR3 induces the expression of BST&#x02010;2 and other restriction factors <xref rid="iid392-bib-0161" ref-type="ref">161</xref>, <xref rid="iid392-bib-0162" ref-type="ref">162</xref>. Although the elements of TLR3&#x02010;mediated induction of BST&#x02010;2 are yet to be determined, TLR3 induces BST&#x02010;2 expression in peripheral blood mononuclear cells (PBMCs) independent of IFN signaling during early immune responses <xref rid="iid392-bib-0145" ref-type="ref">145</xref> and treatment of PBMCs with poly(I&#x02009;&#x000b7;&#x02009;C), a TLR3 agonist increased BST&#x02010;2 levels <xref rid="iid392-bib-0162" ref-type="ref">162</xref>. BST&#x02010;2 promoter contains IRF binding elements and a single IRF binding site renders the BST&#x02010;2 promoter responsive to induction by IFN&#x003b1; <xref rid="iid392-bib-0145" ref-type="ref">145</xref>. Additionally, expression of IRF&#x02010;1 or virus&#x02010;activated forms of IRF&#x02010;3 and IRF&#x02010;7 activates BST&#x02010;2 promoter in the absence of type I IFN signaling <xref rid="iid392-bib-0145" ref-type="ref">145</xref>. Moreover, vesicular stomatitis virus induces BST&#x02010;2 in infected mouse embryonic fibroblasts in an IRF&#x02010;3/IRF&#x02010;7 dependent but type I IFN&#x02010;independent pathway <xref rid="iid392-bib-0145" ref-type="ref">145</xref>.</p></sec><sec id="iid392-sec-0026"><title>TLR4</title><p>Accumulating evidence indicates that TLR4 has both positive and negative regulatory roles on BST&#x02010;2. Ligand activation of TLR4 elicits various signaling pathways including the phosphatidylinositol 3&#x02010;kinase (PI3K)/serine/threonine&#x02010;specific protein kinase (AKT) pathway <xref rid="iid392-bib-0163" ref-type="ref">163</xref>, <xref rid="iid392-bib-0164" ref-type="ref">164</xref>. In macrophages, TLR4 activation induces BST&#x02010;2 expression through a pathway dependent on TRIF and IRF3 signaling <xref rid="iid392-bib-0008" ref-type="ref">8</xref>. Jones et al., found a positive regulatory role for TRIF and IRF3 because deletion of TRIF and IRF3 and pharmacological inhibition of the interactions of TLR4 with TIRAP and TRAM abrogating LPS&#x02010;mediated induction of BST&#x02010;2 in macrophages <xref rid="iid392-bib-0008" ref-type="ref">8</xref>. Surprisingly, the Myd88 and PI3K pathway results in suppression of BST&#x02010;2 expression in macrophages <xref rid="iid392-bib-0008" ref-type="ref">8</xref> (Fig. <xref rid="iid392-fig-0002" ref-type="fig">2</xref> #3). TLR4 and PI3K transcriptionally regulate BST&#x02010;2 expression given that blockade of BST&#x02010;2 transcription with actinomycin D (Act D) disrupts BST&#x02010;2 mRNA stability. These observations from Jones et al., highlight the ability of the host to tightly control BST&#x02010;2 in normal and inflammatory conditions, especially during viral infection. Indeed, during cis&#x02010;infection of HIV&#x02010;1 in the viral synapses between immature dendritic cells and CD4+ T cells, TLR4 induces BST&#x02010;2 expression and prevents HIV&#x02010;1 dissemination across viral synapses <xref rid="iid392-bib-0165" ref-type="ref">165</xref>.</p></sec><sec id="iid392-sec-0027"><title>TLR7/9</title><p>Mammalian TLR7 and TLR9 are endosomal sensors of microbial and self&#x02010;RNA or DNA, respectively <xref rid="iid392-bib-0166" ref-type="ref">166</xref>, <xref rid="iid392-bib-0167" ref-type="ref">167</xref>, <xref rid="iid392-bib-0168" ref-type="ref">168</xref>, <xref rid="iid392-bib-0169" ref-type="ref">169</xref>. Stimulation of TLR7 or TLR9 by nucleic acids in relevant cell types triggers signal transduction cascades that result in secretion of inflammatory molecules including type I IFNs <xref rid="iid392-bib-0169" ref-type="ref">169</xref>, <xref rid="iid392-bib-0170" ref-type="ref">170</xref>, <xref rid="iid392-bib-0171" ref-type="ref">171</xref>. In PBMCs and not CD4+ T cells, activation of TLR9 with the agonist ODN2216 (type A CpG DNA) induces BST&#x02010;2 expression <xref rid="iid392-bib-0162" ref-type="ref">162</xref>. The lack of BST&#x02010;2 induction in CD4+ T cells was attributed to absence of TLR9 expression <xref rid="iid392-bib-0162" ref-type="ref">162</xref>. On the other hand, the relationship between TLR7/9 and BST&#x02010;2 in pDCs is one of a negative regulation <xref rid="iid392-bib-0150" ref-type="ref">150</xref>, <xref rid="iid392-bib-0172" ref-type="ref">172</xref>, that may result in manifestation of diseases, such as lupus and cancer <xref rid="iid392-bib-0122" ref-type="ref">122</xref>, <xref rid="iid392-bib-0173" ref-type="ref">173</xref>.</p></sec></sec><sec id="iid392-sec-0028"><title>Epigenetic Regulation of BST&#x02010;2 Expression</title><p>Epigenetic regulation of gene expression is a stable modification in gene expression and function without alterations in DNA sequence. Recently, in silico analyses of the BST&#x02010;2 gene demonstrates that BST&#x02010;2 expression is epigenetically regulated and that dysregulation of BST&#x02010;2 epigenetic landscape may have pathological consequences <xref rid="iid392-bib-0119" ref-type="ref">119</xref>, <xref rid="iid392-bib-0173" ref-type="ref">173</xref>. BST2 expression is inversely proportional to the methylation status of CpGs located inside and in proximity to its promoter region in human breast tumors and in breast cancer cell lines <xref rid="iid392-bib-0119" ref-type="ref">119</xref>. Importantly, highly invasive cancer cells with elevated BST&#x02010;2 are hypomethylated while luminal breast cancer cells which are mostly noninvasive are low in BST&#x02010;2 and are hypermethylated <xref rid="iid392-bib-0119" ref-type="ref">119</xref>. This pattern of BST&#x02010;2 demethylation in breast cancer may be important for cancer cells to acquire an invasive potential. Regulation of BST&#x02010;2 expression by CpG methylation has been reported in other disease conditions. In lupus, an autoimmune disease <xref rid="iid392-bib-0173" ref-type="ref">173</xref> and cervical cancer <xref rid="iid392-bib-0124" ref-type="ref">124</xref>, BST&#x02010;2 is hypomethylated and BST&#x02010;2 expression is significantly elevated in comparison to control specimens.</p></sec><sec id="iid392-sec-0029"><title>BST&#x02010;2 Regulation by Non&#x02010;Coding RNAs</title><p>RNAseq analysis identified a long non&#x02010;protein&#x02010;coding RNAs named BISPR (BST2 IFN&#x02010;stimulated positive regulator) as a positive regulator of BST&#x02010;2 in IFN&#x003b1;2&#x02010;treated hepatocellular carcinoma (Huh7) cells. BISPR is expressed from same promoter as BST&#x02010;2 but on the opposite direction and its transcription precedes that of BST&#x02010;2 <xref rid="iid392-bib-0174" ref-type="ref">174</xref>, <xref rid="iid392-bib-0175" ref-type="ref">175</xref>. BISPR and BST&#x02010;2 are correlatively upregulated and post&#x02010;transcriptional inhibition of BISPR results in reductions in BST&#x02010;2 mRNA levels <xref rid="iid392-bib-0174" ref-type="ref">174</xref>. Mutant HCV, influenza, and VSV viruses that are able to activate IFN response induce BISPR and BST&#x02010;2 in infected cells, suggesting a functional role for BISPR <xref rid="iid392-bib-0174" ref-type="ref">174</xref>.</p></sec><sec id="iid392-sec-0030"><title>Regulation of BST&#x02010;2 by Oncogenic Viruses</title><p>Studies from the Ross Lab have been instrumental in deciphering the roles of restriction factors and other host proteins in Mouse mammary tumor virus (MMTV)&#x02010;induced mammary oncogenesis <xref rid="iid392-bib-0176" ref-type="ref">176</xref>, <xref rid="iid392-bib-0177" ref-type="ref">177</xref>, <xref rid="iid392-bib-0178" ref-type="ref">178</xref>, <xref rid="iid392-bib-0179" ref-type="ref">179</xref>, <xref rid="iid392-bib-0180" ref-type="ref">180</xref>. Sequences similar to MMTV are present in human breast tumors <xref rid="iid392-bib-0181" ref-type="ref">181</xref>, <xref rid="iid392-bib-0182" ref-type="ref">182</xref>, <xref rid="iid392-bib-0183" ref-type="ref">183</xref> and cultures of human breast cancer cells produce human mammary tumor virus (HMTV) with morphologic and molecular characteristics of MMTV and with 95% homology with MMTV <xref rid="iid392-bib-0184" ref-type="ref">184</xref>. MMTV promotes breast tumor formation following oncogene activation by integrated provirus into breast epithelial cells <xref rid="iid392-bib-0185" ref-type="ref">185</xref> and inhibition of epithelial cell apoptosis <xref rid="iid392-bib-0186" ref-type="ref">186</xref>. Similar to the observation in human breast tumors, levels of BST&#x02010;2 in MMTV&#x02010;induced tumors was significantly elevated <xref rid="iid392-bib-0153" ref-type="ref">153</xref>.</p><p>During MMTV infection, BST&#x02010;2 restricts MMTV release and replication <xref rid="iid392-bib-0004" ref-type="ref">4</xref>, but once infection is established, MMTV dysregulates BST&#x02010;2 expression in a tissue&#x02010;specific manner <xref rid="iid392-bib-0153" ref-type="ref">153</xref>. In immune cells of MMTV infected mice, BST&#x02010;2 expression is first upregulated and then significantly downregulated. Although the initial increase in immune cells BST&#x02010;2 levels may trigger immune response to infection, the down regulation of BST&#x02010;2 in these cells may be a mechanism of optimal virus release for efficient infection of distal targets such as the mammary gland <xref rid="iid392-bib-0153" ref-type="ref">153</xref>. Surprisingly, BST&#x02010;2 expression is elevated in mammary and tumor tissues <xref rid="iid392-bib-0153" ref-type="ref">153</xref>. Elevated tumor&#x02010;associated BST&#x02010;2 in mice <xref rid="iid392-bib-0153" ref-type="ref">153</xref> is in agreement with high BST&#x02010;2 levels in human breast tumors <xref rid="iid392-bib-0119" ref-type="ref">119</xref>, <xref rid="iid392-bib-0131" ref-type="ref">131</xref>. Thus, it is possible that MMTV infection of mammary epithelial cells leads to accumulation of epigenetic aberrations that change BST&#x02010;2 levels and affect the activity of cancer&#x02010;promoting pathways.</p><p>MMTV&#x02010;mediated dysregulation of BST&#x02010;2 in murine mammary tissues is not attributable to IFN since levels of IFN&#x003b1; and IFN&#x003b3; negatively correlate with BST&#x02010;2 <xref rid="iid392-bib-0153" ref-type="ref">153</xref>. Nonetheless, soluble factors released by mammary tumor cells suppress IFN&#x003b1; and IFN&#x003b3; but induce BST&#x02010;2 expression <xref rid="iid392-bib-0153" ref-type="ref">153</xref>. These data indicate that overexpression of BST&#x02010;2 in carcinoma tissues, at least in this infective model cannot be attributed to IFNs but to factors that upregulates BST&#x02010;2 once oncogenesis is initiated.</p></sec><sec id="iid392-sec-0031"><title>Conclusions and Perspectives</title><p>Emerging experimental and clinical evidence suggest that BST&#x02010;2 as a host restriction factor is a moonlight protein (Fig. <xref rid="iid392-fig-0004" ref-type="fig">4</xref>) that is crucial for regulation of cell signaling and maintaining host innate and cellular homeostasis. However, fundamental questions remain relating to how BST&#x02010;2 orchestrates multifunctional roles in protection against and manifestation of disease. Although some structural features of BST&#x02010;2 are shared between these roles, differences abound. For example, the virus tethering function of BST&#x02010;2 may be comparable to its cancer promoting function in cell to cell adhesion but different BST&#x02010;2&#x02010;induced signals may be required for these two processes. Given that BST&#x02010;2 tethers lipid membrane containing viruses and mediates cell to cell adhesion <xref rid="iid392-bib-0131" ref-type="ref">131</xref>, <xref rid="iid392-bib-0132" ref-type="ref">132</xref> and to ECM proteins <xref rid="iid392-bib-0131" ref-type="ref">131</xref>, it remains to be determined whether BST&#x02010;2 can tether other membrane&#x02010;containing pathogens and membrane&#x02010;containing vesicles, such as bacteria and exosomes. Whether the anti&#x02010;viral and pro&#x02010;cancer functions of BST&#x02010;2 reflect cell or tissue specific differences in levels of BST&#x02010;2 is unclear. However, variability in BST&#x02010;2 levels has functional importance as high BST&#x02010;2 expressing cells are poor producers of cell&#x02010;free virus <xref rid="iid392-bib-0006" ref-type="ref">6</xref>, <xref rid="iid392-bib-0045" ref-type="ref">45</xref> whereas high BST&#x02010;2 expressing breast cancer cells are highly invasive both in ex vivo invasion and in vivo animal models <xref rid="iid392-bib-0122" ref-type="ref">122</xref>.</p><fig fig-type="Figure" xml:lang="en" id="iid392-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The &#x0201c;moonlight&#x0201d; protein BST&#x02010;2: BST&#x02010;2 is a protein with several functions that spans the fields of virology, immunology, and cancer biology. The most defining antiviral function of BST&#x02010;2 is tethering of enveloped viruses to the surface of infected cells. Virus tethering results in stimulation of the immune system, prevention, or enhancement of viral replication and spread, as well as initiation of ADCC (pink panel). Viruses from different families have the capacity to antagonize BST&#x02010;2 by means of their accessory proteins. These include HIV&#x02010;1 Vpu, HIV&#x02010;2 Env, SIV Nef, and HHV&#x02010;8 K5 or through their structural and nonstructural proteins, such as Ebola GP, CHIKV nsP1, and HSV&#x02010;2 glycoproteins (yellow panel, left). The mechanisms used by various viral proteins to neutralize BST&#x02010;2 effect include, but not limited to degradation via the proteasomal and lysosomal pathways, removal from lipid rafts, inhibition of anterograde transport, intracellular trapping (in endosomes, ER and Golgi) and unknown mechanisms, all of which result in reduced BST&#x02010;2 surface levels (yellow panel, right). Furthermore, BST&#x02010;2 plays a cell type dependent role in Golgi maintenance, downregulation of viral protein expression, organization of membrane microdomains, regulation of Treg development, and induction of autophagy (light green panel). The role of BST&#x02010;2 in promoting cell&#x02010;to&#x02010;cell interaction, cell&#x02010;to&#x02010;ECM interaction, and enhancement of disease is highlighted. Through significant enhancement of cellular behaviors, BST&#x02010;2 promotes primary tumor growth and metastasis resulting in poor clinical outcomes (gray panel). Therapeutically, BST&#x02010;2 ADCC function has been exploited in the treatment of lung cancer, multiple myeloma, renal cell carcinoma, and endometrial cancer. Anti&#x02010;HM1.24 treatment of astrocytoma was not of therapeutic significance. This treatment may be useful for other high BST&#x02010;2 expressing cancers (dark blue panel). Ligands, such as IFNs (interferons) and ILs (interleukins) or receptors including IFNR, nucleic acid&#x02010;sensing pattern recognition receptors RIG&#x02010;I (retinoic acid&#x02010;inducible gene 1), and TLRs (toll&#x02010;like receptors) regulate BST&#x02010;2. A long non&#x02010;coding RNA named BST&#x02010;2 IFN&#x02010;stimulated positive regulator (BISPR) was found to induce the expression of BST&#x02010;2. In cancer, BST&#x02010;2 expression is epigenetically regulated by hypomethylation of specific CpGs, by TGF&#x02010;&#x003b2; signaling, and by yet to identified mechanisms during viral carcinogenesis (unknown).</p></caption><graphic id="nlm-graphic-9" xlink:href="IID3-4-04-g005"><permissions><copyright-holder>Copyright &#x000a9; 2015 Wiley Periodicals, Inc.</copyright-holder></permissions></graphic></fig><p>Indeed, the role of BST&#x02010;2 in viral pathogenesis, especially HIV&#x02010;1 is still unknown as most HIV&#x02010;1 experiments have been performed in cultured cells. However, using patient&#x02010;derived specimens, it was shown that pandemic HIV&#x02010;1 group M express a Vpu variant that antagonizes BST&#x02010;2 and CD4 whereas Vpu from non&#x02010;pandemic HIV&#x02010;1 strains does not antagonize BST&#x02010;2 <xref rid="iid392-bib-0187" ref-type="ref">187</xref>. Additionally, the neutralizing effect of BST&#x02010;2 by Vpu is not absolute in HIV&#x02010;1 infected patients <xref rid="iid392-bib-0162" ref-type="ref">162</xref> and BST&#x02010;2 has developed an immune sensing function for HIV&#x02010;1 clearance in vivo <xref rid="iid392-bib-0041" ref-type="ref">41</xref>. These data point to the Vpu&#x02010;BST&#x02010;2 antagonistic interaction as a significant determinant of the ability of either HIV&#x02010;1 to promote its spread or of the host to restrict the virus.</p><p>In breast cancer, patients bearing high BST&#x02010;2&#x02010;expressing tumors have poor survival compared to patients bearing low BST&#x02010;2&#x02010;expressing tumors. Corroboration of this observation in mouse model of breast cancer <xref rid="iid392-bib-0131" ref-type="ref">131</xref> demonstrates that pathological BST&#x02010;2 upregulation in tumors may by itself be sufficient to cause or predict clinical disease, and that inhibiting BST&#x02010;2 activity in tumor cells is sufficient to produce good clinical outcome.</p><p>The ability of BST&#x02010;2 to inhibit virus infection and promote carcinogenesis highlights the need to determine whether the antiviral or protumor function of BST&#x02010;2 will dominate in the pathogenesis of oncoviruses or viruses that activate cellular oncogene expression. For example, BST&#x02010;2 expression restricts MMTV release and inhibits MMTV replication <xref rid="iid392-bib-0004" ref-type="ref">4</xref>. However, chronic MMTV infection down&#x02010;regulates BST&#x02010;2 in hematopoietic cells but upregulates BST&#x02010;2 in mammary gland and tumor tissues <xref rid="iid392-bib-0153" ref-type="ref">153</xref>. Perhaps, MMTV&#x02010;mediated BST&#x02010;2 induction and repression in the same host may lead to aberrant BST&#x02010;2 regulation, triggering breast oncogenesis. Whether MMTV&#x02010;mediated BST&#x02010;2 dysregulation is triggered by viral particles or by host responses to MMTV infection is unknown. The tethering and antiviral functions of BST&#x02010;2 are intact in transformed breast epithelial cells <xref rid="iid392-bib-0004" ref-type="ref">4</xref>, so is the protumor role of BST&#x02010;2 in transformed epithelial cells <xref rid="iid392-bib-0131" ref-type="ref">131</xref>. BST&#x02010;2 contains several motifs on its N&#x02010;terminal cytoplasmic tail that may be involved in the activation of multiple kinases thereby expanding the signaling capacity of BST&#x02010;2 to several intracellular pathways that may impact the way cells respond to viral infections and cancer. Also, some motifs on the BST&#x02010;2 cytoplasmic tail may be phosphorylated increasing the complexity and breadth of BST&#x02010;2 than previously thought.</p><p>The involvement of BST&#x02010;2 in viral infection, cancer, and lupus might reflect variable engagement of the host innate and adaptive immune systems regulation and dysregulation under different conditions. The findings that BST&#x02010;2 is epigenetically regulated in cancer and autoimmune diseases indicate the possibility of yet&#x02010;to&#x02010;be discovered BST&#x02010;2&#x02010;related biological pathways of importance in the context of human disease and treatment. Identification of the cellular triggers that regulate BST&#x02010;2 expression and activity in patients infected with BST&#x02010;2&#x02010;susceptible viruses or in patients bearing BST&#x02010;2&#x02010;dependent cancers is of fundamental importance. Evaluation of these triggers and identification of their targets will provide the much needed tools for therapeutic manipulation of BST&#x02010;2 and BST&#x02010;2 signal transduction pathways. Considering the complexity of BST&#x02010;2 expression and its functions, we predict the identification of more diseases in which constitutive or induced BST&#x02010;2 expression or signaling will control, thus broadening the roles of BST&#x02010;2 in protection against or manifestation of disease.</p></sec><sec id="iid392-sec-0033"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="iid392-sec-0032"><title>Acknowledgments</title><p>Our sincere apologies to our colleagues whose work may have been inadvertently omitted in this review. We thank Bryson Okeoma of the University of Iowa for providing constructive criticisms.</p></ack><ref-list id="iid392-bibl-0001" content-type="cited-references"><title>References</title><ref id="iid392-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="iid392-cit-0001">
<string-name>
<surname>Goto</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<given-names>S. J.</given-names>
<surname>Kennel</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Abe</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Takishita</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Kosaka</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Solomon</surname>
</string-name>, and 
<string-name>
<given-names>S.</given-names>
<surname>Saito</surname>
</string-name>. 
<year>1994</year>
<article-title>A novel membrane antigen selectively expressed on terminally differentiated human B cells</article-title>. 
<source>Blood</source>
<volume>84</volume>:<fpage>1922</fpage>&#x02013;<lpage>1930</lpage>.
<pub-id pub-id-type="pmid">8080996</pub-id></mixed-citation></ref><ref id="iid392-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="iid392-cit-0002">
<string-name>
<surname>Swiecki</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Gilfillan</surname>
</string-name>, 
<string-name>
<given-names>D. J.</given-names>
<surname>Lenschow</surname>
</string-name>, and 
<string-name>
<given-names>M.</given-names>
<surname>Colonna</surname>
</string-name>. 
<year>2012</year>
<article-title>Cutting edge: paradoxical roles of BST2/tetherin in promoting type I IFN response and viral infection</article-title>. 
<source>J. Immunol</source>. 
<volume>188</volume>:<fpage>2488</fpage>&#x02013;<lpage>2492</lpage>.
<pub-id pub-id-type="pmid">22327075</pub-id></mixed-citation></ref><ref id="iid392-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="iid392-cit-0003">
<string-name>
<surname>Liberatore</surname>, <given-names>R. A.</given-names>
</string-name>, and 
<string-name>
<given-names>P. D.</given-names>
<surname>Bieniasz</surname>
</string-name>. 
<year>2011</year>
<article-title>Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo</article-title>. 
<source>Proc. Natl. Acad. Sci. USA</source>
<volume>108</volume>:<fpage>18097</fpage>&#x02013;<lpage>18101</lpage>.
<pub-id pub-id-type="pmid">22025715</pub-id></mixed-citation></ref><ref id="iid392-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="iid392-cit-0004">
<string-name>
<surname>Jones</surname>, <given-names>P. H.</given-names>
</string-name>, 
<string-name>
<given-names>H. V.</given-names>
<surname>Mehta</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Maric</surname>
</string-name>, 
<string-name>
<given-names>R. J.</given-names>
<surname>Roller</surname>
</string-name>, and 
<string-name>
<given-names>C. M.</given-names>
<surname>Okeoma</surname>
</string-name>. 
<year>2012</year>
<article-title>Bone marrow stromal cell antigen 2 (BST&#x02010;2) restricts mouse mammary tumor virus (MMTV) replication in vivo</article-title>. 
<source>Retrovirology</source>
<volume>9</volume>:<fpage>10</fpage>.
<pub-id pub-id-type="pmid">22284121</pub-id></mixed-citation></ref><ref id="iid392-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="iid392-cit-0005">
<string-name>
<surname>Erikson</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Adam</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Schmidt</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Lehmann&#x02010;Koch</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Over</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Goffinet</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Harter</surname>
</string-name>, 
<string-name>
<given-names>I.</given-names>
<surname>Bekeredjian&#x02010;Ding</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Sertel</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Lasitschka</surname>
</string-name>, et al. 
<year>2011</year>
<article-title>In vivo expression profile of the antiviral restriction factor and tumor&#x02010;targeting antigen CD317/BST&#x02010;2/HM1. 24/tetherin in humans</article-title>. 
<source>Proc. Natl. Acad. Sci. USA</source>
<volume>108</volume>:<fpage>13688</fpage>&#x02013;<lpage>13693</lpage>.
<pub-id pub-id-type="pmid">21808013</pub-id></mixed-citation></ref><ref id="iid392-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="iid392-cit-0006">
<string-name>
<surname>Van Damme</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Goff</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Katsura</surname>
</string-name>, 
<string-name>
<given-names>R. L.</given-names>
<surname>Jorgenson</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Mitchell</surname>
</string-name>, 
<string-name>
<given-names>M. C.</given-names>
<surname>Johnson</surname>
</string-name>, 
<string-name>
<given-names>E. B.</given-names>
<surname>Stephens</surname>
</string-name>, and 
<string-name>
<given-names>J.</given-names>
<surname>Guatelli</surname>
</string-name>. 
<year>2008</year>
<article-title>The interferon&#x02010;induced protein BST&#x02010;2 restricts HIV&#x02010;1 release and is downregulated from the cell surface by the viral Vpu protein</article-title>. 
<source>Cell Host Microbe</source>. 
<volume>3</volume>:<fpage>245</fpage>&#x02013;<lpage>252</lpage>.
<pub-id pub-id-type="pmid">18342597</pub-id></mixed-citation></ref><ref id="iid392-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="iid392-cit-0007">
<string-name>
<surname>Neil</surname>, <given-names>S. J.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Zang</surname>
</string-name>, and 
<string-name>
<given-names>P. D.</given-names>
<surname>Bieniasz</surname>
</string-name>. 
<year>2008</year>
<article-title>Tetherin inhibits retrovirus release and is antagonized by HIV&#x02010;1 Vpu</article-title>. 
<source>Nature</source>
<volume>451</volume>:<fpage>425</fpage>&#x02013;<lpage>430</lpage>.
<pub-id pub-id-type="pmid">18200009</pub-id></mixed-citation></ref><ref id="iid392-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="iid392-cit-0008">
<string-name>
<surname>Jones</surname>, <given-names>P. H.</given-names>
</string-name>, and 
<string-name>
<given-names>C. M.</given-names>
<surname>Okeoma</surname>
</string-name>. 
<year>2013</year>
<article-title>Phosphatidylinositol 3&#x02010;kinase is involved in Toll&#x02010;like receptor 4&#x02010;mediated BST&#x02010;2/Tetherin regulation</article-title>. 
<source>Cell. Signal</source>. 
<volume>25</volume>:<fpage>2752</fpage>&#x02013;<lpage>2761</lpage>.
<pub-id pub-id-type="pmid">24036213</pub-id></mixed-citation></ref><ref id="iid392-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="iid392-cit-0009">
<string-name>
<surname>Kupzig</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<given-names>V.</given-names>
<surname>Korolchuk</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Rollason</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Sugden</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Wilde</surname>
</string-name>, and 
<string-name>
<given-names>G.</given-names>
<surname>Banting</surname>
</string-name>. 
<year>2003</year>
<article-title>Bst&#x02010;2/HM1.24 is a raft&#x02010;associated apical membrane protein with an unusual topology</article-title>. 
<source>Traffic</source>
<volume>4</volume>:<fpage>694</fpage>&#x02013;<lpage>709</lpage>.
<pub-id pub-id-type="pmid">12956872</pub-id></mixed-citation></ref><ref id="iid392-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="iid392-cit-0010">
<string-name>
<surname>Hammonds</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<given-names>J. J.</given-names>
<surname>Wang</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Yi</surname>
</string-name>, and 
<string-name>
<given-names>P.</given-names>
<surname>Spearman</surname>
</string-name>. 
<year>2010</year>
<article-title>Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV&#x02010;1 virions and the plasma membrane</article-title>. 
<source>PLoS Pathog</source>. 
<volume>6</volume>:<fpage>e000749</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="iid392-cit-0011">
<string-name>
<surname>Andrew</surname>, <given-names>A. J.</given-names>
</string-name>, 
<string-name>
<given-names>E.</given-names>
<surname>Miyagi</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Kao</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>. 
<year>2009</year>
<article-title>The formation of cysteine&#x02010;linked dimers of BST&#x02010;2/tetherin is important for inhibition of HIV&#x02010;1 virus release but not for sensitivity to Vpu</article-title>. 
<source>Retrovirology</source>
<volume>6</volume>:<fpage>80</fpage>.
<pub-id pub-id-type="pmid">19737401</pub-id></mixed-citation></ref><ref id="iid392-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="iid392-cit-0012">
<string-name>
<surname>Ishikawa</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Kaisho</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Tomizawa</surname>
</string-name>, 
<string-name>
<given-names>B. O.</given-names>
<surname>Lee</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Kobune</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Inazawa</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Oritani</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Itoh</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Ochi</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Ishihara</surname>
</string-name>, et al. 
<year>1995</year>
<article-title>Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre&#x02010;B&#x02010;cell growth</article-title>. 
<source>Genomics</source>
<volume>26</volume>:<fpage>527</fpage>&#x02013;<lpage>534</lpage>.
<pub-id pub-id-type="pmid">7607676</pub-id></mixed-citation></ref><ref id="iid392-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="iid392-cit-0013">
<string-name>
<surname>Masuyama</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Kuronita</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Tanaka</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Muto</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Hirota</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Takigawa</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Fujita</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Aso</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Amano</surname>
</string-name>, and 
<string-name>
<given-names>Y.</given-names>
<surname>Tanaka</surname>
</string-name>. 
<year>2009</year>
<article-title>HM1.24 is internalized from lipid rafts by clathrin&#x02010;mediated endocytosis through interaction with alpha&#x02010;adaptin</article-title>. 
<source>J. Biol. Chem</source>. 
<volume>284</volume>:<fpage>15927</fpage>&#x02013;<lpage>15941</lpage>.
<pub-id pub-id-type="pmid">19359243</pub-id></mixed-citation></ref><ref id="iid392-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="iid392-cit-0014">
<string-name>
<surname>Galao</surname>, <given-names>R. P.</given-names>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Le Tortorec</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Pickering</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Kueck</surname>
</string-name>, and 
<string-name>
<given-names>S. J.</given-names>
<surname>Neil</surname>
</string-name>. 
<year>2012</year>
<article-title>Innate sensing of HIV&#x02010;1 assembly by Tetherin induces NFkappaB&#x02010;dependent proinflammatory responses</article-title>. 
<source>Cell Host Microbe</source>. 
<volume>12</volume>:<fpage>633</fpage>&#x02013;<lpage>644</lpage>.
<pub-id pub-id-type="pmid">23159053</pub-id></mixed-citation></ref><ref id="iid392-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="iid392-cit-0015">
<string-name>
<surname>Tokarev</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Skasko</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Fitzpatrick</surname>
</string-name>, and 
<string-name>
<given-names>J.</given-names>
<surname>Guatelli</surname>
</string-name>. 
<year>2009</year>
<article-title>Antiviral activity of the interferon&#x02010;induced cellular protein BST&#x02010;2/tetherin</article-title>. 
<source>AIDS Res. Hum. Retroviruses</source>. 
<volume>25</volume>:<fpage>1197</fpage>&#x02013;<lpage>1210</lpage>.
<pub-id pub-id-type="pmid">19929170</pub-id></mixed-citation></ref><ref id="iid392-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="iid392-cit-0016">
<string-name>
<surname>Matsuda</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Suzuki</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Honda</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Muramatsu</surname>
</string-name>, 
<string-name>
<given-names>O.</given-names>
<surname>Matsuzaki</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Nagano</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Doi</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Shimotohno</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Harada</surname>
</string-name>, 
<string-name>
<given-names>E.</given-names>
<surname>Nishida</surname>
</string-name>, et al. 
<year>2003</year>
<article-title>Large&#x02010;scale identification and characterization of human genes that activate NF&#x02010;kappaB and MAPK signaling pathways</article-title>. 
<source>Oncogene</source>
<volume>22</volume>:<fpage>3307</fpage>&#x02013;<lpage>3318</lpage>.
<pub-id pub-id-type="pmid">12761501</pub-id></mixed-citation></ref><ref id="iid392-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="iid392-cit-0017">
<string-name>
<surname>Cocka</surname>, <given-names>L. J.</given-names>
</string-name>, and 
<string-name>
<given-names>P.</given-names>
<surname>Bates</surname>
</string-name>. 
<year>2012</year>
<article-title>Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities</article-title>. 
<source>PLoS Pathog</source>. 
<volume>8</volume>:<fpage>e002931</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="iid392-cit-0018">
<string-name>
<surname>Swiecki</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>S. M.</given-names>
<surname>Scheaffer</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Allaire</surname>
</string-name>, 
<string-name>
<given-names>D. H.</given-names>
<surname>Fremont</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Colonna</surname>
</string-name>, and 
<string-name>
<given-names>T. J.</given-names>
<surname>Brett</surname>
</string-name>. 
<year>2011</year>
<article-title>Structural and biophysical analysis of BST&#x02010;2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release</article-title>. 
<source>J. Biol. Chem</source>. 
<volume>286</volume>:<fpage>2987</fpage>&#x02013;<lpage>2997</lpage>.
<pub-id pub-id-type="pmid">21084286</pub-id></mixed-citation></ref><ref id="iid392-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="iid392-cit-0019">
<string-name>
<surname>Hinz</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Miguet</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Natrajan</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Usami</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Yamanaka</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Renesto</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Hartlieb</surname>
</string-name>, 
<string-name>
<given-names>A. A.</given-names>
<surname>McCarthy</surname>
</string-name>, 
<string-name>
<given-names>J. P.</given-names>
<surname>Simorre</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Gottlinger</surname>
</string-name>, et al. 
<year>2010</year>
<article-title>Structural basis of HIV&#x02010;1 tethering to membranes by the BST&#x02010;2/tetherin ectodomain</article-title>. 
<source>Cell Host Microbe</source>. 
<volume>7</volume>:<fpage>314</fpage>&#x02013;<lpage>323</lpage>.
<pub-id pub-id-type="pmid">20399176</pub-id></mixed-citation></ref><ref id="iid392-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="iid392-cit-0020">
<string-name>
<surname>Schubert</surname>, <given-names>H. L.</given-names>
</string-name>, 
<string-name>
<given-names>Q.</given-names>
<surname>Zhai</surname>
</string-name>, 
<string-name>
<given-names>V.</given-names>
<surname>Sandrin</surname>
</string-name>, 
<string-name>
<given-names>D. M.</given-names>
<surname>Eckert</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Garcia&#x02010;Maya</surname>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Saul</surname>
</string-name>, 
<string-name>
<given-names>W. I.</given-names>
<surname>Sundquist</surname>
</string-name>, 
<string-name>
<given-names>R. A.</given-names>
<surname>Steiner</surname>
</string-name>, 
<string-name>
<given-names>C. P.</given-names>
<surname>Hill</surname>
</string-name>. 
<year>2010</year>
<article-title>Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations</article-title>. 
<source>Proc. Natl. Acad. Sci. USA</source>
<volume>107</volume>:<fpage>17951</fpage>&#x02013;<lpage>17956</lpage>.
<pub-id pub-id-type="pmid">20880831</pub-id></mixed-citation></ref><ref id="iid392-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="iid392-cit-0021">
<string-name>
<surname>Ohtomo</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Sugamata</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Ozaki</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Ono</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Yoshimura</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Kawai</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Koishihara</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Ozaki</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Kosaka</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Hirano</surname>
</string-name>, et al. 
<year>1999</year>
<article-title>Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells</article-title>. 
<source>Biochem. Biophys. Res. Commun</source>. 
<volume>258</volume>:<fpage>583</fpage>&#x02013;<lpage>591</lpage>.
<pub-id pub-id-type="pmid">10329429</pub-id></mixed-citation></ref><ref id="iid392-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="iid392-cit-0022">
<string-name>
<surname>Perez&#x02010;Caballero</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Zang</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Ebrahimi</surname>
</string-name>, 
<string-name>
<given-names>M. W.</given-names>
<surname>McNatt</surname>
</string-name>, 
<string-name>
<given-names>D. A.</given-names>
<surname>Gregory</surname>
</string-name>, 
<string-name>
<given-names>M. C.</given-names>
<surname>Johnson</surname>
</string-name>, and 
<string-name>
<given-names>P. D.</given-names>
<surname>Bieniasz</surname>
</string-name>. 
<year>2009</year>
<article-title>Tetherin inhibits HIV&#x02010;1 release by directly tethering virions to cells</article-title>. 
<source>Cell</source>
<volume>139</volume>:<fpage>499</fpage>&#x02013;<lpage>511</lpage>.
<pub-id pub-id-type="pmid">19879838</pub-id></mixed-citation></ref><ref id="iid392-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="iid392-cit-0023">
<string-name>
<surname>Fujita</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Fujimoto</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Tokunaga</surname>
</string-name>, and 
<string-name>
<given-names>Y.</given-names>
<surname>Tanaka</surname>
</string-name>. 
<year>2012</year>
<article-title>Intracellular logistics of BST&#x02010;2/Tetherin</article-title>. 
<source>Curr. HIV Res</source>. 
<volume>10</volume>:<fpage>321</fpage>&#x02013;<lpage>326</lpage>.
<pub-id pub-id-type="pmid">22533471</pub-id></mixed-citation></ref><ref id="iid392-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="iid392-cit-0024">
<string-name>
<surname>Rollason</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<given-names>V.</given-names>
<surname>Korolchuk</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Hamilton</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Schu</surname>
</string-name>, and 
<string-name>
<given-names>G.</given-names>
<surname>Banting</surname>
</string-name>. 
<year>2007</year>
<article-title>Clathrin&#x02010;mediated endocytosis of a lipid&#x02010;raft&#x02010;associated protein is mediated through a dual tyrosine motif</article-title>. 
<source>J. Cell Sci</source>. 
<volume>120</volume>:<fpage>3850</fpage>&#x02013;<lpage>3858</lpage>.
<pub-id pub-id-type="pmid">17940069</pub-id></mixed-citation></ref><ref id="iid392-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="iid392-cit-0025">
<string-name>
<surname>Fritz</surname>, <given-names>J. V.</given-names>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Tibroni</surname>
</string-name>, 
<string-name>
<given-names>O. T.</given-names>
<surname>Keppler</surname>
</string-name>, and 
<string-name>
<given-names>O. T.</given-names>
<surname>Fackler</surname>
</string-name>. 
<year>2012</year>
<article-title>HIV&#x02010;1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin</article-title>. 
<source>Virology</source>
<volume>424</volume>:<fpage>33</fpage>&#x02013;<lpage>44</lpage>.
<pub-id pub-id-type="pmid">22222210</pub-id></mixed-citation></ref><ref id="iid392-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="iid392-cit-0026">
<string-name>
<surname>Lopez</surname>, <given-names>L. A.</given-names>
</string-name>, 
<string-name>
<given-names>S. J.</given-names>
<surname>Yang</surname>
</string-name>, 
<string-name>
<given-names>C. M.</given-names>
<surname>Exline</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Rengarajan</surname>
</string-name>, 
<string-name>
<given-names>K. G.</given-names>
<surname>Haworth</surname>
</string-name>, and 
<string-name>
<given-names>P. M.</given-names>
<surname>Cannon</surname>
</string-name>. 
<year>2012</year>
<article-title>Anti&#x02010;tetherin activities of HIV&#x02010;1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts</article-title>. 
<source>J Virol</source>. 
<volume>86</volume>:<fpage>5467</fpage>&#x02013;<lpage>5480</lpage>.
<pub-id pub-id-type="pmid">22398279</pub-id></mixed-citation></ref><ref id="iid392-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="iid392-cit-0027">
<string-name>
<surname>Sarojini</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Theofanis</surname>
</string-name>, and 
<string-name>
<given-names>C. S.</given-names>
<surname>Reiss</surname>
</string-name>. 
<year>2011</year>
<article-title>Interferon&#x02010;induced tetherin restricts vesicular stomatitis virus release in neurons</article-title>. 
<source>DNA Cell Biol</source>. 
<volume>30</volume>:<fpage>965</fpage>&#x02013;<lpage>974</lpage>.
<pub-id pub-id-type="pmid">21919738</pub-id></mixed-citation></ref><ref id="iid392-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="iid392-cit-0028">
<string-name>
<surname>Jones</surname>, <given-names>P. H.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Maric</surname>
</string-name>, 
<string-name>
<given-names>M. N.</given-names>
<surname>Madison</surname>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Maury</surname>
</string-name>, 
<string-name>
<given-names>R. J.</given-names>
<surname>Roller</surname>
</string-name>, and 
<string-name>
<given-names>C. M.</given-names>
<surname>Okeoma</surname>
</string-name>. 
<year>2013</year>
<article-title>BST&#x02010;2/tetherin&#x02010;mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non&#x02010;structural protein 1 (nsP1)</article-title>. 
<source>Virology</source>
<volume>438</volume>:<fpage>37</fpage>&#x02013;<lpage>49</lpage>.
<pub-id pub-id-type="pmid">23411007</pub-id></mixed-citation></ref><ref id="iid392-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="iid392-cit-0029">
<string-name>
<surname>Ooi</surname>, <given-names>Y. S.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Dube</surname>
</string-name>, and 
<string-name>
<given-names>M.</given-names>
<surname>Kielian</surname>
</string-name>. 
<year>2015</year>
<article-title>BST2/tetherin inhibition of alphavirus exit</article-title>. 
<source>Viruses</source>
<volume>7</volume>:<fpage>2147</fpage>&#x02013;<lpage>2167</lpage>.
<pub-id pub-id-type="pmid">25912717</pub-id></mixed-citation></ref><ref id="iid392-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="iid392-cit-0030">
<string-name>
<surname>Radoshitzky</surname>, <given-names>S. R.</given-names>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Dong</surname>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Chi</surname>
</string-name>, 
<string-name>
<given-names>J. C.</given-names>
<surname>Clester</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Retterer</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Spurgers</surname>
</string-name>, 
<string-name>
<given-names>J. H.</given-names>
<surname>Kuhn</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Sandwick</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Ruthel</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Kota</surname>
</string-name>, et al. 
<year>2010</year>
<article-title>Infectious Lassa virus, but not filoviruses, is restricted by BST&#x02010;2/tetherin</article-title>. 
<source>J. Virol</source>. 
<volume>84</volume>:<fpage>10569</fpage>&#x02013;<lpage>10580</lpage>.
<pub-id pub-id-type="pmid">20686043</pub-id></mixed-citation></ref><ref id="iid392-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="iid392-cit-0031">
<string-name>
<surname>Lopez</surname>, <given-names>L. A.</given-names>
</string-name>, 
<string-name>
<given-names>S. J.</given-names>
<surname>Yang</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Hauser</surname>
</string-name>, 
<string-name>
<given-names>C. M.</given-names>
<surname>Exline</surname>
</string-name>, 
<string-name>
<given-names>K. G.</given-names>
<surname>Haworth</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Oldenburg</surname>
</string-name>, and 
<string-name>
<given-names>P. M.</given-names>
<surname>Cannon</surname>
</string-name>. 
<year>2010</year>
<article-title>Ebola virus glycoprotein counteracts BST&#x02010;2/Tetherin restriction in a sequence&#x02010;independent manner that does not require tetherin surface removal</article-title>. 
<source>J Virol</source>. 
<volume>84</volume>:<fpage>7243</fpage>&#x02013;<lpage>7255</lpage>.
<pub-id pub-id-type="pmid">20444895</pub-id></mixed-citation></ref><ref id="iid392-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="iid392-cit-0032">
<string-name>
<surname>Kuhl</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Banning</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Marzi</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Votteler</surname>
</string-name>, 
<string-name>
<given-names>I.</given-names>
<surname>Steffen</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Bertram</surname>
</string-name>, 
<string-name>
<given-names>I.</given-names>
<surname>Glowacka</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Konrad</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Sturzl</surname>
</string-name>, 
<string-name>
<given-names>J. T.</given-names>
<surname>Guo</surname>
</string-name>, et al. 
<year>2011</year>
<article-title>The Ebola virus glycoprotein and HIV&#x02010;1 Vpu employ different strategies to counteract the antiviral factor tetherin</article-title>. 
<source>J. Infect. Dis</source>. 
<volume>204</volume>(<issue>Suppl 3</issue>):<fpage>S850</fpage>&#x02013;<lpage>S860</lpage>.
<pub-id pub-id-type="pmid">21987761</pub-id></mixed-citation></ref><ref id="iid392-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="iid392-cit-0033">
<string-name>
<surname>Douglas</surname>, <given-names>J. L.</given-names>
</string-name>, 
<string-name>
<given-names>J. K.</given-names>
<surname>Gustin</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Viswanathan</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Mansouri</surname>
</string-name>, 
<string-name>
<given-names>A. V.</given-names>
<surname>Moses</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Fruh</surname>
</string-name>. 
<year>2010</year>
<article-title>The great escape: viral strategies to counter BST&#x02010;2/tetherin</article-title>. 
<source>PLoS Pathog</source>. 
<volume>6</volume>:<fpage>e000913</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="iid392-cit-0034">
<string-name>
<surname>Yondola</surname>, <given-names>M. A.</given-names>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Fernandes</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Belicha&#x02010;Villanueva</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Uccelini</surname>
</string-name>, 
<string-name>
<given-names>Q.</given-names>
<surname>Gao</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Carter</surname>
</string-name>, and 
<string-name>
<given-names>P.</given-names>
<surname>Palese</surname>
</string-name>. 
<year>2011</year>
<article-title>Budding capability of the influenza virus neuraminidase can be modulated by tetherin</article-title>. 
<source>J Virol</source>. 
<volume>85</volume>:<fpage>2480</fpage>&#x02013;<lpage>2491</lpage>.
<pub-id pub-id-type="pmid">21209114</pub-id></mixed-citation></ref><ref id="iid392-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="iid392-cit-0035">
<string-name>
<surname>Miyakawa</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Matsunaga</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Watashi</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Sugiyama</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Kimura</surname>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Yamamoto</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Mizokami</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Wakita</surname>
</string-name>, and 
<string-name>
<given-names>A.</given-names>
<surname>Ryo</surname>
</string-name>. 
<year>2015</year>
<article-title>Molecular dissection of HBV evasion from restriction factor tetherin: a new perspective for antiviral cell therapy</article-title>. 
<source>Oncotarget</source>
<volume>6</volume>:<fpage>21840</fpage>&#x02013;<lpage>21852</lpage>.
<pub-id pub-id-type="pmid">26334101</pub-id></mixed-citation></ref><ref id="iid392-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="iid392-cit-0036">
<string-name>
<surname>Pan</surname>, <given-names>X. B.</given-names>
</string-name>, 
<string-name>
<given-names>J. C.</given-names>
<surname>Han</surname>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Cong</surname>
</string-name>, and 
<string-name>
<given-names>L.</given-names>
<surname>Wei</surname>
</string-name>. 
<year>2012</year>
<article-title>BST2/tetherin inhibits dengue virus release from human hepatoma cells</article-title>. 
<source>PloS ONE</source>
<volume>7</volume>:<fpage>e1033</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="iid392-cit-0037">
<string-name>
<surname>Pan</surname>, <given-names>X. B.</given-names>
</string-name>, 
<string-name>
<given-names>X. W.</given-names>
<surname>Qu</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Jiang</surname>
</string-name>, 
<string-name>
<given-names>X. L.</given-names>
<surname>Zhao</surname>
</string-name>, 
<string-name>
<given-names>J. C.</given-names>
<surname>Han</surname>
</string-name>, and 
<string-name>
<given-names>L.</given-names>
<surname>Wei</surname>
</string-name>. 
<year>2013</year>
<article-title>BST2/Tetherin inhibits hepatitis C virus production in human hepatoma cells</article-title>. 
<source>Antiviral Res</source>. 
<volume>98</volume>:<fpage>54</fpage>&#x02013;<lpage>60</lpage>.
<pub-id pub-id-type="pmid">23422647</pub-id></mixed-citation></ref><ref id="iid392-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="iid392-cit-0038">
<string-name>
<surname>Amet</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Byrd</surname>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Hu</surname>
</string-name>, 
<string-name>
<given-names>Q.</given-names>
<surname>Sun</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Li</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Zhao</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Hu</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Grantham</surname>
</string-name>, and 
<string-name>
<given-names>Q.</given-names>
<surname>Yu</surname>
</string-name>. 
<year>2014</year>
<article-title>BST&#x02010;2 expression in human hepatocytes is inducible by all three types of interferons and restricts production of hepatitis C virus</article-title>. 
<source>Curr. Mol. Med</source>. 
<volume>14</volume>:<fpage>349</fpage>&#x02013;<lpage>360</lpage>.
<pub-id pub-id-type="pmid">24236455</pub-id></mixed-citation></ref><ref id="iid392-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="iid392-cit-0039">
<string-name>
<surname>Lim</surname>, <given-names>E. S.</given-names>
</string-name>, and 
<string-name>
<given-names>M.</given-names>
<surname>Emerman</surname>
</string-name>. 
<year>2009</year>
<article-title>Simian immunodeficiency virus SIVagm from African green monkeys does not antagonize endogenous levels of African green monkey tetherin/BST&#x02010;2</article-title>. 
<source>J. Virol</source>. 
<volume>83</volume>:<fpage>11673</fpage>&#x02013;<lpage>11681</lpage>.
<pub-id pub-id-type="pmid">19726508</pub-id></mixed-citation></ref><ref id="iid392-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="iid392-cit-0040">
<string-name>
<surname>Yin</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<given-names>Z.</given-names>
<surname>Hu</surname>
</string-name>, 
<string-name>
<given-names>Q.</given-names>
<surname>Gu</surname>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Wu</surname>
</string-name>, 
<string-name>
<given-names>Y. H.</given-names>
<surname>Zheng</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Wei</surname>
</string-name>, and 
<string-name>
<given-names>X.</given-names>
<surname>Wang</surname>
</string-name>. 
<year>2014</year>
<article-title>Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein</article-title>. 
<source>J. Virol</source>. 
<volume>88</volume>:<fpage>1259</fpage>&#x02013;<lpage>1270</lpage>.
<pub-id pub-id-type="pmid">24227834</pub-id></mixed-citation></ref><ref id="iid392-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="iid392-cit-0041">
<string-name>
<surname>Hotter</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Sauter</surname>
</string-name>, and 
<string-name>
<given-names>F.</given-names>
<surname>Kirchhoff</surname>
</string-name>. 
<year>2013</year>
<article-title>Emerging role of the host restriction factor tetherin in viral immune sensing</article-title>. 
<source>J. Mol. Biol</source>. 
<volume>425</volume>:<fpage>4956</fpage>&#x02013;<lpage>4964</lpage>.
<pub-id pub-id-type="pmid">24075872</pub-id></mixed-citation></ref><ref id="iid392-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="iid392-cit-0042">
<string-name>
<surname>Santa&#x02010;Marta</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>P. M.</given-names>
<surname>de Brito</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Godinho&#x02010;Santos</surname>
</string-name>, and 
<string-name>
<given-names>J.</given-names>
<surname>Goncalves</surname>
</string-name>. 
<year>2013</year>
<article-title>Host factors and HIV&#x02010;1 replication: clinical evidence and potential therapeutic approaches</article-title>. 
<source>Front. Immunol</source>. 
<volume>4</volume>:<fpage>343</fpage>.
<pub-id pub-id-type="pmid">24167505</pub-id></mixed-citation></ref><ref id="iid392-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="iid392-cit-0043">
<string-name>
<surname>Fitzpatrick</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Skasko</surname>
</string-name>, 
<string-name>
<given-names>T. J.</given-names>
<surname>Deerinck</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Crum</surname>
</string-name>, 
<string-name>
<given-names>M. H.</given-names>
<surname>Ellisman</surname>
</string-name>, and 
<string-name>
<given-names>J.</given-names>
<surname>Guatelli</surname>
</string-name>. 
<year>2010</year>
<article-title>Direct restriction of virus release and incorporation of the interferon&#x02010;induced protein BST&#x02010;2 into HIV&#x02010;1 particles</article-title>. 
<source>PLoS Pathog</source>. 
<volume>6</volume>:<fpage>e000701</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="iid392-cit-0044">
<string-name>
<surname>Habermann</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Krijnse&#x02010;Locker</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Oberwinkler</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Eckhardt</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Homann</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Andrew</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>, and 
<string-name>
<given-names>H. G.</given-names>
<surname>Krausslich</surname>
</string-name>. 
<year>2010</year>
<article-title>CD317/tetherin is enriched in the HIV&#x02010;1 envelope and downregulated from the plasma membrane upon virus infection</article-title>. 
<source>J. Virol</source>. 
<volume>84</volume>:<fpage>4646</fpage>&#x02013;<lpage>4658</lpage>.
<pub-id pub-id-type="pmid">20147389</pub-id></mixed-citation></ref><ref id="iid392-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="iid392-cit-0045">
<string-name>
<surname>Mahauad&#x02010;Fernandez</surname>, <given-names>W. D.</given-names>
</string-name>, 
<string-name>
<given-names>P. H.</given-names>
<surname>Jones</surname>
</string-name>, and 
<string-name>
<given-names>C. M.</given-names>
<surname>Okeoma</surname>
</string-name>. 
<year>2014</year>
<article-title>Critical role for BST&#x02010;2 in acute Chikungunya virus infection</article-title>. 
<source>J. Gen. Virol</source>
<volume>95</volume>:<fpage>2450</fpage>&#x02013;<lpage>2461</lpage>.
<pub-id pub-id-type="pmid">25053563</pub-id></mixed-citation></ref><ref id="iid392-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="iid392-cit-0046">
<string-name>
<surname>Tokarev</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Suarez</surname>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Kwan</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Fitzpatrick</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Singh</surname>
</string-name>, and 
<string-name>
<given-names>J.</given-names>
<surname>Guatelli</surname>
</string-name>. 
<year>2013</year>
<article-title>Stimulation of NF&#x02010;kappaB activity by the HIV restriction factor BST2</article-title>. 
<source>J. Virol</source>. 
<volume>87</volume>:<fpage>2046</fpage>&#x02013;<lpage>2057</lpage>.
<pub-id pub-id-type="pmid">23221546</pub-id></mixed-citation></ref><ref id="iid392-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="iid392-cit-0047">
<string-name>
<surname>Galao</surname>, <given-names>R. P.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Pickering</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Curnock</surname>
</string-name>, and 
<string-name>
<given-names>S. J.</given-names>
<surname>Neil</surname>
</string-name>. 
<year>2014</year>
<article-title>Retroviral retention activates a Syk&#x02010;dependent HemITAM in human tetherin</article-title>. 
<source>Cell Host Microbe</source>. 
<volume>16</volume>:<fpage>291</fpage>&#x02013;<lpage>303</lpage>.
<pub-id pub-id-type="pmid">25211072</pub-id></mixed-citation></ref><ref id="iid392-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="iid392-cit-0048">
<string-name>
<surname>Zhang</surname>, <given-names>J.</given-names>
</string-name>, and 
<string-name>
<given-names>C.</given-names>
<surname>Liang</surname>
</string-name>. 
<year>2010</year>
<article-title>BST&#x02010;2 diminishes HIV&#x02010;1 infectivity</article-title>. 
<source>J. Virol</source>. 
<volume>84</volume>:<fpage>12336</fpage>&#x02013;<lpage>12343</lpage>.
<pub-id pub-id-type="pmid">20861258</pub-id></mixed-citation></ref><ref id="iid392-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="iid392-cit-0049">
<string-name>
<surname>Xagorari</surname>, <given-names>A.</given-names>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Chlichlia</surname>
</string-name>. 
<year>2008</year>
<article-title>Toll&#x02010;like receptors and viruses: induction of innate antiviral immune responses</article-title>. 
<source>Open Microbiol. J</source>. 
<volume>2</volume>:<fpage>49</fpage>&#x02013;<lpage>59</lpage>.
<pub-id pub-id-type="pmid">19088911</pub-id></mixed-citation></ref><ref id="iid392-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="iid392-cit-0050">
<string-name>
<surname>Chu</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<given-names>J. J.</given-names>
<surname>Wang</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Qi</surname>
</string-name>, 
<string-name>
<given-names>J. J.</given-names>
<surname>Yoon</surname>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Chen</surname>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Wen</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Hammonds</surname>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Ding</surname>
</string-name>, and 
<string-name>
<given-names>P.</given-names>
<surname>Spearman</surname>
</string-name>. 
<year>2012</year>
<article-title>Tetherin/BST&#x02010;2 is essential for the formation of the intracellular virus&#x02010;containing compartment in HIV&#x02010;infected macrophages</article-title>. 
<source>Cell Host Microbe</source>. 
<volume>12</volume>:<fpage>360</fpage>&#x02013;<lpage>372</lpage>.
<pub-id pub-id-type="pmid">22980332</pub-id></mixed-citation></ref><ref id="iid392-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="iid392-cit-0051">
<string-name>
<surname>Giese</surname>, <given-names>S.</given-names>
</string-name>, and 
<string-name>
<given-names>M.</given-names>
<surname>Marsh</surname>
</string-name>. 
<year>2014</year>
<article-title>Tetherin can restrict cell&#x02010;free and cell&#x02013;cell transmission of HIV from primary macrophages to T cells</article-title>. 
<source>PLoS Pathog</source>. 
<volume>10</volume>:<fpage>e004189</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="iid392-cit-0052">
<string-name>
<surname>Kuhl</surname>, <given-names>B. D.</given-names>
</string-name>, 
<string-name>
<given-names>R. D.</given-names>
<surname>Sloan</surname>
</string-name>, 
<string-name>
<given-names>D. A.</given-names>
<surname>Donahue</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Bar&#x02010;Magen</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Liang</surname>
</string-name>, and 
<string-name>
<given-names>M. A.</given-names>
<surname>Wainberg</surname>
</string-name>. 
<year>2010</year>
<article-title>Tetherin restricts direct cell&#x02010;to&#x02010;cell infection of HIV&#x02010;1</article-title>. 
<source>Retrovirology</source>
<volume>7</volume>:<fpage>115</fpage>.
<pub-id pub-id-type="pmid">21184674</pub-id></mixed-citation></ref><ref id="iid392-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="iid392-cit-0053">
<string-name>
<surname>Casartelli</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Sourisseau</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Feldmann</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Guivel&#x02010;Benhassine</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Mallet</surname>
</string-name>, 
<string-name>
<given-names>A. G.</given-names>
<surname>Marcelin</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Guatelli</surname>
</string-name>, and 
<string-name>
<given-names>O.</given-names>
<surname>Schwartz</surname>
</string-name>. 
<year>2010</year>
<article-title>Tetherin restricts productive HIV&#x02010;1 cell&#x02010;to&#x02010;cell transmission</article-title>. 
<source>PLoS Pathog</source>. 
<volume>6</volume>:<fpage>e000955</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="iid392-cit-0054">
<string-name>
<surname>Pham</surname>, <given-names>T. N.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Lukhele</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Hajjar</surname>
</string-name>, 
<string-name>
<given-names>J. P.</given-names>
<surname>Routy</surname>
</string-name>, and 
<string-name>
<given-names>E. A.</given-names>
<surname>Cohen</surname>
</string-name>. 
<year>2014</year>
<article-title>HIV Nef and Vpu protect HIV&#x02010;infected CD4+ T cells from antibody&#x02010;mediated cell lysis through down&#x02010;modulation of CD4 and B ST2</article-title>. 
<source>Retrovirology</source>
<volume>11</volume>:<fpage>15</fpage>.
<pub-id pub-id-type="pmid">24498878</pub-id></mixed-citation></ref><ref id="iid392-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="iid392-cit-0055">
<string-name>
<surname>Arias</surname>, <given-names>J. F.</given-names>
</string-name>, 
<string-name>
<given-names>L. N.</given-names>
<surname>Heyer</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>von Bredow</surname>
</string-name>, 
<string-name>
<given-names>K. L.</given-names>
<surname>Weisgrau</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Moldt</surname>
</string-name>, 
<string-name>
<given-names>D. R.</given-names>
<surname>Burton</surname>
</string-name>, 
<string-name>
<given-names>E. G.</given-names>
<surname>Rakasz</surname>
</string-name>, and 
<string-name>
<given-names>D. T.</given-names>
<surname>Evans</surname>
</string-name>. 
<year>2014</year>
<article-title>Tetherin antagonism by Vpu protects HIV&#x02010;infected cells from antibody&#x02010;dependent cell&#x02010;mediated cytotoxicity</article-title>. 
<source>Proc. Natl. Acad. Sci. USA</source>
<volume>111</volume>:<fpage>6425</fpage>&#x02013;<lpage>6430</lpage>.
<pub-id pub-id-type="pmid">24733916</pub-id></mixed-citation></ref><ref id="iid392-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="iid392-cit-0056">
<string-name>
<surname>Alvarez</surname>, <given-names>R. A.</given-names>
</string-name>, 
<string-name>
<given-names>R. E.</given-names>
<surname>Hamlin</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Monroe</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Moldt</surname>
</string-name>, 
<string-name>
<given-names>M. T.</given-names>
<surname>Hotta</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Rodriguez Caprio</surname>
</string-name>, 
<string-name>
<given-names>D. S.</given-names>
<surname>Fierer</surname>
</string-name>, 
<string-name>
<given-names>V.</given-names>
<surname>Simon</surname>
</string-name>, and 
<string-name>
<given-names>B. K.</given-names>
<surname>Chen</surname>
</string-name>. 
<year>2014</year>
<article-title>HIV&#x02010;1 Vpu antagonism of Tetherin inhibits antibody&#x02010;dependent cellular cytotoxic responses by natural killer cells</article-title>. 
<source>J. Virol</source>. 
<volume>88</volume>:<fpage>6031</fpage>&#x02013;<lpage>6046</lpage>.
<pub-id pub-id-type="pmid">24623433</pub-id></mixed-citation></ref><ref id="iid392-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="iid392-cit-0057">
<string-name>
<surname>Liu</surname>, <given-names>C. C.</given-names>
</string-name>, 
<string-name>
<given-names>P. M.</given-names>
<surname>Persechini</surname>
</string-name>, and 
<string-name>
<given-names>J. D.</given-names>
<surname>Young</surname>
</string-name>. 
<year>1995</year>
<article-title>Perforin and lymphocyte&#x02010;mediated cytolysis</article-title>. 
<source>Immunol. Rev</source>. 
<volume>146</volume>:<fpage>145</fpage>&#x02013;<lpage>175</lpage>.
<pub-id pub-id-type="pmid">7493752</pub-id></mixed-citation></ref><ref id="iid392-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="iid392-cit-0058">
<string-name>
<surname>Li</surname>, <given-names>S. X.</given-names>
</string-name>, 
<string-name>
<given-names>B. S.</given-names>
<surname>Barrett</surname>
</string-name>, 
<string-name>
<given-names>K. J.</given-names>
<surname>Heilman</surname>
</string-name>, 
<string-name>
<given-names>R. J.</given-names>
<surname>Messer</surname>
</string-name>, 
<string-name>
<given-names>R. A.</given-names>
<surname>Liberatore</surname>
</string-name>, 
<string-name>
<given-names>P. D.</given-names>
<surname>Bieniasz</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Kassiotis</surname>
</string-name>, 
<string-name>
<given-names>K. J.</given-names>
<surname>Hasenkrug</surname>
</string-name>, and 
<string-name>
<given-names>M. L.</given-names>
<surname>Santiago</surname>
</string-name>. 
<year>2014</year>
<article-title>Tetherin promotes the innate and adaptive cell&#x02010;mediated immune response against retrovirus infection in vivo</article-title>. 
<source>J. Immunol</source>. 
<volume>193</volume>:<fpage>306</fpage>&#x02013;<lpage>316</lpage>.
<pub-id pub-id-type="pmid">24872193</pub-id></mixed-citation></ref><ref id="iid392-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="iid392-cit-0059">
<string-name>
<surname>Strebel</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Klimkait</surname>
</string-name>, and 
<string-name>
<given-names>M. A.</given-names>
<surname>Martin</surname>
</string-name>. 
<year>1988</year>
<article-title>A novel gene of HIV&#x02010;1, vpu, and its 16&#x02010;kilodalton product</article-title>. 
<source>Science</source>
<volume>241</volume>:<fpage>1221</fpage>&#x02013;<lpage>1223</lpage>.
<pub-id pub-id-type="pmid">3261888</pub-id></mixed-citation></ref><ref id="iid392-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="iid392-cit-0060">
<string-name>
<surname>Cohen</surname>, <given-names>E. A.</given-names>
</string-name>, 
<string-name>
<given-names>E. F.</given-names>
<surname>Terwilliger</surname>
</string-name>, 
<string-name>
<given-names>J. G.</given-names>
<surname>Sodroski</surname>
</string-name>, and 
<string-name>
<given-names>W. A.</given-names>
<surname>Haseltine</surname>
</string-name>. 
<year>1988</year>
<article-title>Identification of a protein encoded by the vpu gene of HIV&#x02010;1</article-title>. 
<source>Nature</source>
<volume>334</volume>:<fpage>532</fpage>&#x02013;<lpage>534</lpage>.
<pub-id pub-id-type="pmid">3043230</pub-id></mixed-citation></ref><ref id="iid392-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="iid392-cit-0061">
<string-name>
<surname>Willey</surname>, <given-names>R. L.</given-names>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Maldarelli</surname>
</string-name>, 
<string-name>
<given-names>M. A.</given-names>
<surname>Martin</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>. 
<year>1992</year>
<article-title>Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4</article-title>. 
<source>J. Virol</source>. 
<volume>66</volume>:<fpage>7193</fpage>&#x02013;<lpage>7200</lpage>.
<pub-id pub-id-type="pmid">1433512</pub-id></mixed-citation></ref><ref id="iid392-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="iid392-cit-0062">
<string-name>
<surname>Willey</surname>, <given-names>R. L.</given-names>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Maldarelli</surname>
</string-name>, 
<string-name>
<given-names>M. A.</given-names>
<surname>Martin</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>. 
<year>1992</year>
<article-title>Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160&#x02010;CD4 complexes</article-title>. 
<source>J. Virol</source>. 
<volume>66</volume>:<fpage>226</fpage>&#x02013;<lpage>234</lpage>.
<pub-id pub-id-type="pmid">1727486</pub-id></mixed-citation></ref><ref id="iid392-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="iid392-cit-0063">
<string-name>
<surname>Klimkait</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>, 
<string-name>
<given-names>M. D.</given-names>
<surname>Hoggan</surname>
</string-name>, 
<string-name>
<given-names>M. A.</given-names>
<surname>Martin</surname>
</string-name>, and 
<string-name>
<given-names>J. M.</given-names>
<surname>Orenstein</surname>
</string-name>. 
<year>1990</year>
<article-title>The human immunodeficiency virus type 1&#x02010;specific protein vpu is required for efficient virus maturation and release</article-title>. 
<source>J. Virol</source>. 
<volume>64</volume>:<fpage>621</fpage>&#x02013;<lpage>629</lpage>.
<pub-id pub-id-type="pmid">2404139</pub-id></mixed-citation></ref><ref id="iid392-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="iid392-cit-0064">
<string-name>
<surname>Strebel</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Klimkait</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Maldarelli</surname>
</string-name>, and 
<string-name>
<given-names>M. A.</given-names>
<surname>Martin</surname>
</string-name>. 
<year>1989</year>
<article-title>Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein</article-title>. 
<source>J. Virol</source>. 
<volume>63</volume>:<fpage>3784</fpage>&#x02013;<lpage>3791</lpage>.
<pub-id pub-id-type="pmid">2788224</pub-id></mixed-citation></ref><ref id="iid392-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="iid392-cit-0065">
<string-name>
<surname>Terwilliger</surname>, <given-names>E. F.</given-names>
</string-name>, 
<string-name>
<given-names>E. A.</given-names>
<surname>Cohen</surname>
</string-name>, 
<string-name>
<given-names>Y. C.</given-names>
<surname>Lu</surname>
</string-name>, 
<string-name>
<given-names>J. G.</given-names>
<surname>Sodroski</surname>
</string-name>, and 
<string-name>
<given-names>W. A.</given-names>
<surname>Haseltine</surname>
</string-name>. 
<year>1989</year>
<article-title>Functional role of human immunodeficiency virus type 1 vpu</article-title>. 
<source>Proc. Natl. Acad. Sci. USA</source>
<volume>86</volume>:<fpage>5163</fpage>&#x02013;<lpage>5167</lpage>.
<pub-id pub-id-type="pmid">2472639</pub-id></mixed-citation></ref><ref id="iid392-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="iid392-cit-0066">
<string-name>
<surname>Varthakavi</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<given-names>R. M.</given-names>
<surname>Smith</surname>
</string-name>, 
<string-name>
<given-names>S. P.</given-names>
<surname>Bour</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>, and 
<string-name>
<given-names>P.</given-names>
<surname>Spearman</surname>
</string-name>. 
<year>2003</year>
<article-title>Viral protein U counteracts a human host cell restriction that inhibits HIV&#x02010;1 particle production</article-title>. 
<source>Proc. Natl. Acad. Sci. USA</source>
<volume>100</volume>:<fpage>15154</fpage>&#x02013;<lpage>15159</lpage>.
<pub-id pub-id-type="pmid">14657387</pub-id></mixed-citation></ref><ref id="iid392-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="iid392-cit-0067">
<string-name>
<surname>Bartee</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>McCormack</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Fruh</surname>
</string-name>. 
<year>2006</year>
<article-title>Quantitative membrane proteomics reveals new cellular targets of viral immune modulators</article-title>. 
<source>PLoS Pathog</source>. 
<volume>2</volume>:<fpage>e07</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="iid392-cit-0068">
<string-name>
<surname>Schubert</surname>, <given-names>U.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Bour</surname>
</string-name>, 
<string-name>
<given-names>A. V.</given-names>
<surname>Ferrer&#x02010;Montiel</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Montal</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Maldarell</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>. 
<year>1996</year>
<article-title>The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains</article-title>. 
<source>J. Virol</source>. 
<volume>70</volume>:<fpage>809</fpage>&#x02013;<lpage>819</lpage>.
<pub-id pub-id-type="pmid">8551619</pub-id></mixed-citation></ref><ref id="iid392-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="iid392-cit-0069">
<string-name>
<surname>Paul</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Mazumder</surname>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Raja</surname>
</string-name>, and 
<string-name>
<given-names>M. A.</given-names>
<surname>Jabbar</surname>
</string-name>. 
<year>1998</year>
<article-title>Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus&#x02010;like particles from the plasma membrane of mammalian cells</article-title>. 
<source>J. Virol</source>. 
<volume>72</volume>:<fpage>1270</fpage>&#x02013;<lpage>1279</lpage>.
<pub-id pub-id-type="pmid">9445027</pub-id></mixed-citation></ref><ref id="iid392-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="iid392-cit-0070">
<string-name>
<surname>Gupta</surname>, <given-names>R. K.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Hue</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Schaller</surname>
</string-name>, 
<string-name>
<given-names>E.</given-names>
<surname>Verschoor</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Pillay</surname>
</string-name>, and 
<string-name>
<given-names>G. J.</given-names>
<surname>Towers</surname>
</string-name>. 
<year>2009</year>
<article-title>Mutation of a single residue renders human tetherin resistant to HIV&#x02010;1 Vpu&#x02010;mediated depletion</article-title>. 
<source>PLoS Pathog</source>. 
<volume>5</volume>:<fpage>e000443</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="iid392-cit-0071">
<string-name>
<surname>McNatt</surname>, <given-names>M. W.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Zang</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Hatziioannou</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Bartlett</surname>
</string-name>, 
<string-name>
<given-names>I. B.</given-names>
<surname>Fofana</surname>
</string-name>, 
<string-name>
<given-names>W. E.</given-names>
<surname>Johnson</surname>
</string-name>, 
<string-name>
<given-names>S. J.</given-names>
<surname>Neil</surname>
</string-name>, and 
<string-name>
<given-names>P. D.</given-names>
<surname>Bieniasz</surname>
</string-name>. 
<year>2009</year>
<article-title>Species&#x02010;specific activity of HIV&#x02010;1 Vpu and positive selection of tetherin transmembrane domain variants</article-title>. 
<source>PLoS Pathog</source>. 
<volume>5</volume>:<fpage>e000300</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="iid392-cit-0072">
<string-name>
<surname>Rong</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Zhang</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Lu</surname>
</string-name>, 
<string-name>
<given-names>Q.</given-names>
<surname>Pan</surname>
</string-name>, 
<string-name>
<given-names>R. P.</given-names>
<surname>Lorgeoux</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Aloysius</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Guo</surname>
</string-name>, 
<string-name>
<given-names>S. L.</given-names>
<surname>Liu</surname>
</string-name>, 
<string-name>
<given-names>M. A.</given-names>
<surname>Wainberg</surname>
</string-name>, and 
<string-name>
<given-names>C.</given-names>
<surname>Liang</surname>
</string-name>. 
<year>2009</year>
<article-title>The transmembrane domain of BST&#x02010;2 determines its sensitivity to down&#x02010;modulation by human immunodeficiency virus type 1 Vpu</article-title>. 
<source>J. Virol</source>. 
<volume>83</volume>:<fpage>7536</fpage>&#x02013;<lpage>7546</lpage>.
<pub-id pub-id-type="pmid">19474106</pub-id></mixed-citation></ref><ref id="iid392-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="iid392-cit-0073">
<string-name>
<surname>Miyagi</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<given-names>A. J.</given-names>
<surname>Andrew</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Kao</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>. 
<year>2009</year>
<article-title>Vpu enhances HIV&#x02010;1 virus release in the absence of Bst&#x02010;2 cell surface down&#x02010;modulation and intracellular depletion</article-title>. 
<source>Proc. Natl. Acad. Sci. USA</source>
<volume>106</volume>:<fpage>2868</fpage>&#x02013;<lpage>2873</lpage>.
<pub-id pub-id-type="pmid">19196977</pub-id></mixed-citation></ref><ref id="iid392-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="iid392-cit-0074">
<string-name>
<surname>Goffinet</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<given-names>I.</given-names>
<surname>Allespach</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Homann</surname>
</string-name>, 
<string-name>
<given-names>H. M.</given-names>
<surname>Tervo</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Habermann</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Rupp</surname>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Oberbremer</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Kern</surname>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Tibroni</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Welsch</surname>
</string-name>, et al. 
<year>2009</year>
<article-title>HIV&#x02010;1 antagonism of CD317 is species specific and involves Vpu&#x02010;mediated proteasomal degradation of the restriction factor</article-title>. 
<source>Cell Host Microbe</source>. 
<volume>5</volume>:<fpage>285</fpage>&#x02013;<lpage>297</lpage>.
<pub-id pub-id-type="pmid">19286137</pub-id></mixed-citation></ref><ref id="iid392-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="iid392-cit-0075">
<string-name>
<surname>Mitchell</surname>, <given-names>R. S.</given-names>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Katsura</surname>
</string-name>, 
<string-name>
<given-names>M. A.</given-names>
<surname>Skasko</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Fitzpatrick</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Lau</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Ruiz</surname>
</string-name>, 
<string-name>
<given-names>E. B.</given-names>
<surname>Stephens</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Margottin&#x02010;Goguet</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Benarous</surname>
</string-name>, and 
<string-name>
<given-names>J. C.</given-names>
<surname>Guatelli</surname>
</string-name>. 
<year>2009</year>
<article-title>Vpu antagonizes BST&#x02010;2&#x02010;mediated restriction of HIV&#x02010;1 release via beta&#x02010;TrCP and endo&#x02010;lysosomal trafficking</article-title>. 
<source>PLoS Pathog</source>. 
<volume>5</volume>:<fpage>e000450</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="iid392-cit-0076">
<string-name>
<surname>Douglas</surname>, <given-names>J. L.</given-names>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Viswanathan</surname>
</string-name>, 
<string-name>
<given-names>M. N.</given-names>
<surname>McCarroll</surname>
</string-name>, 
<string-name>
<given-names>J. K.</given-names>
<surname>Gustin</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Fruh</surname>
</string-name>, and 
<string-name>
<given-names>A. V.</given-names>
<surname>Moses</surname>
</string-name>. 
<year>2009</year>
<article-title>Vpu directs the degradation of the human immunodeficiency virus restriction factor BST&#x02010;2/Tetherin via a {beta}TrCP&#x02010;dependent mechanism</article-title>. 
<source>J. Virol</source>. 
<volume>83</volume>:<fpage>7931</fpage>&#x02013;<lpage>7947</lpage>.
<pub-id pub-id-type="pmid">19515779</pub-id></mixed-citation></ref><ref id="iid392-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="iid392-cit-0077">
<string-name>
<surname>Blanchet</surname>, <given-names>F. P.</given-names>
</string-name>, 
<string-name>
<given-names>J. P.</given-names>
<surname>Mitchell</surname>
</string-name>, and 
<string-name>
<given-names>V.</given-names>
<surname>Piguet</surname>
</string-name>. 
<year>2012</year>
<article-title>Beta&#x02010;TrCP dependency of HIV&#x02010;1 Vpu&#x02010;induced downregulation of CD4 and BST&#x02010;2/Tetherin</article-title>. 
<source>Curr. HIV Res</source>. 
<volume>10</volume>:<fpage>307</fpage>&#x02013;<lpage>314</lpage>.
<pub-id pub-id-type="pmid">22524179</pub-id></mixed-citation></ref><ref id="iid392-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="iid392-cit-0078">
<string-name>
<surname>Schubert</surname>, <given-names>U.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Schneider</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Henklein</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Hoffmann</surname>
</string-name>, 
<string-name>
<given-names>E.</given-names>
<surname>Berthold</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Hauser</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Pauli</surname>
</string-name>, and 
<string-name>
<given-names>T.</given-names>
<surname>Porstmann</surname>
</string-name>. 
<year>1992</year>
<article-title>Human&#x02010;immunodeficiency&#x02010;virus&#x02010;type&#x02010;1&#x02010;encoded Vpu protein is phosphorylated by casein kinase II</article-title>. 
<source>Eur. J. Biochem</source>. 
<volume>204</volume>:<fpage>875</fpage>&#x02013;<lpage>883</lpage>.
<pub-id pub-id-type="pmid">1541298</pub-id></mixed-citation></ref><ref id="iid392-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="iid392-cit-0079">
<string-name>
<surname>Rollason</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Dunstan</surname>
</string-name>, 
<string-name>
<given-names>P. G.</given-names>
<surname>Billcliff</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Bishop</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Gleeson</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Wise</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Digard</surname>
</string-name>, and 
<string-name>
<given-names>G.</given-names>
<surname>Banting</surname>
</string-name>. 
<year>2013</year>
<article-title>Expression of HIV&#x02010;1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation</article-title>. 
<source>PLoS ONE</source>
<volume>8</volume>:<fpage>e5680</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="iid392-cit-0080">
<string-name>
<surname>Neutzner</surname>, <given-names>M.</given-names>
</string-name>, and 
<string-name>
<given-names>A.</given-names>
<surname>Neutzner</surname>
</string-name>. 
<year>2012</year>
<article-title>Enzymes of ubiquitination and deubiquitination</article-title>. 
<source>Essays Biochem</source>. 
<volume>52</volume>:<fpage>37</fpage>&#x02013;<lpage>50</lpage>.
<pub-id pub-id-type="pmid">22708562</pub-id></mixed-citation></ref><ref id="iid392-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="iid392-cit-0081">
<string-name>
<surname>Janvier</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Pelchen&#x02010;Matthews</surname>
</string-name>, 
<string-name>
<given-names>J. B.</given-names>
<surname>Renaud</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Caillet</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Marsh</surname>
</string-name>, and 
<string-name>
<given-names>C.</given-names>
<surname>Berlioz&#x02010;Torrent</surname>
</string-name>. 
<year>2011</year>
<article-title>The ESCRT&#x02010;0 component HRS is required for HIV&#x02010;1 Vpu&#x02010;mediated BST&#x02010;2/tetherin down&#x02010;regulation</article-title>. 
<source>PLoS Pathog</source>. 
<volume>7</volume>:<fpage>e001265</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="iid392-cit-0082">
<string-name>
<surname>Janvier</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Roy</surname>
</string-name>, and 
<string-name>
<given-names>C.</given-names>
<surname>Berlioz&#x02010;Torrent</surname>
</string-name>. 
<year>2012</year>
<article-title>Role of the endosomal ESCRT machinery in HIV&#x02010;1 Vpu&#x02010;induced down&#x02010;regulation of BST2/Tetherin</article-title>. 
<source>Curr. HIV Res</source>. 
<volume>10</volume>:<fpage>315</fpage>&#x02013;<lpage>320</lpage>.
<pub-id pub-id-type="pmid">22524180</pub-id></mixed-citation></ref><ref id="iid392-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="iid392-cit-0083">
<string-name>
<surname>Raiborg</surname>, <given-names>C.</given-names>
</string-name>, and 
<string-name>
<given-names>H.</given-names>
<surname>Stenmark</surname>
</string-name>. 
<year>2009</year>
<article-title>The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins</article-title>. 
<source>Nature</source>
<volume>458</volume>:<fpage>445</fpage>&#x02013;<lpage>452</lpage>.
<pub-id pub-id-type="pmid">19325624</pub-id></mixed-citation></ref><ref id="iid392-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="iid392-cit-0084">
<string-name>
<surname>Mayers</surname>, <given-names>J. R.</given-names>
</string-name>, 
<string-name>
<given-names>I.</given-names>
<surname>Fyfe</surname>
</string-name>, 
<string-name>
<given-names>A. L.</given-names>
<surname>Schuh</surname>
</string-name>, 
<string-name>
<given-names>E. R.</given-names>
<surname>Chapman</surname>
</string-name>, 
<string-name>
<given-names>J. M.</given-names>
<surname>Edwardson</surname>
</string-name>, and 
<string-name>
<given-names>A.</given-names>
<surname>Audhya</surname>
</string-name>. 
<year>2011</year>
<article-title>ESCRT&#x02010;0 assembles as a heterotetrameric complex on membranes and binds multiple ubiquitinylated cargoes simultaneously</article-title>. 
<source>J. Biol. Chem</source>. 
<volume>286</volume>:<fpage>9636</fpage>&#x02013;<lpage>9645</lpage>.
<pub-id pub-id-type="pmid">21193406</pub-id></mixed-citation></ref><ref id="iid392-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="iid392-cit-0085">
<string-name>
<surname>Dejucq</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Simmons</surname>
</string-name>, and 
<string-name>
<given-names>P. R.</given-names>
<surname>Clapham</surname>
</string-name>. 
<year>2000</year>
<article-title>T&#x02010;cell line adaptation of human immunodeficiency virus type 1 strain S F162: effects on envelope, vpu and macrophage&#x02010;tropism</article-title>. 
<source>J. Gen. Virol</source>. 
<volume>81</volume>:<fpage>2899</fpage>&#x02013;<lpage>2904</lpage>.
<pub-id pub-id-type="pmid">11086121</pub-id></mixed-citation></ref><ref id="iid392-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="iid392-cit-0086">
<string-name>
<surname>Gaines</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<given-names>M. A.</given-names>
<surname>von Sydow</surname>
</string-name>, 
<string-name>
<given-names>L. V.</given-names>
<surname>von Stedingk</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Biberfeld</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Bottiger</surname>
</string-name>, 
<string-name>
<given-names>L. O.</given-names>
<surname>Hansson</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Lundbergh</surname>
</string-name>, 
<string-name>
<given-names>A. B.</given-names>
<surname>Sonnerborg</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Wasserman</surname>
</string-name>, and 
<string-name>
<given-names>O. O.</given-names>
<surname>Strannegaard</surname>
</string-name>. 
<year>1990</year>
<article-title>Immunological changes in primary HIV&#x02010;1 infection</article-title>. 
<source>AIDS</source>
<volume>4</volume>:<fpage>995</fpage>&#x02013;<lpage>999</lpage>.
<pub-id pub-id-type="pmid">2261128</pub-id></mixed-citation></ref><ref id="iid392-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="iid392-cit-0087">
<string-name>
<surname>Lehmann</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Rocha</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Mangeat</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Blanchet</surname>
</string-name>, 
<string-name>
<given-names>I. H.</given-names>
<surname>Uji</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Hofkens</surname>
</string-name>, and 
<string-name>
<given-names>V.</given-names>
<surname>Piguet</surname>
</string-name>. 
<year>2011</year>
<article-title>Quantitative multicolor super&#x02010;resolution microscopy reveals tetherin HIV&#x02010;1 interaction</article-title>. 
<source>PLoS Pathog</source>. 
<volume>7</volume>:<fpage>e002456</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="iid392-cit-0088">
<string-name>
<surname>Arias</surname>, <given-names>J. F.</given-names>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Iwabu</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Tokunaga</surname>
</string-name>. 
<year>2012</year>
<article-title>Sites of action of HIV&#x02010;1 Vpu in BST&#x02010;2/Tetherin downregulation</article-title>. 
<source>Curr. HIV Res</source>. 
<volume>10</volume>:<fpage>283</fpage>&#x02013;<lpage>291</lpage>.
<pub-id pub-id-type="pmid">22524176</pub-id></mixed-citation></ref><ref id="iid392-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="iid392-cit-0089">
<string-name>
<surname>Dube</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>B. B.</given-names>
<surname>Roy</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Guiot&#x02010;Guillain</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Binette</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Mercier</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Chiasson</surname>
</string-name>, and 
<string-name>
<given-names>E. A.</given-names>
<surname>Cohen</surname>
</string-name>. 
<year>2010</year>
<article-title>Antagonism of tetherin restriction of HIV&#x02010;1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment</article-title>. 
<source>PLoS Pathog</source>. 
<volume>6</volume>:<fpage>e000856</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="iid392-cit-0090">
<string-name>
<surname>Andrew</surname>, <given-names>A. J.</given-names>
</string-name>, 
<string-name>
<given-names>E.</given-names>
<surname>Miyagi</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>. 
<year>2011</year>
<article-title>Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST&#x02010;2/tetherin</article-title>. 
<source>J. Virol</source>. 
<volume>85</volume>:<fpage>2611</fpage>&#x02013;<lpage>2619</lpage>.
<pub-id pub-id-type="pmid">21191020</pub-id></mixed-citation></ref><ref id="iid392-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="iid392-cit-0091">
<string-name>
<surname>Schmidt</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<given-names>J. V.</given-names>
<surname>Fritz</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Bitzegeio</surname>
</string-name>, 
<string-name>
<given-names>O. T.</given-names>
<surname>Fackler</surname>
</string-name>, and 
<string-name>
<given-names>O. T.</given-names>
<surname>Keppler</surname>
</string-name>. 
<year>2011</year>
<article-title>HIV&#x02010;1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction</article-title>. 
<source>MBio</source>
<volume>2</volume>:<fpage>e00011</fpage>&#x02013;<lpage>e00036</lpage>.
<pub-id pub-id-type="pmid">21325039</pub-id></mixed-citation></ref><ref id="iid392-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="iid392-cit-0092">
<string-name>
<surname>Lewinski</surname>, <given-names>M. K.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Jafari</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Zhang</surname>
</string-name>, 
<string-name>
<given-names>S. J.</given-names>
<surname>Opella</surname>
</string-name>, and 
<string-name>
<given-names>J.</given-names>
<surname>Guatelli</surname>
</string-name>. 
<year>2015</year>
<article-title>Membrane anchoring by a C&#x02010;terminal tryptophan enables HIV&#x02010;1 Vpu to displace bone marrow stromal antigen 2 (BST2) from sites of viral assembly</article-title>. 
<source>J. Biol. Chem</source>. 
<volume>290</volume>:<fpage>10919</fpage>&#x02013;<lpage>10933</lpage>.
<pub-id pub-id-type="pmid">25759385</pub-id></mixed-citation></ref><ref id="iid392-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="iid392-cit-0093">
<string-name>
<surname>Hauser</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<given-names>L. A.</given-names>
<surname>Lopez</surname>
</string-name>, 
<string-name>
<given-names>S. J.</given-names>
<surname>Yang</surname>
</string-name>, 
<string-name>
<given-names>J. E.</given-names>
<surname>Oldenburg</surname>
</string-name>, 
<string-name>
<given-names>C. M.</given-names>
<surname>Exline</surname>
</string-name>, 
<string-name>
<given-names>J. C.</given-names>
<surname>Guatelli</surname>
</string-name>, and 
<string-name>
<given-names>P. M.</given-names>
<surname>Cannon</surname>
</string-name>. 
<year>2010</year>
<article-title>HIV&#x02010;1 Vpu and HIV&#x02010;2 Env counteract BST&#x02010;2/tetherin by sequestration in a perinuclear compartment</article-title>. 
<source>Retrovirology</source>
<volume>7</volume>:<fpage>51</fpage>.
<pub-id pub-id-type="pmid">20529266</pub-id></mixed-citation></ref><ref id="iid392-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="iid392-cit-0094">
<string-name>
<surname>Le Tortorec</surname>, <given-names>A.</given-names>
</string-name>, and 
<string-name>
<given-names>S. J.</given-names>
<surname>Neil</surname>
</string-name>. 
<year>2009</year>
<article-title>Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein</article-title>. 
<source>J. Virol</source>. 
<volume>83</volume>:<fpage>11966</fpage>&#x02013;<lpage>11978</lpage>.
<pub-id pub-id-type="pmid">19740980</pub-id></mixed-citation></ref><ref id="iid392-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="iid392-cit-0095">
<string-name>
<surname>Bour</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<given-names>U.</given-names>
<surname>Schubert</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Peden</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>. 
<year>1996</year>
<article-title>The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu&#x02010;like factor</article-title>? 
<source>J. Virol</source>. 
<volume>70</volume>:<fpage>820</fpage>&#x02013;<lpage>829</lpage>.
<pub-id pub-id-type="pmid">8551620</pub-id></mixed-citation></ref><ref id="iid392-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="iid392-cit-0096">
<string-name>
<surname>Ritter</surname>
<suffix>Jr.</suffix>, <given-names>G. D.</given-names>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Yamshchikov</surname>
</string-name>, 
<string-name>
<given-names>S. J.</given-names>
<surname>Cohen</surname>
</string-name>, and 
<string-name>
<given-names>M. J.</given-names>
<surname>Mulligan</surname>
</string-name>. 
<year>1996</year>
<article-title>Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain</article-title>. 
<source>J. Virol</source>. 
<volume>70</volume>:<fpage>2669</fpage>&#x02013;<lpage>2673</lpage>.
<pub-id pub-id-type="pmid">8642705</pub-id></mixed-citation></ref><ref id="iid392-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="iid392-cit-0097">
<string-name>
<surname>Bour</surname>, <given-names>S.</given-names>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>. 
<year>1996</year>
<article-title>The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses</article-title>. 
<source>J. Virol</source>. 
<volume>70</volume>:<fpage>8285</fpage>&#x02013;<lpage>8300</lpage>.
<pub-id pub-id-type="pmid">8970948</pub-id></mixed-citation></ref><ref id="iid392-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="iid392-cit-0098">
<string-name>
<surname>Abada</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Noble</surname>
</string-name>, and 
<string-name>
<given-names>P. M.</given-names>
<surname>Cannon</surname>
</string-name>. 
<year>2005</year>
<article-title>Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production</article-title>. 
<source>J. Virol</source>. 
<volume>79</volume>:<fpage>3627</fpage>&#x02013;<lpage>3638</lpage>.
<pub-id pub-id-type="pmid">15731257</pub-id></mixed-citation></ref><ref id="iid392-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="iid392-cit-0099">
<string-name>
<surname>Noble</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Abada</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Nunez&#x02010;Iglesias</surname>
</string-name>, and 
<string-name>
<given-names>P. M.</given-names>
<surname>Cannon</surname>
</string-name>. 
<year>2006</year>
<article-title>Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release</article-title>. 
<source>J. Virol</source>. 
<volume>80</volume>:<fpage>2924</fpage>&#x02013;<lpage>2932</lpage>.
<pub-id pub-id-type="pmid">16501101</pub-id></mixed-citation></ref><ref id="iid392-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="iid392-cit-0100">
<string-name>
<surname>Lau</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Kwan</surname>
</string-name>, and 
<string-name>
<given-names>J.</given-names>
<surname>Guatelli</surname>
</string-name>. 
<year>2011</year>
<article-title>Role of the endocytic pathway in the counteraction of BST&#x02010;2 by human lentiviral pathogens</article-title>. 
<source>J. Virol</source>. 
<volume>85</volume>:<fpage>9834</fpage>&#x02013;<lpage>9846</lpage>.
<pub-id pub-id-type="pmid">21813615</pub-id></mixed-citation></ref><ref id="iid392-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="iid392-cit-0101">
<string-name>
<surname>Gustin</surname>, <given-names>J. K.</given-names>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Bai</surname>
</string-name>, 
<string-name>
<given-names>A. V.</given-names>
<surname>Moses</surname>
</string-name>, and 
<string-name>
<given-names>J. L.</given-names>
<surname>Douglas</surname>
</string-name>. 
<year>2015</year>
<article-title>Ebola virus glycoprotein promotes enhanced viral egress by preventing Ebola VP 40 from associating with the host restriction factor BST2/Tetherin</article-title>. 
<source>J. Infect. Dis</source>. 
<volume>212</volume>:<fpage>181</fpage>&#x02013;<lpage>190</lpage>.
</mixed-citation></ref><ref id="iid392-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="iid392-cit-0102">
<string-name>
<surname>Yasuda</surname>, <given-names>J.</given-names>
</string-name>
<year>2012</year>
<article-title>Ebolavirus replication and Tetherin/BST&#x02010;2</article-title>. 
<source>Front. Microbiol</source>. 
<volume>3</volume>:<fpage>111</fpage>.
<pub-id pub-id-type="pmid">22485110</pub-id></mixed-citation></ref><ref id="iid392-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="iid392-cit-0103">
<string-name>
<surname>Mansouri</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Viswanathan</surname>
</string-name>, 
<string-name>
<given-names>J. L.</given-names>
<surname>Douglas</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Hines</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Gustin</surname>
</string-name>, 
<string-name>
<given-names>A. V.</given-names>
<surname>Moses</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Fruh</surname>
</string-name>. 
<year>2009</year>
<article-title>Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma&#x02010;associated herpesvirus</article-title>. 
<source>J. Virol</source>. 
<volume>83</volume>:<fpage>9672</fpage>&#x02013;<lpage>9681</lpage>.
<pub-id pub-id-type="pmid">19605472</pub-id></mixed-citation></ref><ref id="iid392-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="iid392-cit-0104">
<string-name>
<surname>Liu</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Luo</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>He</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Zhang</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Wang</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Li</surname>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Huang</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Hu</surname>
</string-name>, 
<string-name>
<given-names>G. E.</given-names>
<surname>Griffin</surname>
</string-name>, 
<string-name>
<given-names>R. J.</given-names>
<surname>Shattock</surname>
</string-name>, et al. 
<year>2015</year>
<article-title>Tetherin restricts HSV&#x02010;2 release and is counteracted by multiple viral glycoproteins</article-title>. 
<source>Virology</source>
<volume>475</volume>:<fpage>96</fpage>&#x02013;<lpage>109</lpage>.
<pub-id pub-id-type="pmid">25462350</pub-id></mixed-citation></ref><ref id="iid392-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="iid392-cit-0105">
<string-name>
<surname>Blondeau</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Pelchen&#x02010;Matthews</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Mlcochova</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Marsh</surname>
</string-name>, 
<string-name>
<given-names>R. S.</given-names>
<surname>Milne</surname>
</string-name>, and 
<string-name>
<given-names>G. J.</given-names>
<surname>Towers</surname>
</string-name>. 
<year>2013</year>
<article-title>Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M</article-title>. 
<source>J. Virol</source>. 
<volume>87</volume>:<fpage>13124</fpage>&#x02013;<lpage>13133</lpage>.
<pub-id pub-id-type="pmid">24067975</pub-id></mixed-citation></ref><ref id="iid392-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="iid392-cit-0106">
<string-name>
<surname>Viswanathan</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<given-names>M. S.</given-names>
<surname>Smith</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Malouli</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Mansouri</surname>
</string-name>, 
<string-name>
<given-names>J. A.</given-names>
<surname>Nelson</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Fruh</surname>
</string-name>. 
<year>2011</year>
<article-title>BST2/Tetherin enhances entry of human cytomegalovirus</article-title>. 
<source>PLoS Pathog</source>. 
<volume>7</volume>:<fpage>e002332</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="iid392-cit-0107">
<string-name>
<surname>Bampi</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Rasga</surname>
</string-name>, and 
<string-name>
<given-names>L.</given-names>
<surname>Roux</surname>
</string-name>. 
<year>2013</year>
<article-title>Antagonism to human BST&#x02010;2/tetherin by Sendai virus glycoproteins</article-title>. 
<source>J. Gen. Virol</source>. 
<volume>94</volume>:<fpage>1211</fpage>&#x02013;<lpage>1219</lpage>.
<pub-id pub-id-type="pmid">23468424</pub-id></mixed-citation></ref><ref id="iid392-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="iid392-cit-0108">
<string-name>
<surname>Lv</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Zhang</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Shi</surname>
</string-name>, 
<string-name>
<given-names>Z.</given-names>
<surname>Han</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Zhang</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Zhou</surname>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Zhang</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Niu</surname>
</string-name>, and 
<string-name>
<given-names>X. F.</given-names>
<surname>Yu</surname>
</string-name>. 
<year>2015</year>
<article-title>Identification of BST&#x02010;2/tetherin&#x02010;induced hepatitis B virus restriction and hepatocyte&#x02010;specific BST&#x02010;2 inactivation</article-title>. 
<source>Sci. Rep</source>. 
<volume>5</volume>:<fpage>11736</fpage>.
<pub-id pub-id-type="pmid">26119070</pub-id></mixed-citation></ref><ref id="iid392-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="iid392-cit-0109">
<string-name>
<surname>Serra&#x02010;Moreno</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Zimmermann</surname>
</string-name>, 
<string-name>
<given-names>L. J.</given-names>
<surname>Stern</surname>
</string-name>, and 
<string-name>
<given-names>D. T.</given-names>
<surname>Evans</surname>
</string-name>. 
<year>2013</year>
<article-title>Tetherin/BST&#x02010;2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin&#x02010;mediated endocytosis</article-title>. 
<source>PLoS Pathog</source>. 
<volume>9</volume>:<fpage>e003487</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="iid392-cit-0110">
<string-name>
<surname>Zhang</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<given-names>W. N.</given-names>
<surname>Landford</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Ng</surname>
</string-name>, 
<string-name>
<given-names>M. W.</given-names>
<surname>McNatt</surname>
</string-name>, 
<string-name>
<given-names>P. D.</given-names>
<surname>Bieniasz</surname>
</string-name>, and 
<string-name>
<given-names>T.</given-names>
<surname>Hatziioannou</surname>
</string-name>. 
<year>2011</year>
<article-title>SIV Nef proteins recruit the AP&#x02010;2 complex to antagonize Tetherin and facilitate virion release</article-title>. 
<source>PLoS Pathog</source>. 
<volume>7</volume>:<fpage>e002039</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="iid392-cit-0111">
<string-name>
<surname>Zhang</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<given-names>S. J.</given-names>
<surname>Wilson</surname>
</string-name>, 
<string-name>
<given-names>W. C.</given-names>
<surname>Landford</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Virgen</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Gregory</surname>
</string-name>, 
<string-name>
<given-names>M. C.</given-names>
<surname>Johnson</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Munch</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Kirchhoff</surname>
</string-name>, 
<string-name>
<given-names>P. D.</given-names>
<surname>Bieniasz</surname>
</string-name>, and 
<string-name>
<given-names>T.</given-names>
<surname>Hatziioannou</surname>
</string-name>. 
<year>2009</year>
<article-title>Nef proteins from simian immunodeficiency viruses are tetherin antagonists</article-title>. 
<source>Cell Host Microbe</source>. 
<volume>6</volume>:<fpage>54</fpage>&#x02013;<lpage>67</lpage>.
<pub-id pub-id-type="pmid">19501037</pub-id></mixed-citation></ref><ref id="iid392-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="iid392-cit-0112">
<string-name>
<surname>Roeth</surname>, <given-names>J. F.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Williams</surname>
</string-name>, 
<string-name>
<given-names>M. R.</given-names>
<surname>Kasper</surname>
</string-name>, 
<string-name>
<given-names>T. M.</given-names>
<surname>Filzen</surname>
</string-name>, and 
<string-name>
<given-names>K. L.</given-names>
<surname>Collins</surname>
</string-name>. 
<year>2004</year>
<article-title>HIV&#x02010;1 Nef disrupts MHC&#x02010;I trafficking by recruiting AP&#x02010;1 to the MHC&#x02010;I cytoplasmic tail</article-title>. 
<source>J. Cell Biol</source>. 
<volume>167</volume>:<fpage>903</fpage>&#x02013;<lpage>913</lpage>.
<pub-id pub-id-type="pmid">15569716</pub-id></mixed-citation></ref><ref id="iid392-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="iid392-cit-0113">
<string-name>
<surname>Jin</surname>, <given-names>Y. J.</given-names>
</string-name>, 
<string-name>
<given-names>C. Y.</given-names>
<surname>Cai</surname>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Zhang</surname>
</string-name>, 
<string-name>
<given-names>H. T.</given-names>
<surname>Zhang</surname>
</string-name>, 
<string-name>
<given-names>J. A.</given-names>
<surname>Hirst</surname>
</string-name>, and 
<string-name>
<given-names>S. J.</given-names>
<surname>Burakoff</surname>
</string-name>. 
<year>2005</year>
<article-title>HIV Nef&#x02010;mediated CD4 down&#x02010;regulation is adaptor protein complex 2 depen</article-title>. 
<source>J. Immunol</source>. 
<volume>175</volume>:<fpage>3157</fpage>&#x02013;<lpage>3164</lpage>.
<pub-id pub-id-type="pmid">16116206</pub-id></mixed-citation></ref><ref id="iid392-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="iid392-cit-0114">
<string-name>
<surname>Manes</surname>, <given-names>T. D.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Hoer</surname>
</string-name>, 
<string-name>
<given-names>W. A.</given-names>
<surname>Muller</surname>
</string-name>, 
<string-name>
<given-names>P. J.</given-names>
<surname>Lehner</surname>
</string-name>, and 
<string-name>
<given-names>J. S.</given-names>
<surname>Pober</surname>
</string-name>. 
<year>2010</year>
<article-title>Kaposi's sarcoma&#x02010;associated herpesvirus K3 and K5 proteins block distinct steps in transendothelial migration of effector memory CD4+ T cells by targeting different endothelial proteins</article-title>. 
<source>J. Immunol</source>. 
<volume>184</volume>:<fpage>5186</fpage>&#x02013;<lpage>5192</lpage>.
<pub-id pub-id-type="pmid">20357254</pub-id></mixed-citation></ref><ref id="iid392-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="iid392-cit-0115">
<string-name>
<surname>Pardieu</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Vigan</surname>
</string-name>, 
<string-name>
<given-names>S. J.</given-names>
<surname>Wilson</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Calvi</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Zang</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Bieniasz</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Kellam</surname>
</string-name>, 
<string-name>
<given-names>G. J.</given-names>
<surname>Towers</surname>
</string-name>, and 
<string-name>
<given-names>S. J.</given-names>
<surname>Neil</surname>
</string-name>. 
<year>2010</year>
<article-title>The RING&#x02010;CH ligase K5 antagonizes restriction of KSHV and HIV&#x02010;1 particle release by mediating ubiquitin&#x02010;dependent endosomal degradation of tetherin</article-title>. 
<source>PLoS Pathog</source>. 
<volume>6</volume>:<fpage>e000843</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="iid392-cit-0116">
<string-name>
<surname>Watanabe</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<given-names>G. P.</given-names>
<surname>Leser</surname>
</string-name>, and 
<string-name>
<given-names>R. A.</given-names>
<surname>Lamb</surname>
</string-name>. 
<year>2011</year>
<article-title>Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin</article-title>. 
<source>Virology</source>
<volume>417</volume>:<fpage>50</fpage>&#x02013;<lpage>56</lpage>.
<pub-id pub-id-type="pmid">21621240</pub-id></mixed-citation></ref><ref id="iid392-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="iid392-cit-0117">
<string-name>
<surname>Mangeat</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Cavagliotti</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Lehmann</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Gers&#x02010;Huber</surname>
</string-name>, 
<string-name>
<given-names>I.</given-names>
<surname>Kaur</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Thomas</surname>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Kaiser</surname>
</string-name>, and 
<string-name>
<given-names>V.</given-names>
<surname>Piguet</surname>
</string-name>. 
<year>2012</year>
<article-title>Influenza virus partially counteracts restriction imposed by Tetherin/BST&#x02010;2</article-title>. 
<source>J. Biol. Chem</source>. 
<volume>287</volume>:<fpage>22015</fpage>&#x02013;<lpage>22029</lpage>.
<pub-id pub-id-type="pmid">22493439</pub-id></mixed-citation></ref><ref id="iid392-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="iid392-cit-0118">
<string-name>
<surname>Bruce</surname>, <given-names>E. A.</given-names>
</string-name>, 
<string-name>
<given-names>T. E.</given-names>
<surname>Abbink</surname>
</string-name>, 
<string-name>
<given-names>H. M.</given-names>
<surname>Wise</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Rollason</surname>
</string-name>, 
<string-name>
<given-names>R. P.</given-names>
<surname>Galao</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Banting</surname>
</string-name>, 
<string-name>
<given-names>S. J.</given-names>
<surname>Neil</surname>
</string-name>, and 
<string-name>
<given-names>P.</given-names>
<surname>Digard</surname>
</string-name>. 
<year>2012</year>
<article-title>Release of filamentous and spherical influenza A virus is not restricted by tetherin</article-title>. 
<source>J. Gen. Virol</source>. 
<volume>93</volume>:<fpage>963</fpage>&#x02013;<lpage>969</lpage>.
<pub-id pub-id-type="pmid">22258861</pub-id></mixed-citation></ref><ref id="iid392-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="iid392-cit-0119">
<string-name>
<surname>Mahauad&#x02010;Fernandez</surname>, <given-names>W. D.</given-names>
</string-name>, 
<string-name>
<given-names>N. C.</given-names>
<surname>Borcherding</surname>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Zhang</surname>
</string-name>, and 
<string-name>
<given-names>C. M.</given-names>
<surname>Okeoma</surname>
</string-name>. 
<year>2015</year>
<article-title>Bone marrow stromal antigen 2 (BST&#x02010;2) DNA is demethylated in breast tumors and breast cancer cells</article-title>. 
<source>PLoS ONE</source>
<volume>10</volume>:<fpage>e123931</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="iid392-cit-0120">
<string-name>
<surname>Fang</surname>, <given-names>K. H.</given-names>
</string-name>, 
<string-name>
<given-names>H. K.</given-names>
<surname>Kao</surname>
</string-name>, 
<string-name>
<given-names>L. M.</given-names>
<surname>Chi</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Liang</surname>
</string-name>, 
<string-name>
<given-names>S. C.</given-names>
<surname>Liu</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Hseuh</surname>
</string-name>, 
<string-name>
<given-names>C. T.</given-names>
<surname>Liao</surname>
</string-name>, 
<string-name>
<given-names>T. C.</given-names>
<surname>Yen</surname>
</string-name>, 
<string-name>
<given-names>J. S.</given-names>
<surname>Yu</surname>
</string-name>, and 
<string-name>
<given-names>K. P.</given-names>
<surname>Chang</surname>
</string-name>. 
<year>2014</year>
<article-title>Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer</article-title>. 
<source>Laryngoscope</source>
<volume>124</volume>:<fpage>E354</fpage>&#x02013;<lpage>E360</lpage>.
<pub-id pub-id-type="pmid">24706327</pub-id></mixed-citation></ref><ref id="iid392-bib-0121"><label>121</label><mixed-citation publication-type="journal" id="iid392-cit-0121">
<string-name>
<surname>Wang</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Nishioka</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Ozaki</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Jalili</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Abe</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Kakiuchi</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Kishuku</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Minakuchi</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Matsumoto</surname>
</string-name>, and 
<string-name>
<given-names>S.</given-names>
<surname>Sone</surname>
</string-name>. 
<year>2009</year>
<article-title>HM1. 24 (CD317) is a novel target against lung cancer for immunotherapy using anti&#x02010;HM1. 24 antibody</article-title>. 
<source>Cancer Immunol. Immunother</source>. 
<volume>58</volume>:<fpage>967</fpage>&#x02013;<lpage>976</lpage>.
<pub-id pub-id-type="pmid">18979097</pub-id></mixed-citation></ref><ref id="iid392-bib-0122"><label>122</label><mixed-citation publication-type="journal" id="iid392-cit-0122">
<string-name>
<surname>Mahauad&#x02010;Fernandez</surname>, <given-names>W. D.</given-names>
</string-name>, 
<string-name>
<given-names>K. A.</given-names>
<surname>DeMali</surname>
</string-name>, 
<string-name>
<given-names>A. K.</given-names>
<surname>Olivier</surname>
</string-name>, and 
<string-name>
<given-names>C. M.</given-names>
<surname>Okeoma</surname>
</string-name>. 
<year>2014</year>
<article-title>Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasi</article-title>. 
<source>Breast Cancer Res</source>. 
<volume>16</volume>(<issue>6</issue>):<fpage>493</fpage>, doi: 10.1186/s13058&#x02010;014&#x02010;0493&#x02010;8.
<pub-id pub-id-type="pmid">25499888</pub-id></mixed-citation></ref><ref id="iid392-bib-0123"><label>123</label><mixed-citation publication-type="journal" id="iid392-cit-0123">
<string-name>
<surname>Sayeed</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Luciani&#x02010;Torres</surname>
</string-name>, 
<string-name>
<given-names>Z.</given-names>
<surname>Meng</surname>
</string-name>, 
<string-name>
<given-names>J. L.</given-names>
<surname>Bennington</surname>
</string-name>, 
<string-name>
<given-names>D. H.</given-names>
<surname>Moore</surname>
</string-name>, and 
<string-name>
<given-names>S. H.</given-names>
<surname>Dairkee</surname>
</string-name>. 
<year>2013</year>
<article-title>Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells</article-title>. 
<source>PLoS ONE</source>
<volume>8</volume>:<fpage>e7191</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0124"><label>124</label><mixed-citation publication-type="journal" id="iid392-cit-0124">
<string-name>
<surname>Milutin Gasperov</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<given-names>S. A.</given-names>
<surname>Farkas</surname>
</string-name>, 
<string-name>
<given-names>T. K.</given-names>
<surname>Nilsson</surname>
</string-name>, and 
<string-name>
<given-names>M.</given-names>
<surname>Grce</surname>
</string-name>. 
<year>2014</year>
<article-title>Epigenetic activation of immune genes in cervical cancer</article-title>. 
<source>Immunol. Lett</source>. 
<volume>162</volume>:<fpage>256</fpage>&#x02013;<lpage>257</lpage>.
<pub-id pub-id-type="pmid">25310935</pub-id></mixed-citation></ref><ref id="iid392-bib-0125"><label>125</label><mixed-citation publication-type="journal" id="iid392-cit-0125">
<string-name>
<surname>Tai</surname>, <given-names>Y. T.</given-names>
</string-name>, 
<string-name>
<given-names>H. M.</given-names>
<surname>Horton</surname>
</string-name>, 
<string-name>
<given-names>S. Y.</given-names>
<surname>Kong</surname>
</string-name>, 
<string-name>
<given-names>E.</given-names>
<surname>Pong</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Chen</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Cemerski</surname>
</string-name>, 
<string-name>
<given-names>M. J.</given-names>
<surname>Bernett</surname>
</string-name>, 
<string-name>
<given-names>D. H.</given-names>
<surname>Nguyen</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Karki</surname>
</string-name>, 
<string-name>
<given-names>S. Y.</given-names>
<surname>Chu</surname>
</string-name>, et al. 
<year>2012</year>
<article-title>Potent in vitro and in vivo activity of an Fc&#x02010;engineered humanized anti&#x02010;HM1. 24 antibody against multiple myeloma via augmented effector function</article-title>. 
<source>Blood</source>
<volume>119</volume>:<fpage>2074</fpage>&#x02013;<lpage>2082</lpage>.
<pub-id pub-id-type="pmid">22246035</pub-id></mixed-citation></ref><ref id="iid392-bib-0126"><label>126</label><mixed-citation publication-type="journal" id="iid392-cit-0126">
<string-name>
<surname>Staudinger</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Glorius</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Burger</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Kellner</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Klausz</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Gunther</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Repp</surname>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Klapper</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Gramatzki</surname>
</string-name>, and 
<string-name>
<given-names>M.</given-names>
<surname>Peipp</surname>
</string-name>. 
<year>2014</year>
<article-title>The novel immunotoxin HM1. 24&#x02010;ETA' induces apoptosis in multiple myeloma cells</article-title>. 
<source>Blood Cancer J</source>. 
<volume>4</volume>:<fpage>e19</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0127"><label>127</label><mixed-citation publication-type="journal" id="iid392-cit-0127">
<string-name>
<surname>Yokoyama</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Enomoto</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Serada</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Morimoto</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Matsuzaki</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Ueda</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Yoshino</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Fujita</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Kyo</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Iwahori</surname>
</string-name>, et al. 
<year>2012</year>
<article-title>Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer</article-title>. 
<source>Int. J. Cancer</source>
<volume>132</volume>:<fpage>472</fpage>&#x02013;<lpage>484</lpage>.
<pub-id pub-id-type="pmid">22729361</pub-id></mixed-citation></ref><ref id="iid392-bib-0128"><label>128</label><mixed-citation publication-type="journal" id="iid392-cit-0128">
<string-name>
<surname>Wainwright</surname>, <given-names>D. A.</given-names>
</string-name>, 
<string-name>
<given-names>I. V.</given-names>
<surname>Balyasnikova</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Han</surname>
</string-name>, and 
<string-name>
<given-names>M. S.</given-names>
<surname>Lesniak</surname>
</string-name>. 
<year>2011</year>
<article-title>The expression of BST2 in human and experimental mouse brain tumors</article-title>. 
<source>Exp. Mol. Pathol</source>. 
<volume>91</volume>:<fpage>440</fpage>&#x02013;<lpage>446</lpage>.
<pub-id pub-id-type="pmid">21565182</pub-id></mixed-citation></ref><ref id="iid392-bib-0129"><label>129</label><mixed-citation publication-type="journal" id="iid392-cit-0129">
<string-name>
<surname>Cai</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Cao</surname>
</string-name>, 
<string-name>
<given-names>Z.</given-names>
<surname>Li</surname>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Zheng</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Yao</surname>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Li</surname>
</string-name>, and 
<string-name>
<given-names>Z.</given-names>
<surname>Yuan</surname>
</string-name>. 
<year>2009</year>
<article-title>Up&#x02010;regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis</article-title>. 
<source>BMC Cancer</source>
<volume>9</volume>:<fpage>102</fpage>.
<pub-id pub-id-type="pmid">19338666</pub-id></mixed-citation></ref><ref id="iid392-bib-0130"><label>130</label><mixed-citation publication-type="journal" id="iid392-cit-0130">
<string-name>
<surname>Gu</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Zhao</surname>
</string-name>, and 
<string-name>
<given-names>Z.</given-names>
<surname>Yin</surname>
</string-name>. 
<year>2012</year>
<article-title>P. BST&#x02010;2 binding with cellular MT1&#x02010;MMP blocks cell growth and migration via decreasing MMP2 activity</article-title>. 
<source>J. Cell Biochem</source>. 
<volume>113</volume>:<fpage>1013</fpage>&#x02013;<lpage>1021</lpage>.
<pub-id pub-id-type="pmid">22065321</pub-id></mixed-citation></ref><ref id="iid392-bib-0131"><label>131</label><mixed-citation publication-type="journal" id="iid392-cit-0131">
<string-name>
<surname>Mahauad&#x02010;Fernandez</surname>, <given-names>W. D.</given-names>
</string-name>, 
<string-name>
<given-names>K. A.</given-names>
<surname>DeMali</surname>
</string-name>, 
<string-name>
<given-names>A. K.</given-names>
<surname>Olivier</surname>
</string-name>, and 
<string-name>
<given-names>C. M.</given-names>
<surname>Okeoma</surname>
</string-name>. 
<year>2014</year>
<article-title>Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis</article-title>. 
<source>Breast Cancer Res</source>. 
<volume>16</volume>:<fpage>493</fpage>.
<pub-id pub-id-type="pmid">25499888</pub-id></mixed-citation></ref><ref id="iid392-bib-0132"><label>132</label><mixed-citation publication-type="journal" id="iid392-cit-0132">
<string-name>
<surname>Yoo</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<given-names>S. H.</given-names>
<surname>Park</surname>
</string-name>, 
<string-name>
<given-names>S. K.</given-names>
<surname>Ye</surname>
</string-name>, and 
<string-name>
<given-names>M.</given-names>
<surname>Kim</surname>
</string-name>. 
<year>2011</year>
<article-title>IFN&#x02010;gamma&#x02010;induced BST2 mediates monocyte adhesion to human endothelial cells</article-title>. 
<source>Cell Immunol</source>. 
<volume>267</volume>:<fpage>23</fpage>&#x02013;<lpage>29</lpage>.
<pub-id pub-id-type="pmid">21094940</pub-id></mixed-citation></ref><ref id="iid392-bib-0133"><label>133</label><mixed-citation publication-type="journal" id="iid392-cit-0133">
<string-name>
<surname>Kim</surname>, <given-names>Y. N.</given-names>
</string-name>, 
<string-name>
<given-names>K. H.</given-names>
<surname>Koo</surname>
</string-name>, 
<string-name>
<given-names>J. Y.</given-names>
<surname>Sung</surname>
</string-name>, 
<string-name>
<given-names>U. J.</given-names>
<surname>Yun</surname>
</string-name>, and 
<string-name>
<given-names>H.</given-names>
<surname>Kim</surname>
</string-name>. 
<year>2012</year>
<article-title>Anoikis resistance: an essential prerequisite for tumor metastasis</article-title>. 
<source>Int. J. Cell Biol</source>. 
<volume>2012</volume>:<fpage>306879</fpage>.
<pub-id pub-id-type="pmid">22505926</pub-id></mixed-citation></ref><ref id="iid392-bib-0134"><label>134</label><mixed-citation publication-type="journal" id="iid392-cit-0134">
<string-name>
<surname>Tan</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Goldstein</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Crowe</surname>
</string-name>, and 
<string-name>
<given-names>J. L.</given-names>
<surname>Yang</surname>
</string-name>. 
<year>2013</year>
<article-title>Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis</article-title>. 
<source>J. Cancer Res. Clin. Oncol</source>. 
<volume>139</volume>:<fpage>1795</fpage>&#x02013;<lpage>1805</lpage>.
<pub-id pub-id-type="pmid">23912151</pub-id></mixed-citation></ref><ref id="iid392-bib-0135"><label>135</label><mixed-citation publication-type="journal" id="iid392-cit-0135">
<string-name>
<surname>Ozaki</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Kosaka</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Harada</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Nishitani</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Odomi</surname>
</string-name>, and 
<string-name>
<given-names>T.</given-names>
<surname>Matsumoto</surname>
</string-name>. 
<year>1998</year>
<article-title>Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24</article-title>. 
<source>Cancer</source>
<volume>82</volume>:<fpage>2184</fpage>&#x02013;<lpage>2190</lpage>.
<pub-id pub-id-type="pmid">9610698</pub-id></mixed-citation></ref><ref id="iid392-bib-0136"><label>136</label><mixed-citation publication-type="journal" id="iid392-cit-0136">
<string-name>
<surname>Harada</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Ozaki</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Oda</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Tsuji</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Ikegame</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Iwasa</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Udaka</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Fujii</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Nakamura</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Miki</surname>
</string-name>, et al. 
<year>2013</year>
<article-title>Combination with a defucosylated anti&#x02010;HM1. 24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors</article-title>. 
<source>PloS ONE</source>
<volume>8</volume>:<fpage>e3905</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0137"><label>137</label><mixed-citation publication-type="journal" id="iid392-cit-0137">
<string-name>
<surname>Harada</surname>, <given-names>T.</given-names>
</string-name>, and 
<string-name>
<given-names>S.</given-names>
<surname>Ozaki</surname>
</string-name>. 
<year>2014</year>
<article-title>Targeted therapy for HM1.24 (CD317) on multiple myeloma cells</article-title>. 
<source>Biomed. Res. Int</source>. 
<volume>2014</volume>:<fpage>965384</fpage>.
<pub-id pub-id-type="pmid">25143955</pub-id></mixed-citation></ref><ref id="iid392-bib-0138"><label>138</label><mixed-citation publication-type="journal" id="iid392-cit-0138">
<string-name>
<surname>Wang</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Nishioka</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Ozaki</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Jalili</surname>
</string-name>, 
<string-name>
<given-names>V. K.</given-names>
<surname>Verma</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Hanibuchi</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Abe</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Minakuchi</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Matsumoto</surname>
</string-name>, and 
<string-name>
<given-names>S.</given-names>
<surname>Sone</surname>
</string-name>. 
<year>2009</year>
<article-title>Chimeric and humanized anti&#x02010;HM1. 24 antibodies mediate antibody&#x02010;dependent cellular cytotoxicity against lung cancer cells</article-title>. 
<source>Lung Cancer</source>
<volume>63</volume>:<fpage>23</fpage>&#x02013;<lpage>31</lpage>.
<pub-id pub-id-type="pmid">18524412</pub-id></mixed-citation></ref><ref id="iid392-bib-0139"><label>139</label><mixed-citation publication-type="journal" id="iid392-cit-0139">
<string-name>
<surname>Kawai</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Azuma</surname>
</string-name>, 
<string-name>
<given-names>E.</given-names>
<surname>Fujii</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Furugaki</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Ozaki</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Matsumoto</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Kosaka</surname>
</string-name>, and 
<string-name>
<given-names>H.</given-names>
<surname>Yamada&#x02010;Okabe</surname>
</string-name>. 
<year>2008</year>
<article-title>Interferon&#x02010;alpha enhances CD317 expression and the antitumor activity of anti&#x02010;CD317 monoclonal antibody in renal cell carcinoma xenograft models</article-title>. 
<source>Cancer Sci</source>. 
<volume>99</volume>:<fpage>2461</fpage>&#x02013;<lpage>2466</lpage>.
<pub-id pub-id-type="pmid">19032371</pub-id></mixed-citation></ref><ref id="iid392-bib-0140"><label>140</label><mixed-citation publication-type="journal" id="iid392-cit-0140">
<string-name>
<surname>Miyagi</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Andrew</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Kao</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Yoshida</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Strebel</surname>
</string-name>. 
<year>2011</year>
<article-title>Antibody&#x02010;mediated enhancement of HIV&#x02010;1 and HIV&#x02010;2 production from BST&#x02010;2/tetherin&#x02010;positive cells</article-title>. 
<source>J. Virol</source>. 
<volume>85</volume>:<fpage>11981</fpage>&#x02013;<lpage>11994</lpage>.
<pub-id pub-id-type="pmid">21917971</pub-id></mixed-citation></ref><ref id="iid392-bib-0141"><label>141</label><mixed-citation publication-type="journal" id="iid392-cit-0141">
<string-name>
<surname>Epeldegui</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Blom</surname>
</string-name>, and 
<string-name>
<given-names>C. H.</given-names>
<surname>Uittenbogaart</surname>
</string-name>. 
<year>2015</year>
<article-title>BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells</article-title>. 
<source>Eur. J. Immunol</source>. 
<volume>45</volume>:<fpage>728</fpage>&#x02013;<lpage>737</lpage>.
<pub-id pub-id-type="pmid">25408362</pub-id></mixed-citation></ref><ref id="iid392-bib-0142"><label>142</label><mixed-citation publication-type="journal" id="iid392-cit-0142">
<string-name>
<surname>Zou</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Li</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Misra</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Yue</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Song</surname>
</string-name>, 
<string-name>
<given-names>Q.</given-names>
<surname>Chen</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Guo</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Yi</surname>
</string-name>, 
<string-name>
<given-names>J. T.</given-names>
<surname>Kimata</surname>
</string-name>, and 
<string-name>
<given-names>L.</given-names>
<surname>Liu</surname>
</string-name>. 
<year>2015</year>
<article-title>The viral restriction factor tetherin prevents leucine&#x02010;rich pentatricopeptide repeat&#x02010;containing protein (LRPPRC) from association with beclin 1 and B&#x02010;cell CLL/lymphoma 2 (Bcl&#x02010;2) and enhances autophagy and mitophagy</article-title>. 
<source>J. Biol. Chem</source>. 
<volume>290</volume>:<fpage>7269</fpage>&#x02013;<lpage>7279</lpage>.
<pub-id pub-id-type="pmid">25631043</pub-id></mixed-citation></ref><ref id="iid392-bib-0143"><label>143</label><mixed-citation publication-type="journal" id="iid392-cit-0143">
<string-name>
<surname>Li</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Kaloyanova</surname>
</string-name>, 
<string-name>
<given-names>M</given-names>. <surname>van Eijk</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Eerland</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>van der Goot</surname>
</string-name>, 
<string-name>
<given-names>V.</given-names>
<surname>Oorschot</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Klumperman</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Lottspeich</surname>
</string-name>, 
<string-name>
<given-names>V.</given-names>
<surname>Starkuviene</surname>
</string-name>, 
<string-name>
<given-names>F. T.</given-names>
<surname>Wieland</surname>
</string-name>, et al. 
<year>2007</year>
<article-title>Involvement of a Golgi&#x02010;resident GPI&#x02010;anchored protein in maintenance of the Golgi structure</article-title>. 
<source>Mol. Biol. Cell</source>
<volume>18</volume>:<fpage>1261</fpage>&#x02013;<lpage>1271</lpage>.
<pub-id pub-id-type="pmid">17251550</pub-id></mixed-citation></ref><ref id="iid392-bib-0144"><label>144</label><mixed-citation publication-type="journal" id="iid392-cit-0144">
<string-name>
<surname>Billcliff</surname>, <given-names>P. G.</given-names>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Rollason</surname>
</string-name>, 
<string-name>
<given-names>I.</given-names>
<surname>Prior</surname>
</string-name>, 
<string-name>
<given-names>D. M.</given-names>
<surname>Owen</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Gaus</surname>
</string-name>, and 
<string-name>
<given-names>G.</given-names>
<surname>Banting</surname>
</string-name>. 
<year>2013</year>
<article-title>CD317/tetherin is an organiser of membrane microdomains</article-title>. 
<source>J. Cell Sci</source>. 
<volume>126</volume>:<fpage>1553</fpage>&#x02013;<lpage>1564</lpage>.
<pub-id pub-id-type="pmid">23378022</pub-id></mixed-citation></ref><ref id="iid392-bib-0145"><label>145</label><mixed-citation publication-type="journal" id="iid392-cit-0145">
<string-name>
<surname>Bego</surname>, <given-names>M. G.</given-names>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Mercier</surname>
</string-name>, and 
<string-name>
<given-names>E. A.</given-names>
<surname>Cohen</surname>
</string-name>. 
<year>2012</year>
<article-title>Virus&#x02010;activated interferon regulatory factor 7 upregulates expression of the interferon&#x02010;regulated BST2 gene independently of interferon signaling</article-title>. 
<source>J. Virol</source>. 
<volume>86</volume>:<fpage>3513</fpage>&#x02013;<lpage>3527</lpage>.
<pub-id pub-id-type="pmid">22301143</pub-id></mixed-citation></ref><ref id="iid392-bib-0146"><label>146</label><mixed-citation publication-type="journal" id="iid392-cit-0146">
<string-name>
<surname>Savan</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Ravichandran</surname>
</string-name>, 
<string-name>
<given-names>J. R.</given-names>
<surname>Collins</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Sakai</surname>
</string-name>, and 
<string-name>
<given-names>H. A.</given-names>
<surname>Young</surname>
</string-name>. 
<year>2009</year>
<article-title>Structural conservation of interferon gamma among vertebrates</article-title>. 
<source>Cytokine Growth Factor Rev</source>. 
<volume>20</volume>:<fpage>115</fpage>&#x02013;<lpage>124</lpage>.
<pub-id pub-id-type="pmid">19268624</pub-id></mixed-citation></ref><ref id="iid392-bib-0147"><label>147</label><mixed-citation publication-type="journal" id="iid392-cit-0147">
<string-name>
<surname>Hu</surname>, <given-names>Z.</given-names>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Wu</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Ge</surname>
</string-name>, and 
<string-name>
<given-names>X.</given-names>
<surname>Wang</surname>
</string-name>. 
<year>2013</year>
<article-title>Inhibition of virus replication and induction of human tetherin gene expression by equine IFN&#x02010;alpha1</article-title>. 
<source>Veter. Immunol. Immunopathol</source>. 
<volume>156</volume>:<fpage>107</fpage>&#x02013;<lpage>113</lpage>.
</mixed-citation></ref><ref id="iid392-bib-0148"><label>148</label><mixed-citation publication-type="journal" id="iid392-cit-0148">
<string-name>
<surname>Thippeshappa</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Ruan</surname>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Wang</surname>
</string-name>, 
<string-name>
<given-names>P.</given-names>
<surname>Zhou</surname>
</string-name>, and 
<string-name>
<given-names>J. T.</given-names>
<surname>Kimata</surname>
</string-name>. 
<year>2013</year>
<article-title>A variant macaque&#x02010;tropic human immunodeficiency virus type 1 is resistant to alpha interferon&#x02010;induced restriction in pig&#x02010;tailed macaque CD4+ T cells</article-title>. 
<source>J. Virol</source>. 
<volume>87</volume>:<fpage>6678</fpage>&#x02013;<lpage>6692</lpage>.
<pub-id pub-id-type="pmid">23552412</pub-id></mixed-citation></ref><ref id="iid392-bib-0149"><label>149</label><mixed-citation publication-type="journal" id="iid392-cit-0149">
<string-name>
<surname>Ge</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<given-names>A. A.</given-names>
<surname>Dombkowski</surname>
</string-name>, 
<string-name>
<given-names>K. M.</given-names>
<surname>LaFiura</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Tatman</surname>
</string-name>, 
<string-name>
<given-names>R. S.</given-names>
<surname>Yedidi</surname>
</string-name>, 
<string-name>
<given-names>M. L.</given-names>
<surname>Stout</surname>
</string-name>, 
<string-name>
<given-names>S. A.</given-names>
<surname>Buck</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Massey</surname>
</string-name>, 
<string-name>
<given-names>D. L.</given-names>
<surname>Becton</surname>
</string-name>, 
<string-name>
<given-names>H. J.</given-names>
<surname>Weinstein</surname>
</string-name>, et al. 
<year>2006</year>
<article-title>Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia</article-title>. 
<source>Blood</source>
<volume>107</volume>:<fpage>1570</fpage>&#x02013;<lpage>1581</lpage>.
<pub-id pub-id-type="pmid">16249385</pub-id></mixed-citation></ref><ref id="iid392-bib-0150"><label>150</label><mixed-citation publication-type="journal" id="iid392-cit-0150">
<string-name>
<surname>Cao</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Bover</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Cho</surname>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Wen</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Hanabuchi</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Bao</surname>
</string-name>, 
<string-name>
<given-names>D. B.</given-names>
<surname>Rosen</surname>
</string-name>, 
<string-name>
<given-names>Y. H.</given-names>
<surname>Wang</surname>
</string-name>, 
<string-name>
<given-names>J. L.</given-names>
<surname>Shaw</surname>
</string-name>, 
<string-name>
<given-names>Q.</given-names>
<surname>Du</surname>
</string-name>, et al. 
<year>2009</year>
<article-title>Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction</article-title>. 
<source>J. Exp. Med</source>. 
<volume>206</volume>:<fpage>1603</fpage>&#x02013;<lpage>1614</lpage>.
<pub-id pub-id-type="pmid">19564354</pub-id></mixed-citation></ref><ref id="iid392-bib-0151"><label>151</label><mixed-citation publication-type="journal" id="iid392-cit-0151">
<string-name>
<surname>Wenzel</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Bekisch</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Uerlich</surname>
</string-name>, 
<string-name>
<given-names>O.</given-names>
<surname>Haller</surname>
</string-name>, 
<string-name>
<given-names>T.</given-names>
<surname>Bieber</surname>
</string-name>, and 
<string-name>
<given-names>T.</given-names>
<surname>Tuting</surname>
</string-name>. 
<year>2005</year>
<article-title>Type I interferon&#x02010;associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions</article-title>. 
<source>Am. J. Clin Pathol</source>. 
<volume>124</volume>:<fpage>37</fpage>&#x02013;<lpage>48</lpage>.
<pub-id pub-id-type="pmid">15923172</pub-id></mixed-citation></ref><ref id="iid392-bib-0152"><label>152</label><mixed-citation publication-type="journal" id="iid392-cit-0152">
<string-name>
<surname>Dunn</surname>, <given-names>G. P.</given-names>
</string-name>, 
<string-name>
<given-names>C. M.</given-names>
<surname>Koebel</surname>
</string-name>, and 
<string-name>
<given-names>R. D.</given-names>
<surname>Schreiber</surname>
</string-name>. 
<year>2006</year>
<article-title>Interferons, immunity and cancer immunoediting</article-title>. 
<source>Nat. Rev. Immunol</source>. 
<volume>6</volume>:<fpage>836</fpage>&#x02013;<lpage>848</lpage>.
<pub-id pub-id-type="pmid">17063185</pub-id></mixed-citation></ref><ref id="iid392-bib-0153"><label>153</label><mixed-citation publication-type="journal" id="iid392-cit-0153">
<string-name>
<surname>Jones</surname>, <given-names>P. H.</given-names>
</string-name>, 
<string-name>
<given-names>W. D.</given-names>
<surname>Mahauad&#x02010;Fernandez</surname>
</string-name>, 
<string-name>
<given-names>M. N.</given-names>
<surname>Madison</surname>
</string-name>, and 
<string-name>
<given-names>C. M.</given-names>
<surname>Okeoma</surname>
</string-name>. 
<year>2013</year>
<article-title>BST&#x02010;2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV&#x02010;induced mammary cancer</article-title>. 
<source>Virology</source>
<volume>444</volume>:<fpage>124</fpage>&#x02013;<lpage>139</lpage>.
<pub-id pub-id-type="pmid">23806386</pub-id></mixed-citation></ref><ref id="iid392-bib-0154"><label>154</label><mixed-citation publication-type="journal" id="iid392-cit-0154">
<string-name>
<surname>Guzzo</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Jung</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Graveline</surname>
</string-name>, 
<string-name>
<given-names>B. W.</given-names>
<surname>Banfield</surname>
</string-name>, and 
<string-name>
<given-names>K.</given-names>
<surname>Gee</surname>
</string-name>. 
<year>2012</year>
<article-title>IL&#x02010;27 increases BST&#x02010;2 expression in human monocytes and T cells independently of type I IFN</article-title>. 
<source>Sci. Rep</source>. 
<volume>2</volume>:<fpage>974</fpage>.
<pub-id pub-id-type="pmid">23240078</pub-id></mixed-citation></ref><ref id="iid392-bib-0155"><label>155</label><mixed-citation publication-type="journal" id="iid392-cit-0155">
<string-name>
<surname>Kastelein</surname>, <given-names>R. A.</given-names>
</string-name>, 
<string-name>
<given-names>C. A.</given-names>
<surname>Hunter</surname>
</string-name>, and 
<string-name>
<given-names>D. J.</given-names>
<surname>Cua</surname>
</string-name>. 
<year>2007</year>
<article-title>Discovery and biology of IL&#x02010;23 and IL&#x02010;27: related but functionally distinct regulators of inflammation</article-title>. 
<source>Annu. Rev. Immunol</source>. 
<volume>25</volume>:<fpage>221</fpage>&#x02013;<lpage>242</lpage>.
<pub-id pub-id-type="pmid">17291186</pub-id></mixed-citation></ref><ref id="iid392-bib-0156"><label>156</label><mixed-citation publication-type="journal" id="iid392-cit-0156">
<string-name>
<surname>Fakruddin</surname>, <given-names>J. M.</given-names>
</string-name>, 
<string-name>
<given-names>R. A.</given-names>
<surname>Lempicki</surname>
</string-name>, 
<string-name>
<given-names>R. J.</given-names>
<surname>Gorelick</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Yang</surname>
</string-name>, 
<string-name>
<given-names>J. W.</given-names>
<surname>Adelsberger</surname>
</string-name>, 
<string-name>
<given-names>A. J.</given-names>
<surname>Garcia&#x02010;Pineres</surname>
</string-name>, 
<string-name>
<given-names>L. A.</given-names>
<surname>Pinto</surname>
</string-name>, 
<string-name>
<given-names>H. C.</given-names>
<surname>Lane</surname>
</string-name>, and 
<string-name>
<given-names>T.</given-names>
<surname>Imamichi</surname>
</string-name>. 
<year>2007</year>
<article-title>Noninfectious papilloma virus&#x02010;like particles inhibit HIV&#x02010;1 replication: implications for immune control of HIV&#x02010;1 infection by IL&#x02010;27</article-title>. 
<source>Blood</source>
<volume>109</volume>:<fpage>1841</fpage>&#x02013;<lpage>1849</lpage>.
<pub-id pub-id-type="pmid">17068156</pub-id></mixed-citation></ref><ref id="iid392-bib-0157"><label>157</label><mixed-citation publication-type="journal" id="iid392-cit-0157">
<string-name>
<surname>Imamichi</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Yang</surname>
</string-name>, 
<string-name>
<given-names>D. W.</given-names>
<surname>Huang</surname>
</string-name>, 
<string-name>
<given-names>T. W.</given-names>
<surname>Brann</surname>
</string-name>, 
<string-name>
<given-names>B. A.</given-names>
<surname>Fullmer</surname>
</string-name>, 
<string-name>
<given-names>J. W.</given-names>
<surname>Adelsberger</surname>
</string-name>, 
<string-name>
<given-names>R. A.</given-names>
<surname>Lempicki</surname>
</string-name>, 
<string-name>
<given-names>M. W.</given-names>
<surname>Baseler</surname>
</string-name>, and 
<string-name>
<given-names>H. C.</given-names>
<surname>Lane</surname>
</string-name>. 
<year>2008</year>
<article-title>IL&#x02010;27, a novel anti&#x02010;HIV cytokine, activates multiple interferon&#x02010;inducible genes in macrophages</article-title>. 
<source>AIDS</source>
<volume>22</volume>:<fpage>39</fpage>&#x02013;<lpage>45</lpage>.
<pub-id pub-id-type="pmid">18090390</pub-id></mixed-citation></ref><ref id="iid392-bib-0158"><label>158</label><mixed-citation publication-type="journal" id="iid392-cit-0158">
<string-name>
<surname>Greenwell&#x02010;Wild</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Vazquez</surname>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Jin</surname>
</string-name>, 
<string-name>
<given-names>Z.</given-names>
<surname>Rangel</surname>
</string-name>, 
<string-name>
<given-names>P. J.</given-names>
<surname>Munson</surname>
</string-name>, and 
<string-name>
<given-names>S. M.</given-names>
<surname>Wahl</surname>
</string-name>. 
<year>2009</year>
<article-title>Interleukin&#x02010;27 inhibition of HIV&#x02010;1 involves an intermediate induction of type I interferon</article-title>. 
<source>Blood</source>
<volume>114</volume>:<fpage>1864</fpage>&#x02013;<lpage>1874</lpage>.
<pub-id pub-id-type="pmid">19556424</pub-id></mixed-citation></ref><ref id="iid392-bib-0159"><label>159</label><mixed-citation publication-type="journal" id="iid392-cit-0159">
<string-name>
<surname>Perissi</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Menini</surname>
</string-name>, 
<string-name>
<given-names>E.</given-names>
<surname>Cottone</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Capello</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Sacco</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Montaldo</surname>
</string-name>, and 
<string-name>
<given-names>M.</given-names>
<surname>De Bortoli</surname>
</string-name>. 
<year>2000</year>
<article-title>AP&#x02010;2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen</article-title>. 
<source>Oncogene</source>
<volume>19</volume>:<fpage>280</fpage>&#x02013;<lpage>288</lpage>.
<pub-id pub-id-type="pmid">10645007</pub-id></mixed-citation></ref><ref id="iid392-bib-0160"><label>160</label><mixed-citation publication-type="journal" id="iid392-cit-0160">
<string-name>
<surname>Zhou</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Wang</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Liu</surname>
</string-name>, 
<string-name>
<given-names>Q.</given-names>
<surname>Hu</surname>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Song</surname>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Ye</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Zhou</surname>
</string-name>, and 
<string-name>
<given-names>W.</given-names>
<surname>Ho</surname>
</string-name>. 
<year>2010</year>
<article-title>A critical function of toll&#x02010;like receptor&#x02010;3 in the induction of anti&#x02010;human immunodeficiency virus activities in macrophages</article-title>. 
<source>Immunology</source>
<volume>131</volume>:<fpage>40</fpage>&#x02013;<lpage>49</lpage>.
<pub-id pub-id-type="pmid">20636339</pub-id></mixed-citation></ref><ref id="iid392-bib-0161"><label>161</label><mixed-citation publication-type="journal" id="iid392-cit-0161">
<string-name>
<surname>Sang</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>J. B.</given-names>
<surname>Liu</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Dai</surname>
</string-name>, 
<string-name>
<given-names>J. G.</given-names>
<surname>Wu</surname>
</string-name>, and 
<string-name>
<given-names>W. Z.</given-names>
<surname>Ho</surname>
</string-name>. 
<year>2014</year>
<article-title>Toll&#x02010;like receptor 3 signaling inhibits simian immunodeficiency virus replication in macrophages from <italic>Rhesus macaques</italic>
</article-title>. 
<source>Antiviral Res</source>. 
<volume>112</volume>:<fpage>103</fpage>&#x02013;<lpage>112</lpage>.
<pub-id pub-id-type="pmid">25453343</pub-id></mixed-citation></ref><ref id="iid392-bib-0162"><label>162</label><mixed-citation publication-type="journal" id="iid392-cit-0162">
<string-name>
<surname>Homann</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Smith</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Little</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Richman</surname>
</string-name>, and 
<string-name>
<given-names>J.</given-names>
<surname>Guatelli</surname>
</string-name>. 
<year>2011</year>
<article-title>Upregulation of BST&#x02010;2/Tetherin by HIV infection in vivo</article-title>. 
<source>J. Virol</source>. 
<volume>85</volume>:<fpage>10659</fpage>&#x02013;<lpage>10668</lpage>.
<pub-id pub-id-type="pmid">21849457</pub-id></mixed-citation></ref><ref id="iid392-bib-0163"><label>163</label><mixed-citation publication-type="journal" id="iid392-cit-0163">
<string-name>
<surname>Bauerfeld</surname>, <given-names>C. P.</given-names>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Rastogi</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Pirockinaite</surname>
</string-name>, 
<string-name>
<given-names>I.</given-names>
<surname>Lee</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>H&#x000fc;ttemann</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Monks</surname>
</string-name>, 
<string-name>
<given-names>M. J.</given-names>
<surname>Birnbaum</surname>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Franchi</surname>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Nu&#x000f1;ez</surname>
</string-name>, and 
<string-name>
<given-names>L.</given-names>
<surname>Samavati</surname>
</string-name>. 
<year>2012</year>
<article-title>TLR4&#x02010;mediated AKT activation is Myd88/TRIF dependent and critical for induction of oxidative phosphorylation and mitochondrial transcription factor a in murine macrophages</article-title>. 
<source>J. Immunol</source>. 
<volume>188</volume>:<fpage>2847</fpage>&#x02013;<lpage>2857</lpage>.
<pub-id pub-id-type="pmid">22312125</pub-id></mixed-citation></ref><ref id="iid392-bib-0164"><label>164</label><mixed-citation publication-type="journal" id="iid392-cit-0164">
<string-name>
<surname>Arbibe</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<given-names>J. P.</given-names>
<surname>Mira</surname>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Teusch</surname>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Kline</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Guha</surname>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Mackman</surname>
</string-name>, 
<string-name>
<given-names>P. J.</given-names>
<surname>Godowski</surname>
</string-name>, 
<string-name>
<given-names>R. J.</given-names>
<surname>Ulevitch</surname>
</string-name>, and 
<string-name>
<given-names>U. G.</given-names>
<surname>Knaus</surname>
</string-name>. 
<year>2000</year>
<article-title>Toll&#x02010;like receptor 2&#x02010;mediated NF&#x02010;&#x003ba;B activation requires a Rac I&#x02010;dependent pathway</article-title>. 
<source>Nat. Immunol</source>. 
<volume>1</volume>:<fpage>533</fpage>&#x02013;<lpage>540</lpage>.
<pub-id pub-id-type="pmid">11101877</pub-id></mixed-citation></ref><ref id="iid392-bib-0165"><label>165</label><mixed-citation publication-type="journal" id="iid392-cit-0165">
<string-name>
<surname>Blanchet</surname>, <given-names>F. P.</given-names>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Stalder</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Czubala</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Lehmann</surname>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Rio</surname>
</string-name>, 
<string-name>
<given-names>B.</given-names>
<surname>Mangeat</surname>
</string-name>, and 
<string-name>
<given-names>V.</given-names>
<surname>Piguet</surname>
</string-name>. 
<year>2013</year>
<article-title>TLR&#x02010;4 engagement of dendritic cells confers a BST&#x02010;2/tetherin&#x02010;mediated restriction of HIV&#x02010;1 infection to CD4+ T cells across the virological synapse</article-title>. 
<source>Retrovirology</source>
<volume>10</volume>:<fpage>6</fpage>.
<pub-id pub-id-type="pmid">23311681</pub-id></mixed-citation></ref><ref id="iid392-bib-0166"><label>166</label><mixed-citation publication-type="journal" id="iid392-cit-0166">
<string-name>
<surname>Jarrossay</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Napolitani</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Colonna</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Sallusto</surname>
</string-name>, and 
<string-name>
<given-names>A.</given-names>
<surname>Lanzavecchia</surname>
</string-name>. 
<year>2001</year>
<article-title>Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells</article-title>. 
<source>Eur. J. Immunol</source>. 
<volume>31</volume>:<fpage>3388</fpage>&#x02013;<lpage>3393</lpage>.
<pub-id pub-id-type="pmid">11745357</pub-id></mixed-citation></ref><ref id="iid392-bib-0167"><label>167</label><mixed-citation publication-type="journal" id="iid392-cit-0167">
<string-name>
<surname>Kadowaki</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Ho</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Antonenko</surname>
</string-name>, 
<string-name>
<given-names>R. W.</given-names>
<surname>Malefyt</surname>
</string-name>, 
<string-name>
<given-names>R. A.</given-names>
<surname>Kastelein</surname>
</string-name>, 
<string-name>
<given-names>F.</given-names>
<surname>Bazan</surname>
</string-name>, and 
<string-name>
<given-names>Y. J.</given-names>
<surname>Liu</surname>
</string-name>. 
<year>2001</year>
<article-title>Subsets of human dendritic cell precursors express different toll&#x02010;like receptors and respond to different microbial antigens</article-title>. 
<source>J. Exp. Med</source>. 
<volume>194</volume>:<fpage>863</fpage>&#x02013;<lpage>869</lpage>.
<pub-id pub-id-type="pmid">11561001</pub-id></mixed-citation></ref><ref id="iid392-bib-0168"><label>168</label><mixed-citation publication-type="journal" id="iid392-cit-0168">
<string-name>
<surname>Liu</surname>, <given-names>Y. J.</given-names>
</string-name>
<year>2005</year>
<article-title>IPC: professional type 1 interferon&#x02010;producing cells and plasmacytoid dendritic cell precursors</article-title>. 
<source>Annu. Rev. Immunol</source>. 
<volume>23</volume>:<fpage>275</fpage>&#x02013;<lpage>306</lpage>.
<pub-id pub-id-type="pmid">15771572</pub-id></mixed-citation></ref><ref id="iid392-bib-0169"><label>169</label><mixed-citation publication-type="journal" id="iid392-cit-0169">
<string-name>
<surname>Gilliet</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>W.</given-names>
<surname>Cao</surname>
</string-name>, and 
<string-name>
<given-names>Y. J.</given-names>
<surname>Liu</surname>
</string-name>. 
<year>2008</year>
<article-title>Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases</article-title>. 
<source>Nat. Rev. Immunol</source>. 
<volume>8</volume>:<fpage>594</fpage>&#x02013;<lpage>606</lpage>.
<pub-id pub-id-type="pmid">18641647</pub-id></mixed-citation></ref><ref id="iid392-bib-0170"><label>170</label><mixed-citation publication-type="journal" id="iid392-cit-0170">
<string-name>
<surname>Colonna</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>G.</given-names>
<surname>Trinchieri</surname>
</string-name>, and 
<string-name>
<given-names>Y. J.</given-names>
<surname>Liu</surname>
</string-name>. 
<year>2004</year>
<article-title>Plasmacytoid dendritic cells in immunity</article-title>. 
<source>Nat. Immunol</source>. 
<volume>5</volume>:<fpage>1219</fpage>&#x02013;<lpage>1226</lpage>.
<pub-id pub-id-type="pmid">15549123</pub-id></mixed-citation></ref><ref id="iid392-bib-0171"><label>171</label><mixed-citation publication-type="journal" id="iid392-cit-0171">
<string-name>
<surname>Piqueras</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Connolly</surname>
</string-name>, 
<string-name>
<given-names>H.</given-names>
<surname>Freitas</surname>
</string-name>, 
<string-name>
<given-names>A. K.</given-names>
<surname>Palucka</surname>
</string-name>, and 
<string-name>
<given-names>J.</given-names>
<surname>Banchereau</surname>
</string-name>. 
<year>2006</year>
<article-title>Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors</article-title>. 
<source>Blood</source>
<volume>107</volume>:<fpage>2613</fpage>&#x02013;<lpage>2618</lpage>.
<pub-id pub-id-type="pmid">16317096</pub-id></mixed-citation></ref><ref id="iid392-bib-0172"><label>172</label><mixed-citation publication-type="journal" id="iid392-cit-0172">
<string-name>
<surname>Cao</surname>, <given-names>W.</given-names>
</string-name>, and 
<string-name>
<given-names>L.</given-names>
<surname>Bover</surname>
</string-name>. 
<year>2010</year>
<article-title>Signaling and ligand interaction of IL T7: receptor&#x02010;mediated regulatory mechanisms for plasmacytoid dendritic cells</article-title>. 
<source>Immunol. Rev</source>. 
<volume>234</volume>:<fpage>163</fpage>&#x02013;<lpage>176</lpage>.
<pub-id pub-id-type="pmid">20193018</pub-id></mixed-citation></ref><ref id="iid392-bib-0173"><label>173</label><mixed-citation publication-type="journal" id="iid392-cit-0173">
<string-name>
<surname>Jeffries</surname>, <given-names>M. A.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Dozmorov</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Tang</surname>
</string-name>, 
<string-name>
<given-names>J. T.</given-names>
<surname>Merrill</surname>
</string-name>, 
<string-name>
<given-names>J. D.</given-names>
<surname>Wren</surname>
</string-name>, and 
<string-name>
<given-names>A. H.</given-names>
<surname>Sawalha</surname>
</string-name>. 
<year>2011</year>
<article-title>Genome&#x02010;wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus</article-title>. 
<source>Epigenetics</source>
<volume>6</volume>:<fpage>593</fpage>&#x02013;<lpage>601</lpage>.
<pub-id pub-id-type="pmid">21436623</pub-id></mixed-citation></ref><ref id="iid392-bib-0174"><label>174</label><mixed-citation publication-type="journal" id="iid392-cit-0174">
<string-name>
<surname>Barriocanal</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<given-names>E.</given-names>
<surname>Carnero</surname>
</string-name>, 
<string-name>
<given-names>V.</given-names>
<surname>Segura</surname>
</string-name>, and 
<string-name>
<given-names>P.</given-names>
<surname>Fortes</surname>
</string-name>. 
<year>2014</year>
<article-title>Long non&#x02010;coding RNA BST2/BISPR is induced by IFN and regulates the expression of the antiviral factor Tetherin</article-title>. 
<source>Front. Immunol</source>. 
<volume>5</volume>:<fpage>655</fpage>.
<pub-id pub-id-type="pmid">25620967</pub-id></mixed-citation></ref><ref id="iid392-bib-0175"><label>175</label><mixed-citation publication-type="journal" id="iid392-cit-0175">
<string-name>
<surname>Kambara</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Gunawardane</surname>
</string-name>, 
<string-name>
<given-names>E.</given-names>
<surname>Zebrowski</surname>
</string-name>, 
<string-name>
<given-names>L.</given-names>
<surname>Kostadinova</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Jobava</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Krokowski</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Hatzoglou</surname>
</string-name>, 
<string-name>
<given-names>D. D.</given-names>
<surname>Anthony</surname>
</string-name>, and 
<string-name>
<given-names>S.</given-names>
<surname>Valadkhan</surname>
</string-name>. 
<year>2014</year>
<article-title>Regulation of interferon&#x02010;stimulated gene BST2 by a lncRNA transcribed from a shared bidirectional promoter</article-title>. 
<source>Front Immunol</source>. 
<volume>5</volume>:<fpage>676</fpage>.
<pub-id pub-id-type="pmid">25688240</pub-id></mixed-citation></ref><ref id="iid392-bib-0176"><label>176</label><mixed-citation publication-type="journal" id="iid392-cit-0176">
<string-name>
<surname>Okeoma</surname>, <given-names>C. M.</given-names>
</string-name>, 
<string-name>
<given-names>N.</given-names>
<surname>Lovsin</surname>
</string-name>, 
<string-name>
<given-names>B. M.</given-names>
<surname>Peterlin</surname>
</string-name>, and 
<string-name>
<given-names>S. R.</given-names>
<surname>Ross</surname>
</string-name>. 
<year>2007</year>
<article-title>APOBEC3 inhibits mouse mammary tumour virus replication in vivo</article-title>. 
<source>Nature</source>
<volume>445</volume>:<fpage>927</fpage>&#x02013;<lpage>930</lpage>.
<pub-id pub-id-type="pmid">17259974</pub-id></mixed-citation></ref><ref id="iid392-bib-0177"><label>177</label><mixed-citation publication-type="journal" id="iid392-cit-0177">
<string-name>
<surname>Okeoma</surname>, <given-names>C. M.</given-names>
</string-name>, 
<string-name>
<given-names>A. L.</given-names>
<surname>Huegel</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Lingappa</surname>
</string-name>, 
<string-name>
<given-names>M. D.</given-names>
<surname>Feldman</surname>
</string-name>, and 
<string-name>
<given-names>S. R.</given-names>
<surname>Ross</surname>
</string-name>. 
<year>2010</year>
<article-title>APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk&#x02010;borne virions</article-title>. 
<source>Cell Host Microbe</source>. 
<volume>8</volume>:<fpage>534</fpage>&#x02013;<lpage>543</lpage>.
<pub-id pub-id-type="pmid">21147467</pub-id></mixed-citation></ref><ref id="iid392-bib-0178"><label>178</label><mixed-citation publication-type="journal" id="iid392-cit-0178">
<string-name>
<surname>Kim</surname>, <given-names>H. H.</given-names>
</string-name>, 
<string-name>
<given-names>S. M.</given-names>
<surname>Grande</surname>
</string-name>, 
<string-name>
<given-names>J. G.</given-names>
<surname>Monroe</surname>
</string-name>, and 
<string-name>
<given-names>S. R.</given-names>
<surname>Ross</surname>
</string-name>. 
<year>2012</year>
<article-title>Mouse mammary tumor virus suppresses apoptosis of mammary epithelial cells through ITAM&#x02010;mediated signaling</article-title>. 
<source>J. Virol</source>. 
<volume>86</volume>:<fpage>13232</fpage>&#x02013;<lpage>13240</lpage>.
<pub-id pub-id-type="pmid">23015704</pub-id></mixed-citation></ref><ref id="iid392-bib-0179"><label>179</label><mixed-citation publication-type="journal" id="iid392-cit-0179">
<string-name>
<surname>Kim</surname>, <given-names>H. H.</given-names>
</string-name>, 
<string-name>
<given-names>A. P.</given-names>
<surname>van den Heuvel</surname>
</string-name>, 
<string-name>
<given-names>J. W.</given-names>
<surname>Schmidt</surname>
</string-name>, and 
<string-name>
<given-names>S. R.</given-names>
<surname>Ross</surname>
</string-name>. 
<year>2011</year>
<article-title>Novel common integration sites targeted by mouse mammary tumor virus insertion in mammary tumors have oncogenic activity</article-title>. 
<source>PLoS ONE</source>
<volume>6</volume>:<fpage>e7425</fpage>.
</mixed-citation></ref><ref id="iid392-bib-0180"><label>180</label><mixed-citation publication-type="journal" id="iid392-cit-0180">
<string-name>
<surname>Ross</surname>, <given-names>S. R.</given-names>
</string-name>
<year>2010</year>
<article-title>Mouse mammary tumor virus molecular biology and oncogenesis</article-title>. 
<source>Viruses</source>
<volume>2</volume>:<fpage>2000</fpage>&#x02013;<lpage>2012</lpage>.
<pub-id pub-id-type="pmid">21274409</pub-id></mixed-citation></ref><ref id="iid392-bib-0181"><label>181</label><mixed-citation publication-type="journal" id="iid392-cit-0181">
<string-name>
<surname>Melana</surname>, <given-names>S. M.</given-names>
</string-name>, 
<string-name>
<given-names>M. A.</given-names>
<surname>Picconi</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Rossi</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Mural</surname>
</string-name>, 
<string-name>
<given-names>L. V.</given-names>
<surname>Alonio</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Teyssie</surname>
</string-name>, 
<string-name>
<given-names>J. F.</given-names>
<surname>Holland</surname>
</string-name>, and 
<string-name>
<given-names>B. G.</given-names>
<surname>Pogo</surname>
</string-name>. 
<year>2002</year>
<article-title>[Detection of murine mammary tumor virus (MMTV) env gene&#x02010;like sequences in breast cancer from Argentine patients]</article-title>. 
<source>Medicina</source>
<volume>62</volume>:<fpage>323</fpage>&#x02013;<lpage>327</lpage>.
<pub-id pub-id-type="pmid">12325488</pub-id></mixed-citation></ref><ref id="iid392-bib-0182"><label>182</label><mixed-citation publication-type="journal" id="iid392-cit-0182">
<string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<given-names>J. F.</given-names>
<surname>Holland</surname>
</string-name>, 
<string-name>
<given-names>I. J.</given-names>
<surname>Bleiweiss</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Melana</surname>
</string-name>, 
<string-name>
<given-names>X.</given-names>
<surname>Liu</surname>
</string-name>, 
<string-name>
<given-names>I.</given-names>
<surname>Pelisson</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Cantarella</surname>
</string-name>, 
<string-name>
<given-names>K.</given-names>
<surname>Stellrecht</surname>
</string-name>, 
<string-name>
<given-names>S.</given-names>
<surname>Mani</surname>
</string-name>, and 
<string-name>
<given-names>B. G.</given-names>
<surname>Pogo</surname>
</string-name>. 
<year>1995</year>
<article-title>Detection of mammary tumor virus env gene&#x02010;like sequences in human breast cancer</article-title>. 
<source>Cancer Res</source>. 
<volume>55</volume>:<fpage>5173</fpage>&#x02013;<lpage>5179</lpage>.
<pub-id pub-id-type="pmid">7585568</pub-id></mixed-citation></ref><ref id="iid392-bib-0183"><label>183</label><mixed-citation publication-type="journal" id="iid392-cit-0183">
<string-name>
<surname>Zammarchi</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Pistello</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Piersigilli</surname>
</string-name>, 
<string-name>
<given-names>R.</given-names>
<surname>Murr</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Di Cristofano</surname>
</string-name>, 
<string-name>
<given-names>A. G.</given-names>
<surname>Naccarato</surname>
</string-name>, and 
<string-name>
<given-names>G.</given-names>
<surname>Bevilacqua</surname>
</string-name>. 
<year>2006</year>
<article-title>MMTV&#x02010;like sequences in human breast cancer: a fluorescent PCR/laser microdissection approach</article-title>. 
<source>J Pathol</source>. 
<volume>209</volume>:<fpage>436</fpage>&#x02013;<lpage>444</lpage>.
<pub-id pub-id-type="pmid">16710841</pub-id></mixed-citation></ref><ref id="iid392-bib-0184"><label>184</label><mixed-citation publication-type="journal" id="iid392-cit-0184">
<string-name>
<surname>Melana</surname>, <given-names>S. M.</given-names>
</string-name>, 
<string-name>
<given-names>I.</given-names>
<surname>Nepomnaschy</surname>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Sakalian</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Abbott</surname>
</string-name>, 
<string-name>
<given-names>J.</given-names>
<surname>Hasa</surname>
</string-name>, 
<string-name>
<given-names>J. F.</given-names>
<surname>Holland</surname>
</string-name>, and 
<string-name>
<given-names>B. G.</given-names>
<surname>Pogo</surname>
</string-name>. 
<year>2007</year>
<article-title>Characterization of viral particles isolated from primary cultures of human breast cancer cells</article-title>. 
<source>Cancer Res</source>. 
<volume>67</volume>:<fpage>8960</fpage>&#x02013;<lpage>8965</lpage>.
<pub-id pub-id-type="pmid">17875739</pub-id></mixed-citation></ref><ref id="iid392-bib-0185"><label>185</label><mixed-citation publication-type="journal" id="iid392-cit-0185">
<string-name>
<surname>Wang</surname>, <given-names>Y</given-names>
</string-name>., 
<string-name>
<given-names>J. D.</given-names>
<surname>Jiang</surname>
</string-name>, 
<string-name>
<given-names>D.</given-names>
<surname>Xu</surname>
</string-name>, 
<string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Qu</surname>
</string-name>, 
<string-name>
<given-names>J. F.</given-names>
<surname>Holland</surname>
</string-name>, and 
<string-name>
<given-names>B. G.</given-names>
<surname>Pogo</surname>
</string-name>. 
<year>2004</year>
<article-title>A mouse mammary tumor virus&#x02010;like long terminal repeat superantigen in human breast cancer</article-title>. 
<source>Cancer Res</source>. 
<volume>64</volume>:<fpage>4105</fpage>&#x02013;<lpage>4111</lpage>.
<pub-id pub-id-type="pmid">15205319</pub-id></mixed-citation></ref><ref id="iid392-bib-0186"><label>186</label><mixed-citation publication-type="journal" id="iid392-cit-0186">
<string-name>
<surname>Feldman</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<given-names>M.</given-names>
<surname>Roniger</surname>
</string-name>, 
<string-name>
<given-names>A.</given-names>
<surname>Bar&#x02010;Sinai</surname>
</string-name>, 
<string-name>
<given-names>O.</given-names>
<surname>Braitbard</surname>
</string-name>, 
<string-name>
<given-names>C.</given-names>
<surname>Natan</surname>
</string-name>, 
<string-name>
<given-names>D. C.</given-names>
<surname>Love</surname>
</string-name>, 
<string-name>
<given-names>J. A.</given-names>
<surname>Hanover</surname>
</string-name>, and 
<string-name>
<given-names>J.</given-names>
<surname>Hochman</surname>
</string-name>. 
<year>2012</year>
<article-title>The signal peptide of mouse mammary tumor virus&#x02010;env: a phosphoprotein tumor modulator</article-title>. 
<source>Mol Cancer Res</source>. 
<volume>10</volume>:<fpage>1077</fpage>&#x02013;<lpage>1086</lpage>.
<pub-id pub-id-type="pmid">22740636</pub-id></mixed-citation></ref><ref id="iid392-bib-0187"><label>187</label><mixed-citation publication-type="journal" id="iid392-cit-0187">
<string-name>
<surname>Yang</surname>, <given-names>S. J.</given-names>
</string-name>, 
<string-name>
<given-names>L. A.</given-names>
<surname>Lopez</surname>
</string-name>, 
<string-name>
<given-names>C. M.</given-names>
<surname>Exline</surname>
</string-name>, 
<string-name>
<given-names>K. G.</given-names>
<surname>Haworth</surname>
</string-name>, and 
<string-name>
<given-names>P. M.</given-names>
<surname>Cannon</surname>
</string-name>. 
<year>2011</year>
<article-title>Lack of adaptation to human tetherin in HIV&#x02010;1 group O and P</article-title>. 
<source>Retrovirology</source>
<volume>8</volume>:<fpage>78</fpage>.
<pub-id pub-id-type="pmid">21955466</pub-id></mixed-citation></ref></ref-list></back></article>